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Introduction to the thesis
Dementia with Lewy bodies (DLB) is a common neurodegenerative disease of the elderly. 
It accounts for approximately 5% of all patients with clinically diagnosed dementia.1,2 
However, the true prevalence is probably higher due to the fact that DLB is often overlooked 
and misdiagnosed.3,4 Typical clinical features of DLB include progressive cognitive decline 
accompanied by parkinsonism, hallucinations, fluctuating cognition and REM-sleep 
behavior disorders. Other common symptoms are autonomic dysfunction, anxiety and 
depression.5 Currently, there is no cure for DLB and treatment options are only available to 
lessen symptoms.6 Patients with DLB have a median survival of approximately four years 
from diagnosis.7 The mixture and severity of symptoms, lack of disease-modifying treatment 
options, and poor prognosis makes DLB a dreadful disease.
 DLB shares clinical and pathological features with Parkinson’s disease (PD) and 
Alzheimer’s disease (AD).6 Pathological hallmarks of DLB and PD are Lewy bodies and 
Lewy neurites.8 This Lewy pathology is spread throughout the cortical regions of the brain in 
DLB, in contrast to PD where Lewy pathology is largely confined to subcortical regions, at 
least in the initial disease stages.9 Additionally, AD pathology is observed in the majority of 
DLB patients.10,11 
 In contrast to genetic research in PD and AD, few genetic studies have been 
performed in DLB. Recently, a considerable genetic component has been suggested in the 
pathogenesis of DLB.12 Nonetheless, only some genetic factors (the apolipoprotein E ɛ4 
allele, and specific variants in the glucocerebrosidase and α-synuclein genes), previously 
associated with AD and PD, have also been associated with DLB.13,14
 The aim of this thesis is to shed more light on the genetics of DLB, which could lead to 
a better understanding of the causes of DLB and its associated pathobiology. This knowledge 
could lead to the development of biomarkers, which are very important in the diagnostic and 
prognostic process, and may ultimately contribute to the identification of new targets for the 
development of disease-modifying treatments.
 Chapter 1.2 provides an overview of the genetics of DLB. Little is known about possible 
differences between DLB patients with a positive family history of dementia or PD, as opposed 
to DLB patients with a negative family history of these diseases. In Part 2 differences in 
phenotype between these two groups are described. Considering the overlap between DLB, 
AD and PD, in Part 3 we investigated whether the known AD and PD genes are also associated 
with DLB. To increase the chances of finding genetic associations, we focused on two specific 
patient groups. We directed our analyses on DLB patients with a positive family history of 
dementia or PD in Chapter 3.1 and on pathologically confirmed DLB patients with rapid 
disease progression (clinically suspected of Creutzfeldt-Jakob’s disease) in Chapter 3.2. 
In Part 4 and Part 5, the focus shifts to the search for novel genes associated with DLB. The 
LRP10 gene was recently nominated as a novel gene associated with PD, PD dementia, and 
DLB15, and is, therefore, the principal focus of Part 4. This gene was analyzed in clinically 
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diagnosed PD and DLB patients (Chapter 4.1), dementia patients with Lewy pathology, 
dementia patients with parkinsonism without Lewy pathology (Chapter 4.2), and patients 
with progressive supranuclear palsy (Chapter 4.3). In Part 5, a multimodal approach is used 
to search for novel genes. Cerebrospinal fluid (CSF) proteomic analysis in DLB patients is 
described in Chapter 5.1. This dataset was used in the Appendix to Chapter 5.1 to combine 
genetic and proteomic data to find novel candidate genes in a pilot study. Part 6 entails a 
general discussion of the thesis in the context of the current literature and provides suggestions 
for future research. Finally, Part 7 summarizes the principal findings of the thesis.
Introduction to the thesis
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Abstract
The genetic architecture of dementia with Lewy bodies (DLB) is increasingly taking shape. 
Initially, genetic research focused mainly on linkage and candidate gene studies in small 
series of DLB patients. More recently, association and exome sequencing studies in larger 
groups have been conducted, and have shown that several variants in GBA and the APOE 
ε4 allele are important genetic risk factors for DLB. However, genetic research in DLB is 
still in its infancy. So far, many genetic studies have been biased and performed in clinically 
and pathologically heterogeneous populations. Therefore, it is likely that multiple DLB-
specific genetic determinants still have to be identified. To further our understanding of the 
role of genetics in DLB, future genetic studies should be unbiased and performed in large 
series of DLB patients, ideally with both a clinical diagnosis and pathological confirmation. 
The combination of genomic techniques with other research modalities, such as proteomic 
research, is a promising approach to identify novel genetic determinants. More knowledge 
about the genetics of DLB will increase our understanding of the pathophysiology of the 
disease and its relation with Parkinson’s disease and Alzheimer’s disease, and may eventually 
lead to the development of disease modifying treatments.
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Introduction
Dementia with Lewy bodies (DLB) is a common neurodegenerative disease in 
the elderly.1 DLB is characterized by progressive cognitive decline with variable 
combinations of fluctuating cognition, parkinsonism, visual hallucinations, neuro- 
leptic sensitivity and rapid eye movement (REM)-sleep behavior disorders.2 Clinical features 
of DLB are not specific to the disease and overlap with those of Parkinson’s disease (PD) and 
Alzheimer’s disease (AD).1 In addition, neuropathological features also overlap between these 
diseases. Cortical Lewy bodies and neurites, which mainly comprise abnormal aggregated 
α-synuclein3, are the pathological hallmarks of DLB, but are also observed in advanced PD 
and Parkinson’s disease dementia (PDD)4. Furthermore, AD pathology is present in most 
DLB patients4-6, which may aggravate the clinical manifestation of the disease and may 
increase the risk of mortality7-9. Due to these overlapping features, DLB is often considered 
as part of a spectrum with DLB placed between PD and AD (Figure 1).10
 Over the last years, the genetic architecture of DLB is increasingly taking shape.10-13 
Defects in genes associated with PD (such as α-synuclein (SNCA)14-17, leucine-rich repeat 
kinase 2 (LRRK2)18 and glucocerebrosidase (GBA)19-21) or AD (such as presenilin 1 
(PSEN1)22-24, presenilin 2 (PSEN2)13,24,25, amyloid precursor protein (APP)11,26, apolipoprotein 
E (APOE)11,13,24,27-30 and microtubule-associated protein tau (MAPT)31) have also been 
associated with DLB. In addition to the clinical and pathological overlap, these findings also 
suggest a genetic overlap of DLB with PD and AD (Figure 1).10
 In this article, we present a comprehensive overview of the genetics of DLB and 
discuss the genetic overlap of DLB with PD and AD. In addition, we describe promising 
genetic research methods, which in the near future will further our understanding about the 
pathophysiology of DLB and the clinicopathological spectrum between DLB, PD and AD.
Figure 1: Disease spectrum of PD-DLB-AD (simplified representation).
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18
Genetics of DLB
Multiple studies have been published on the genetics of DLB. The first genetic 
studies involving DLB patients mainly focused on families with multiple affected 
members with variable phenotypes ranging from DLB to PD and AD.14-18,22-26,32-36 
These studies used linkage analysis or a candidate gene approach to find rare variants (usually 
defined as variants with an allele frequency of less than 1% in the general population) 
with a large risk of disease development.37,38 In such families, two disease-associated loci 
(2q35-q36 and 2p1335-36) and twelve disease-associated rare variants in six genes have been 
identified11,13-18,22-26,32,34 (Table 1). Rare disease-associated variants have also been identified 
by candidate gene studies in series of unrelated DLB patients (Supplementary Table 1).13,19-
21,24,39-47 Some of these variants reside in genes previously associated with DLB in familial 
studies, which supports a role for these genes in DLB. Interestingly, rare disease-associated 
variants in GBA are often observed in unrelated DLB patients.19-21,39-41,43
 Association studies in large cohorts of patients and controls generally take the approach 
of identifying common variants (usually defined as variants with an allele frequency 
of more than 1% in the general population) with a small to intermediate risk of disease 
development.37,38 These studies with candidate genes have shown an association between 
DLB and, among others, the APOE ε4 allele11,13,24,27-30 and the MAPT H1G haplotype.31 A 
genome wide association (GWA) study, which is hypothesis free and typically identifies 
new disease-associated loci37,38, has not yet been reported for DLB. Other relatively new and 
unbiased genetic approaches37,38, such as whole exome and genome sequencing studies, have 
also not yet been reported.
 Genes associated with DLB are discussed in more detail in the next sections.
Rare variants in SNCA
Several defects in SNCA (p.E46K, p.A53T variant and duplication) have been 
described in DLB patients with family members diagnosed with PD or PDD (Table 1).14-17 
A SNCA duplication was also found in a DLB patient without affected family members 
(Supplementary Table 1).24 These defects were previously identified in multiple familial PD 
patients and are considered pathogenic.14,16,48,49 Although evidence is scarce, there are some 
indications that specific genetic variability within SNCA could lead to different phenotypes in 
the PD-DLB spectrum. For example, the p.A30P variant50 and duplications of SNCA are more 
often associated with PD and sometimes with PDD with a long disease course51,52, whereas 
the p.E46K variant, the p.A53T variant and triplications are associated with PD and DLB 
with an early age of onset, severe clinical symptoms and a short survival53. The difference of 
phenotype with the type of variant may be related to the position of the variant and its impact 
on protein function.14 Similarly, the kind of multiplication and genomic range of the SNCA 
multiplication may influence the clinical phenotype.17
An update on the genetics of dementia with Lewy bodies
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Rare variants in LRRK2
Mutations in LRRK2 are an important genetic cause of PD. The most common mutation 
is p.G2019S, with mean frequencies ranging from 1% in sporadic, to 4% in familial PD 
worldwide.54 However, the p.G2019S frequency varies significantly between populations, 
with higher frequencies in North African Arabs, Ashkenazi Jews and patients from the 
Middle East and southern Europe.54,55 Disease-associated rare variants in LRRK2 have rarely 
been found in DLB patients. Only one of 417 patients with clinical DLB and 355 patients 
with neuropathological confirmed Lewy body disease carried the p.G2019S mutation 
(Supplementary Table 1).42 In addition, the p.G2019S mutation was only observed in one 
single patient with DLB from a family with several members affected with PD (Table 1).18 
This suggests that LRRK2 disease-associated rare variants are, in contrast to PD, not a 
common cause of DLB.
Rare variants in PSEN1, PSEN2, APP
Mutations in PSEN1, PSEN2 and APP are typically associated with familial AD, but have also 
been associated with other phenotypes including DLB.56,57 Several defects (PSEN1: p.A79V 
variant and p.T440 deletion22-24, PSEN2: p.R71W, p.A85V and p.D439A variant13,24,25 and 
APP: p.V717I variant and duplication11,26) were found in families with DLB and dementia 
or PD (Table 1). Most of these defects (except from the PSEN1 p.T440 deletion and PSEN2 
p.A85V variant) have previously been identified in (familial) AD and are considered 
pathogenic (except from PSEN2: p.R71W and p.D439A variant).58-64 
 There are a number of possible reasons for finding defects in PSEN1, PSEN2 and APP 
in DLB patients. First, patients may have been misdiagnosed as having DLB instead of 
AD, as neuropathological confirmation was not always available. Second, in addition to 
AD pathology, Lewy pathology is frequently observed in patients with familial AD. Lewy 
pathology is found (especially in the amygdala) in more than 60% of the familial AD 
cases, and approximately 30% of PSEN1 or PSEN2 mutation carriers have cortical Lewy 
pathology.65,66 Previous studies have suggested that specific genetic defects in PSEN1 and 
PSEN2 influence the amount of coincidental Lewy pathology in AD patients, which may lead 
to a more DLB-like phenotype in patients with a higher Lewy pathology load.65,67,68
Rare (and common) variants in GBA
The frequency of GBA variants in DLB patients varies between populations, ranging from 
3.5% in a cohort of neuropathological confirmed DLB cases from the United States20 to 
33% in a clinical DLB cohort of Ashkenazi Jews, a population in which variants in GBA 
are overrepresented21,69. Variations in this frequency are due to differences in population and 
diagnostic criteria (clinically diagnosed patients versus pathologically diagnosed patients), 
as well as differences in research methods (e.g. genotyping of specific variants versus whole 
coding region) and selection criteria of identified variants (e.g. inclusion of all variants 
An update on the genetics of dementia with Lewy bodies
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versus rare pathogenic variants). Currently, the largest multicenter study has reported a 
disease-associated rare variant frequency of 7.5% in 721 clinically diagnosed DLB patients, 
compared to 0.97% in 1962 controls.19
 Recent studies show that DLB patients carrying disease-associated GBA variants 
may have a different clinical disease course than those without such variants.19,21,43 
A study among Ashkenazi Jews with DLB has shown more severe motor complaints, 
REM-sleep behavior disorders, and cognitive dysfunction in carriers than in non-carriers.21 
Furthermore, several studies have shown an earlier age of disease onset and death in DLB 
patients carrying a rare GBA variant than in non-carriers.19,21,43
 Many rare and common disease-associated variants in GBA have been found in DLB and 
PD patients.19-21,39-41,43,70 The risk of disease or a particular phenotype is dependent on the type 
of disease-associated variant.69,71
Rare variants in SNCB
The SNCB: p.P123H variant has been found in a family with DLB32,34 (Table 1) and 
the p.V70M variant in a DLB patient without affected family members32 (Supplementary 
Table 1). The clinical diagnosis of DLB was pathologically confirmed in the patient with the 
p.P123H variant, but did not fully cosegregate in his family. The p.P123H and p.V70M variants 
have not been found in other DLB patients, PD patients, or in 331 control individuals from 
the population of the affected patients.32 Possible pathogenicity is supported by the location 
of the variants, as they reside in highly conserved regions.32 It is also supported by research in 
transgenic mice expressing the p.P123H variant, where progressive neurodegeneration was 
observed.72 Further studies are necessary to replicate these findings.
Other rare variants with unclear pathogenicity
Other genes harboring rare variants with unclear pathogenicity which have been associated 
with DLB are parkin (PARK2)13,24, PTEN induced putative kinase 1 (PINK1)24, granulin 
(GRN)24,44,45, triggering receptor expressed on myeloid cells 2 (TREM2)45, charged 
multivesicular body protein 2B (CHMP2B)13, sequestosome (SQSTM1)13, microtubule-
associated protein tau (MAPT)24 and prion protein (PRNP)46 (Supplementary Table 1). 
Defects in these genes have previously been associated with other neurodegenerative 
diseases, such as PD and frontotemporal dementia (FTD), but have only sporadically been 
found in DLB patients. Rare variants in coiled-coil-helix-coiled-coil-helix domain containing 
2 (CHCHD2)47, eukaryotic translation initiation factor 4 gamma 1 (EIF4G1)13 and GRB10 
interacting GYF protein 2 (GIGYF2)13 have also incidentally been associated with DLB 
(Supplementary Table 1). However, the role of these genes in neurodegeneration has not yet 
been conclusively established.
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Common variants in APOE
The APOE ε4 allele has repeatedly been associated with DLB.11,13,24,27-30 Its frequency 
in DLB patients varies between studies, but is approximately 30% in Caucasian DLB 
patients11,13,24,27,28,30 in comparison to 14% in Caucasian controls free of neurodegenerative 
and neuropsychiatric diseases73.
 The effect of the APOE ε4 allele on different levels of Lewy and AD pathology was 
studied in 640 patients with dementia and 269 cognitively normal controls. This study 
showed that APOE ε4 allele carriers have an increased risk of both AD and Lewy pathology: 
APOE ε4 allele carriers had a 13-fold increased risk of developing a dementia with Lewy and 
AD pathology, a 10-fold increased risk of developing a dementia with only AD pathology, 
and a 6-fold increased risk of developing a dementia with Lewy pathology in comparison 
with non-carriers.28 These findings suggest that the APOE ε4 allele may be a larger risk factor 
for dementia with both Lewy and AD pathology than for dementia with AD pathology only, 
and may contribute to the development of dementia through mechanisms unrelated to AD 
pathology.28 Studies investigating the influence of the APOE ε4 allele on disease course report 
that DLB patients carrying an APOE ε4 allele have a shorter survival than non-carriers.11,13 In 
contrast to APOE ε4 allele carriers, APOE ε2 allele carriers have a reduced risk of developing 
DLB in comparison with non-carriers.74
Common variants in MAPT
Recently, an association study was performed in which MAPT haplotypes were investigated 
in clinically diagnosed DLB patients (n=431), patients with Lewy pathology and a high 
likelihood of clinical DLB (n=347), and in individuals without dementia or movement 
disorders (n=1049). The H1G haplotype was associated with a higher risk of DLB in 
comparison with controls (2.8% vs. 1.0%, OR=2.2). In line with findings in PD, the H2 
haplotype was associated with a lower risk of DLB in comparison with controls (20.9% vs. 
23.6%, OR=0.8).31,75 Other MAPT haplotypes (e.g. H1C and H1P) have also been linked 
to PD, PDD or AD76-78, which suggests that different haplotypes may increase the risk of 
a specific phenotype31. Replication of findings in larger cohorts of patients is necessary to 
validate these genetic associations.
Other common variants
The largest association study to date not only showed an association between the APOE 
locus, but also between the SNCA and scavenger receptor class B member 2 (SCARB2) loci 
and DLB. This study investigated 54 genomic regions, that were previously implicated in 
PD or AD, and was conducted in 788 clinically diagnosed DLB cases, of which 85% were 
neuropathologically confirmed, and 2624 controls.12 Interestingly, the associations observed 
in this study for the SNCA and SCARB2 loci were different than those previously found 
for PD.12 This suggests that these loci may play a subtle different role in these diseases. In 
addition, a common variant in butyrylcholinesterase (BuChE) has been associated with a 
decreased risk of DLB (n=174) in comparison with controls (n=86) in a recent study.79
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Genetic overlap between DLB, AD and PD
Genetic research in DLB has mainly focused on genes associated with PD and AD. Because 
of this biased approach, nearly all disease-associated variants found in DLB overlap with 
those associated with PD and AD (Figure 2). To assess the genetic overlap in a more unbiased 
way, an analysis of genetic correlation of DLB, PD and AD was performed.80 In this study, 
a genome-wide genotyping was conducted on 788 clinically diagnosed DLB cases of which 
85% were neuropathologically confirmed, 804 PD cases, and 959 clinically diagnosed AD 
cases. The proportion of variance explained by all single nucleotide polymorphisms (SNPs) 
for DLB was 0.31, for AD 0.60 and for PD 0.28. When comparing DLB with PD and DLB 
with AD for these SNPs, a correlation of 0.36 and 0.58 was found, respectively. No genetic 
correlation between PD and AD was found. Limitations of this study were the relatively small 
sample size, the inclusion of common risk loci only, and possible selection bias of the array. 
Nevertheless, the results of this study are interesting. First, the study suggests a larger overlap 
between DLB and AD than between DLB and PD. Secondly, the absence of an association 
between AD and PD indicates that the mechanisms underlying the association of DLB with 
AD and with PD are completely different. Finally, this study also suggests that, although 
genetic factors overlap with AD and PD, it is likely that DLB-specific genetic factors exist.80
 Taken together, studies in DLB show that identical genetic defects are associated with 
several phenotypes in the PD-DLB-AD spectrum. This suggests that these diseases share 
some underlying mechanisms, but that other genetic or non-genetic factors may also play 
a role. There are also indications that specific genetic defects within an identical gene are 
linked to different clinical and pathological features in the PD-DLB-AD spectrum. This 
in turn suggests that the underlying mechanisms may be similar, but are, for example, 
dependent on the severity of the defect, which could be reflected in the level of pathology 
and clinical symptoms. Only a few studies indicate a role of DLB-specific genetic factors in 
the development of the disease.
 However, a number of limitations to these current genetic studies may influence their 
quality. These, and the outlook for future research are discussed in the next two sections.
Limitations of current genetic studies
When interpreting genetic findings in DLB, a number of aspects have to be taken into 
account. First, genetic studies have often been performed in clinically and pathologically 
heterogeneous groups of patients. In the past, different diagnostic and pathologic criteria 
and nomenclature for DLB were used, which has made comparison of studies problematic. 
Applying the revised consensus diagnostic criteria of McKeith et al., 20052 led to greater 
homogeneity of diagnosis. Although these criteria have a high specificity (90%), the low 
sensitivity (54%)81 is the main reason why a definite DLB diagnosis can only be made after 
autopsy. However, accurate clinical information is still required to differentiate between DLB 
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and late stage PD or PDD, as these diseases cannot be reliably distinguished based on the 
neuropathology alone.82 Currently, the differentiation between DLB and PDD is based on the 
‘one year rule’, in which DLB is diagnosed when dementia presents before or within a year 
after the onset of parkinsonism.2 PDD is diagnosed when dementia starts more than one year 
after an established PD diagnosis. This is a somewhat artificial rule for differing between two 
conditions on the same spectrum of Lewy body diseases.83 However, the rule is still applied 
as it increases the homogeneity of the study population and research comparability.2 Only a 
selected group of genetic studies have been performed on patients with both a clinical and a 
neuropathological diagnosis of DLB. Misdiagnosis is possible in those studies with a lack of 
either neuropathological confirmation or detailed clinical information.
 Secondly, only a few genetic findings from family studies have been reported. In addition, 
in these studies segregation of the variant of interest was not always studied and genetic 
analysis was not always performed in the DLB patients, but instead in affected relatives.
 Thirdly, the pathogenicity of many of the identified variants is unclear, which leads 
to the question whether these variants are directly related to DLB or are just coincidental 
findings. Support of pathogenicity can, for example, be obtained from well-designed studies 
in which the prevalence of a specific variant is significantly higher in affected individuals in 
comparison with controls. Well-established in vitro or in vivo functional studies on specific 
variants can also support the claim of pathogenicity.84 Genetic studies with large sample sizes 
Figure 2: Variant risk versus variant frequency for DLB.
Genes previously associated with PD, AD, FTD and Creutzfeldt-Jacob's disease, and no other 
neurodegenerative disease are depicted in black, white, green, grey, and blue respectively. Evidence 
for the association between genes and DLB is stronger for those genes that are underlined than not 
underlined.
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of affected and control patients are scarce for DLB. Furthermore, very few functional and 
replication studies have been performed in DLB.
Future research
To increase our understanding of the role of genetics in DLB, we believe that future 
genetic studies should focus on the optimization of conventional research methods, on the 
implementation of next generation sequencing technologies, and on the combination of 
different research modalities.
Optimization of conventional genetic research methods
Ideally, future genetic studies should focus on DLB patients with both a clinical and 
pathological diagnosis of DLB, while taking the amount of coincidental pathological 
findings (especially AD pathology) into account. For this, multicenter studies are essential 
to ensure substantial patient numbers. A systematic analysis of genes previously associated 
with neurodegenerative diseases in a large group of these patients can lead to a better 
understanding of the role of these genes in DLB. Another interesting, but biased, approach 
is to select genes that play a role in pathways related to PD and AD. In addition to single 
nucleotide variants, structural variants, such as copy-number variants and inversions, must 
also be taken into account.85 However, to find new genetic determinants, unbiased research 
is necessary. Unbiased linkage studies may in general be a powerful tool in the search for 
new disease-causing defects, but these are not feasible for the identification of new genetic 
determinants in DLB given the rarity and often small size of DLB-families. GWA studies 
may be a source of unbiased information about new loci containing common variants with 
small to moderate effect sizes. Yet, functional and replication studies are still necessary when 
resolving the role of genetic defects with unclear pathogenicity in DLB.
Next generation sequencing
Whole exome or genome sequencing studies which provide the opportunity to screen 
simultaneously for genetic variants in the entire exome or genome37,38, have not yet been 
reported for DLB. Applying these techniques in homogeneous, well-phenotyped groups, 
such as families, patients with a similar disease course or identical amount of (coincidental) 
pathology, may increase the chances of finding new genetic variants for DLB. Whole exome 
and genome sequencing may especially help in the identification of genetic variants with a 
low frequency and intermediate effect size that are hard to detect with conventional research 
techniques.37
Multimodal approach
Applying combinations of different research modalities, such as genomics, 
transcriptomics and proteomics, may further increase the chance of finding new 
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genetic determinants for DLB. A challenge when using these techniques is the selection of 
the variable of interest from a large amount of data. However, combining these techniques 
can reduce the number of potential disease-associated genetic variants. The application of 
whole exome sequencing in combination with proteomic research has been successful in 
identifying new genetic variants in several diseases.86,87 For example, Wong et al., 201586 
reported a rare autosomal dominant neurodegenerative disorder comprising of parkinsonism 
and dementia in a large family, and found the causal mutation in protein kinase cAMP-
dependent type I regulatory subunit beta (PRKAR1B) by combining linkage analysis, whole 
exome sequencing, and proteomics.
 Currently, four proteomic studies88-91 and one transcriptomic study92 have been performed 
in DLB patients (Supplementary Table 2). The results have not directly led to a reduction in 
the number of potential disease-associated genetic variants, as the proteomic profile found in 
these studies varies substantially because of the use of different inclusion criteria, research 
techniques, and different specimens (e.g. blood versus brain tissue) at different stages of the 
disease.
 In future, multimodal research, the combination of unbiased genomic analysis and 
proteomics may prove particularly valuable for researching diseases like DLB, in which 
easily discernable and large pathological inclusions may provide a large amount of material 
for proteomic analyses.
Conclusion
To date, rare variants in GBA and the APOE ε4 allele are the strongest known risk factors for 
DLB. Defects in other genes have also been found in DLB patients. However, the risk profile 
of many of these defects has yet to be determined. Most of the genes associated with DLB 
overlap with genes associated with PD and AD, which suggests common neurobiological 
mechanisms for these diseases. However, because of the different phenotypes, other genetic 
and non-genetic factors may also play a role. Because no large unbiased genetic studies 
have been performed, it is likely that multiple DLB-specific determinants still have to 
be identified. The combination of different research modalities, such as next generation 
sequencing and proteomics may help in the identification of these determinants. The search 
for DLB-specific genetic determinants is important as it will give us a better understanding of 
the pathophysiology of DLB and its relation with PD and AD. This in turn could ultimately 
lead to the development of disease modifying treatments.
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Abstract
It is currently unknown whether patients with dementia with Lewy bodies (DLB) with 
relatives with dementia or Parkinson’s disease (PD) (familial DLB patients) have a different 
phenotype than sporadic DLB patients. In this study, we aimed to examine disease onset, 
rate of cognitive decline, survival and Alzheimer’s disease (AD) biomarkers in patients with 
familial DLB (n=154) and sporadic DLB (n=137), using linear mixed model analysis and Cox 
regression analysis, among others. Familial patients had a shorter survival (8.0 years) and 
more often elevated CSF AD biomarkers (47%) than sporadic patients (9.0 years; p=<0.001; 
30%, p=0.037). Our findings suggest that genetic factors are important in DLB and that the 
identification of new genetic factors will probably improve the prediction of prognosis.
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Introduction
Dementia with Lewy bodies (DLB) is one of the most common forms of degenerative 
dementia in the older population.1 DLB is diagnosed when dementia is accompanied by at 
least two of the following four core clinical features: parkinsonism, visual hallucinations, 
fluctuating cognition, and rapid eye movement (REM)-sleep behavior disorders (RBD). DLB 
can also be diagnosed based on dementia with one core clinical feature, in the presence 
of reduced dopamine transporter uptake in the basal ganglia, abnormal 123iodine-MIBG 
myocardial scintigraphy, or polysomnographic confirmation of RBD.2 Symptoms of DLB 
are not specific to the disease, but overlap with clinical features of Parkinson’s disease (PD), 
PD dementia (PDD) and Alzheimer’s disease (AD).1 The distinction between DLB and 
PDD is most challenging, and based on differences in time between onset of dementia and 
parkinsonism. In PDD, dementia occurs in the context of well-established PD as opposed 
to DLB, in which dementia occurs before or concurrently with parkinsonism.2 In addition, 
pathological and genetic features are also shared between DLB, PD(D) and AD.1,3,4 For 
example, Lewy bodies containing the α-synuclein protein are the pathological hallmark 
of DLB, but are also observed in PD(D)1, and genetic factors, such as the APOE ε4 allele 
and GBA variants, are risk factors for DLB as well as for AD and PD(D), respectively3,4. 
However, genetic risk factors for AD and PD seem to explain a part of the total phenotypic 
variance in DLB only.5-7 
 Recent studies have indicated that genetic factors play an important role in DLB. The 
heritable component of DLB has even been estimated at 60%.7 Families with multiple 
DLB patients have rarely been described.3,8 However, it has been reported that siblings of 
DLB patients are at higher risk of developing DLB compared to siblings of AD patients.9 
Furthermore, DLB patients more often have a family history of PD or dementia than 
controls.10,11 This finding supports the notion that DLB, PD and dementia share, at least 
partially, the same genetic factors. This in turn might lead to shared molecular pathways and 
possibly similar phenotypes.
 The APOE ε4 allele has been associated with a shorter survival in DLB12-14 and disease-
associated genetic variants in GBA have been associated with an earlier age of onset and 
death in DLB15-17. However, it is currently unknown whether DLB patients with relatives 
with dementia or PD (familial DLB) have a different phenotype than sporadic DLB patients. 
The main aim of this study is to examine the role of family history, used as a proxy of genetic 
factors, in relation to disease onset, rate of cognitive decline, survival and AD biomarkers. 
The secondary aim of this study is to explore the aforementioned features in DLB patients 
with relatives with dementia or PD to examine if their phenotype is more similar to AD or 
PD. 
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Materials and methods
Patients and study design
This is a retrospective study in which demographic and clinical data were collected from 
patients’ medical records. Information on the occurrence of dementia and/or PD in first-
degree relatives was based on medical records (41%) or a standardized assessment (59%), 
using a questionnaire or an additional patient/family member interview. A nation-wide 
registration system containing demographic data about all Dutch citizens was consulted to 
obtain information about dates of death (collected until December 2018). 
 A total of 291 patients with probable DLB according to the criteria of Mckeith et al. 
(2005)18 were enrolled from three hospitals in the Netherlands (Elisabeth-TweeSteden 
Hospital, Tilburg; Erasmus Medical Center, Rotterdam; Amsterdam University Medical 
Center, Amsterdam). Patients visited the outpatient clinics of the Neurology departments 
between 2000 and 2018 and were diagnosed by expert neurologists. Dopamine transporter 
uptake scans were performed in 128 patients, and were used in the diagnostic process. 
Familial patients were defined as patients with at least one first-degree relative with dementia 
or PD. Sporadic patients were defined as patients without first-degree relatives with dementia 
or PD. Patients were excluded from the study when no dementia or PD was diagnosed in 
relatives together with no information on the occurrence of the other disease in relatives (e.g. 
no relatives with PD and no information of the occurrence of dementia, or vice versa), and 
when no information on family history was available at all. The distribution of the different 
groups according to family history is depicted in Supplementary Figure 1. 
 The study was performed according to the ethical principles of the Declaration of 
Helsinki and was approved by the local ethics committees (Elisabeth-TweeSteden Hospital: 
MEC-2016-608, L0318.2016; Erasmus Medical Center: MEC-2015-304, MEC-2016-608; 
Amsterdam University Medical Center: MEC-2016-061, MEC-2017-2116). 
Outcome measures
Several clinical features and AD biomarkers (i.e. the presence of medial temporal lobe atrophy 
(MTA)19, a CSF tau/amyloid-β1-42 (Aβ1-42) ratio of >0.5220 and ≥1 APOE ε4 allele(s)21), were 
explored with respect to family history in DLB.
 Age of onset and type of first symptom were based on anamnestic information from the 
patient or family members. We categorized the type of first symptom into cognitive decline, 
parkinsonism and hallucinations. Cognitive decline included descriptions of memory 
impairment and executive function impairment. Parkinsonism was based on bradykinesia 
with muscular rigidity, rest tremor or postural instability22 or when parkinsonism was noted 
in the medical files in absence of more specific information. Rate of cognitive decline was 
based on the available Mini-Mental State Examination (MMSE) scores23. Survival was 
defined as the time between age of onset and death. Magnetic resonance imaging (MRI) 
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scans were evaluated visually and rated according to the MTA scale19 by radiologists for 
clinical purposes. CSF was collected by lumbar puncture in polypropylene tubes (Starstedt, 
Nümbrecht, Germany). Levels of Aβ1-42, total tau and p-tau were measured with commercially 
ELISAs (Innotest®, Fujirebio, Gent, Belgium). APOE genotyping was performed using 
the LightCycler APOE mutation detection method (Roche Diagnostics GmbH, Mannheim, 
Germany) after genomic DNA extraction.
Data analysis
Differences in sex, age of onset, type of first symptom and APOE genotype between familial 
and sporadic DLB were explored using the χ2 test, Fisher’s Exact Test, Fisher-Freeman-Halton 
test, independent Student t test or Mann-Whitney U test, where appropriate. We analyzed the 
MTA score and CSF tau/Aβ1-42 ratio of >0.52 (CSF AD biomarkers) between the groups using 
linear and logistic regression, respectively, with time between age of onset and date of MRI 
or lumbar puncture as covariate to correct for possible confounding by disease stage. Linear 
mixed model analysis were performed to assess changes in MMSE levels over time, while 
accounting for the correlation between the repeated measurements of each patient. The model 
included time since first MMSE, family history and an interaction effect between time and 
family history to assess differences in the course of cognitive decline between groups. All 
MMSEs which were administered within 6 months from the previous MMSE were removed, 
because of possible learning effects. In the random effect structure, covariance type was 
set on unstructured and a random intercept was included. Differences in survival between 
familial and sporadic DLB were explored using Kaplan-Meier analysis and Cox regression 
analysis. We included sex, age of onset and study center to correct for possible confounding 
Figure 1: Survival distribution (Kaplan-Meier curve) of DLB patients with a negative family history 
as compared to DLB patients with a positive family history.
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in the linear mixed model analysis and the Cox regression analysis.
 In addition, differences in phenotype between DLB patients with a family history of 
either dementia or PD were explored. Statistical analyses were performed as described above.
 Statistical significance for all tests was established at p<0.05 (two-tailed). The data was 
analyzed using SPSS software (Version 24).
Results
Differences in phenotype between patients with familial and sporadic DLB
The 154 familial DLB patients and the 137 sporadic DLB patients did not differ in sex, age 
of onset, type of first symptom (Table 1) or rate of cognitive decline (Table 2). Significantly 
more familial DLB patients had elevated CSF biomarkers for AD (47%), compared to those 
with sporadic DLB (30%, p=0.039). This finding remained significant after correction for 
time between age of onset and date of lumbar puncture (p=0.037, Table 1). In addition, a 
borderline significant result was found concerning the APOE ε4 allele, with a higher frequency 
of this allele in familial patients (65%) compared to sporadic patients (51%, p=0.069). MTA 
score was not different between the groups (Table 1).
Differences in survival between patients with familial and sporadic DLB
A total of 154 patients (53.1%) were deceased with a median survival of 7.0 years (IQR 
5.0–9.0). Uncorrected survival analysis showed that patients with familial DLB had a 
significantly shorter survival (median 8.0 years, SE 0.51) compared to patients with sporadic 
DLB (median 9.0 years, SE 0.63, p=<0.001, Table 2 and Figure 1). This finding remained 
significant after correction for sex, age of onset and study center (HR 1.64, 95% CI: 1.16-
2.31, p=0.005, Table 2).  
Differences in phenotype between DLB patients with a family history of either dementia 
or PD
A total of 84 patients had a family history of either dementia (n=69) or PD (n=15) 
(Supplementary Figure 1). Parkinsonism was more prevalent as first symptom in DLB 
patients with a family history of PD (33%) compared to the patients with a family history 
of dementia (6%, p=0.008). These groups did not differ in sex, age of onset (Supplementary 
Table 1) or rate of cognitive decline (Supplementary Table 2).
 In addition, there were no significant differences in the presence of the APOE ε4 allele, 
CSF AD biomarkers and MTA score between the groups (Supplementary Table 1).
Differences in survival between DLB patients with a family history of either dementia or 
PD
A total of 43 patients (51.2%) were deceased with a median survival of 8.0 years (IQR 
5.0–10.0). There were no differences in survival between DLB patients with relatives with 
dementia as compared to DLB patients with relatives with PD (Supplementary Table 2). 
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Table 2: Statistical models regarding rate of cognitive decline and survival in the total study group.
Rate of cognitive decline β SE 95% CI p value
Uncorrected
(Linear mixed model analysis)
Baseline -0.47 0.59 -1.63-0.70 0.43
Change over time -0.0090 0.017 -0.041-0.024 0.59
With correction for sex, age of onset, 
and study center
(Linear mixed model analysis)
Baseline -0.34 0.59 -1.50-0.81 0.56
Change over time -0.0091 0.016 -0.042-0.023 0.59
Survival Mediana SE 95% CI p value
Uncorrected
(Kaplan-Meier analysis)
Sporadic DLB 9.0 0.63 7.77-10.23
<0.001*
 Familial DLB 8.0 0.51 7.00-9.00
B SE HR 95% CI p value Z-score
With correction for sex, age of onset, 
and study center 
(Cox regression analysis)
0.50 0.18 1.64 1.16-2.31 0.005* 5.71
aTime between age of onset and death,* p<0.05.
Table 1: Demographic features, clinical features and biomarkers in the total study group, and group 
differences.
Total (n=291) Familial DLB 
(n=154)
Sporadic DLB 
(n=137)
p value
Study center
Elisabeth-TweeSteden Hospital
Erasmus Medical Center
Amsterdam University Medical Center
35 (12%)
54 (19%)
202 (69%)
24 (16%)
20 (13%)
110 (71%)
11 (8%)
34 (25%)
92 (67%)
0.011*
Sex, male 232 (80%) 122 (79%) 110 (80%) 0.82
Age of onset, years 66.0 (7.6) 66.6 (8.4) 65.3 (6.7) 0.14
First symptom
Cognitive decline
Parkinsonism
Hallucinations
245 (84%)
29 (10%)
17 (6%)
133 (86%)
14 (9%)
7 (5%)
112 (82%)
15 (11%)
10 (7%)
0.28
0.60
0.32
MTA score (average of right and left) (n=199[98;101]) 1 (0.5-1.5) 1 (0.5-1.5) 1 (0-1.1) 0.10a
CSF tau/Aβ1-42 ratio >0.52 (n=169[83;86]) 65 (38%) 40 (47%) 25 (30%) 0.037a*
APOE ε4 carrier (n=160[76;84]) 94 (59%) 55 (65%) 39 (51%) 0.069
Values are presented as mean (SD), median (IQR) or n (%). DLB: dementia with Lewy bodies, PD: Parkinson’s 
disease, CSF:cerebrospinal fluid, MTA: medial temporal lobe atrophy, Aβ1-42: amyloid-β1-42,a corrected for time 
between age of onset and date of MRI or date of lumbar puncture, * p<0.05.
Discussion
The main finding of this study is that patients with familial DLB have a shorter survival than 
patients with sporadic DLB. We also found a higher percentage of familial DLB patients 
with elevated AD biomarkers in their CSF compared to sporadic DLB patients. Several 
longitudinal studies in DLB showed that concomitant AD pathology is associated with a 
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higher mortality.24-26 The shorter survival in familial DLB compared to sporadic DLB may be 
due to concomitant AD pathology in familial DLB, which is reflected in a higher CSF tau/
Aβ1-42 ratio in familial patients compared to sporadic patients. Genetic factors, such as the 
APOE ε4 allele, contribute to the presence of concomitant AD pathology.25,27 Interestingly, 
although only borderline statistically significant, a higher frequency of the APOE ε4 allele in 
familial patients compared to sporadic patients was seen. This suggests that genetic factors 
are associated with survival, possibly by influencing neuropathology. 
 Previous studies have shown several possible risk factors for a shorter survival in 
DLB, such as a the presence of a fluctuating cognition, hallucinations at onset and a low 
MMSE score.14,26 Other variables have also been reported to be associated with survival, 
but are contradictory between different studies (e.g female and male sex, early and late age 
of onset).14,26 There were no significant differences in these clinical characteristics between 
familial and sporadic DLB patients in our study (data not shown for a fluctuating cognition and 
MMSE score). This might indicate that family history has an effect on survival independent 
of these clinical characteristics. 
 In addition, we found parkinsonism to be a more frequent presenting symptom in 
patients with a positive family history of PD than in patients with a positive family history 
of dementia. This might be based on more ‘pure’ Lewy pathology in patients with relatives 
with PD, and mixed pathology (Lewy pathology and AD pathology) in patients with relatives 
with dementia. However, this finding could also be based on recall bias due to familiarity 
with PD symptoms. Other AD or PD features were equally distributed between patients with 
a positive family history of dementia or PD, respectively. These results should be interpreted 
with caution due to the relative small number of patients in the group with relatives with PD 
and the presence of non-AD dementias in the group with relatives with dementia. 
 About half of the DLB patients in this study had at least one first-degree relative with 
dementia or PD. This is in line with previous studies, in which a positive family history 
for dementia was observed in 39-44% and for PD in 10-24% of patients with DLB.10,11 
Nonetheless, the percentages that we found could be an overestimation as patients with 
insufficient information on family history were not taken into account. These patients might 
be less likely to have relatives with relevant diseases. However, the most important limitation 
of this study is its retrospective character. Furthermore, information on family history and 
disease onset was based on anamnestic information, and may have introduced a recall bias. In 
addition, the patients in this study were predominantly male (80%), which may not be a good 
representation of the general DLB population.28 However, our main finding (familial DLB 
patients have a shorter survival than sporadic DLB patients) stayed significant after correction 
for sex. At last, the DLB diagnoses in this study were not pathologically confirmed. 
 Strengths of this study include its large sample size and the enrollment of patients 
from university medical centers as well as from a general hospital. The latter increases the 
generalizability of our findings.
 In conclusion, we are the first to report that DLB patients with a positive family history 
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of dementia or PD have a shorter survival than DLB patients with a negative family history 
of these diseases. This suggests that genetic factors contribute to disease course, possibly by 
influencing the amount of concomitant AD pathology, which is supported by our data. Future 
studies are necessary to identify which genetic and other contributing factors are accountable 
for our findings. This knowledge will lead to a better understanding of the pathophysiology 
of the disease and the overlap with AD and PD(D), and will probably improve the prediction 
of prognosis. 
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Supplementary Figure 1: Distribution of different groups according to family history. 
Family members with PDD were assigned to the subcategory ‘Family history of dementia & PD’, 
and family members with DLB were assigned to the subcategory ‘Family history of dementia’. DLB: 
dementia with Lewy bodies, PD: Parkinson’s disease, PDD: Parkinson’s disease dementia.
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Supplementary Information
Supplementary Table 1: Differences in demographic features, clinical features and biomarkers 
between DLB patients with either a family history of dementia or a family history of PD.
Family history of 
dementia only
(n=69)
Family history of 
PD only
(n=15)
p value
Study center
Elisabeth-TweeSteden Hospital
Erasmus Medical Center
Amsterdam University Medical Center
11 (16%)
7 (10%)
51 (74%)
3 (20%)
2 (13%)
10 (67%)
0.72
Sex, male 55 (80%) 13 (87%) 0.73
Age of onset, years 64.6 (8.0) 64.5 (8.7) 0.99
First symptom
Cognitive decline
Parkinsonism
Hallucinations
60 (87%)
4 (6%)
5 (7%)
10 (67%)
5 (33%)
0 (0%)
0.12
0.008*
0.58
MTA score (average of right and left) (n=51;9) 1 (0.5-1.5) 1 (0-1.3) 0.24a
CSF tau/Aβ1-42 ratio >0.52 (n=43;6) 22 (51%) 1(17%) 0.13a
APOE ε4 carrier (n=43;6) 28 (65%) 4 (67%) 1.00
Data are presented as mean (SD), median (IQR) or n (%). DLB: dementia with Lewy bodies, PD: Parkinson’s 
disease, CSF: cerebrospinal fluid, MTA: medial temporal lobe atrophy, Aβ1-42: amyloid-β1-42, a corrected for time 
between age of onset and date of MRI or date of lumbar puncture, * p<0.05.
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Supplementary Table 2: Statistical models regarding rate of cognitive decline and survival in the 
group of DLB patients with either a family history of dementia or a family history of PD.
Rate of cognitive decline β SE 95% CI p value
Uncorrected Baseline 0.67 1.51 -2.33-3.66 0.66
(Lineair mixed model analysis) Change over time -0.022 0.045 -0.11-0.067 0.62
With correction for sex, age of 
onset, and study center  
(Linear mixed model analysis)
Baseline 0.34 1.50 -2.63-3.31 0.82
Change over time -0.015 0.045 -0.10-0.074 0.73
Survival Mediana SE 95% CI p value
Uncorrected
(Kaplan-Meier analysis)
Family history of 
dementia only
10.0 0.65 8.72-11.28
0.97
xx
Family history of 
PD only
10.0 1.98 6.12-13.88 xx
B SE HR 95% CI p value Z-score
With correction for sex, age of 
onset, and study center
(Cox regression analysis)
0.20 0.46 1.23 0.50-3.03 0.66 2.17
a Time between age of onset and death, * p<0.05.
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Abstract
Introduction
The genetic architecture of dementia with Lewy bodies (DLB) is poorly understood, but 
overlaps with Parkinson’s disease (PD) and Alzheimer’s disease (AD). Here, we performed 
a comprehensive analysis of genes known to be involved in PD or AD in a series of familial 
DLB patients, to gain more insight into their involvement in DLB.
Methods
We included twenty clinically diagnosed DLB patients with a positive family history. 
Neuropathological confirmation was available in 55% of the patients. By whole exome 
sequencing, we investigated variants in all the genes known to be involved in PD and AD. 
Copy number variants in selected genes, the C9orf72 repeat expansion and the APOE risk 
allele were also investigated. Last, genotype-phenotype correlations of GBA variants and the 
APOE ε4 allele were explored.
Results
We identified five GBA variants (p.D140H, p.E326K, p.T369M, p.N370S, and p.R463C) in 
35% of our patients. Furthermore, 20% of the patients carried a rare variant with unknown 
significance in LRRK2, PARK2, ABCA7 or SORL1. The APOE ε4 allele frequency was 38%. 
Conclusion
GBA variants and the APOE ε4 allele were frequently found. This confirms the importance of 
these two genes in DLB and the genetic overlap between DLB, PD and AD. Future genetic 
stratification may help to predict disease course and to select patients for disease-modifying 
clinical trials. 
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Introduction
Dementia with Lewy bodies (DLB) is one of the most prevalent types of dementia1 and is 
characterized by cognitive decline in combination with parkinsonism, visual hallucinations, 
cognitive fluctuations, and REM-sleep behavior disorders2,3. 
 Although its heritable component has been estimated to be 36% in a recent cohort of 1743 
DLB patients4, only few large association or exome sequencing studies have been reported4-9. 
These studies have shown that specific variants in glucocerebrosidase (GBA) and the 
apolipoprotein E (APOE) risk allele, which have previously been associated with Parkinson’s 
disease (PD)10 and Alzheimer’s disease (AD) respectively11,12, are also prominent risk factors 
for DLB. Moreover, variants in genes previously associated with PD, such as α-synuclein 
(SNCA) and leucine-rich repeat kinase 2 (LRRK2), or in genes previously associated with 
AD, such as presenilin 1 (PSEN1), presenilin 2 (PSEN2) and amyloid precursor protein 
(APP), have been identified in some patients with DLB by family studies.13 However, large 
families with multiple DLB patients are rarely reported, and genetic research has mainly been 
conducted in families with different phenotypes ranging within the DLB-PD-AD spectrum. 
Studies based on highly-selected series of pathologically-confirmed familial DLB patients, 
might facilitate the identification of novel genetic variants involved in the disease etiology.13
 In this study, we aimed to further elucidate the genetic underpinnings of DLB and its 
overlap with PD and AD by studying a series of familial DLB patients. 
Materials and Methods
Participants
Two groups of patients with clinically and/or pathologically diagnosed DLB and a positive 
family history (at least one first- or second-degree relative with DLB, PD or dementia) were 
studied.
 The first group includes all patients (n=10) who visited the outpatient clinic of the 
Erasmus Medical Center in Rotterdam or the VU University Medical Center in Amsterdam 
between 2015 and 2017, who received a clinical diagnosis of probable DLB2, and also had 
at least one first-degree relative affected with DLB, PD or dementia available for genetic 
studies. Pathological confirmation of the disease was available in one index patient. When 
possible, affected and non-affected relatives were also included in the study.
 The second group includes all patients (n=10) from the Netherlands Brain Bank (NBB), 
who donated their brain between 1999 and 2013, had pathologically confirmed DLB (Braak 
α-synuclein stage: >414; Braak neurofibrillary tangle stage: <415), a retrospective clinical 
diagnosis of probable DLB2 and a positive family history. Nine of these patients had at least 
one first-degree relative affected with DLB, PD or dementia, whereas one patient had one 
second-degree affected relative.
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 Clinical features were collected and genetic analyses were performed in all the 20 index 
patients. When possible, co-segregation studies were also carried out.
 This study was approved by the relevant Medical Ethical Authorities, and all patients 
or their legal representative signed informed consent for use of clinical records, DNA, and 
pathological data for research purposes.
Sample preparation, exome capture and exome sequencing
Genomic DNA was isolated from blood in group 1 and from blood or cerebellar tissue in 
group 2 using standard methods. Whole exome sequencing (WES) was performed using 
the Nimblegen SeqCap EZ Exome v.2.0 44Mb kit (Roche Nimblegen, Inc., Madison, WI) 
on a HiSeq2000 sequencer (paired-end 2x100). Reads were aligned to the human reference 
genome (hg19) using the Burrows-Wheeler alignment16  tool and processed using Picard 
(http://broadinstitute.github.io/picard) and the Genome Analysis Toolkit (GATK)17 following 
standard procedures18. Single nucleotide variations were determined using GATKs Haplotype 
Caller and annotated using ANNOVAR19.
Filtering 
Non-synonymous, stop-gain or stop-loss variants in exons, and variants near splice sites 
in genes with a well-established involvement in PD or AD were extracted from the WES 
data (Supplementary Table 1). Subsequently, variants were selected based on a minor allele 
frequency (MAF) of <1% in the ExAC-NFE (Exome Aggregation Consortium-Non Finnish 
Europeans) database and the GoNL (Genome of the Netherlands) database. For GBA, variants 
were followed up regardless the allele frequency reported in public databases to include both 
rare and common variants.
Sanger sequencing
Variants that fulfilled our filtering criteria were validated by Sanger sequencing (Supplementary 
Text; Supplementary Table 2). Exons and exon-intron boundaries with low coverage (<10 
reads) in the WES analysis were also Sanger sequenced to exclude false-negative calls.
 Both DNA strands were directly sequenced using the Big Dye Terminator chemistry 
ver.3.1 (Applied Biosystems) on an ABI3130/ABI3730 genetic analyzer (Applied Biosystems, 
Foster City, CA, USA). Subsequent analysis was performed with SeqScape (ver.2.6). 
Copy number analysis
Multiplex Ligation-dependent Probe Amplification (MLPA) was performed to analyze copy 
dosage of SNCA, PARK2, PARK7, PINK1 and APP. The P051-D1 Parkinson and P170-C2 
APP MLPA kits (MRC Holland) were used according to the manufacturer’s protocol. 
Subsequent analysis was performed on an ABI3130/ABI3730 genetic analyzer (Applied 
Biosystems, Foster City, CA, USA). The MLPA data were analyzed using GeneMarker 
Ver.2.4.0 (SoftGenetics, State College, PA, USA). 
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C9orf72 repeat expansion analysis
A previously described repeat-primed PCR assay20 was used to screen for the presence of a 
pathogenic chromosome 9p21 GGGGCC hexanucleotide repeat expansion. Fragment length 
analysis was performed on an ABI3130 genetic analyzer (Applied Biosystems, Foster City, 
CA, USA). Subsequent data were analyzed using GeneMarker Ver.2.4.0 (SoftGenetics, State 
College, PA, USA). A pathogenic C9orf72 expansion was defined as more than 30 repeats.20 
Positive controls were included in this analysis.
Table 1: Demographic, clinical and pathological features.
Total
(n=20)
Group 1
 (n=10)
Group 2
 (n=10)
Probable DLB
Sex, male
Age of onset, years
20 (100%)
15 (75%)
66.5 (8.6)
10 (100%)
8 (80%)
64.4 (8.5)
10 (100%)
7 (70%)
68.6 (8.6)
First symptom
Parkinsonism
Cognition
Hallucinations
Parkinsonism during disease course
Disease durationa, years (n=2;10)
Deceased
9 (45%)
10 (50%)
1 (5%)
18 (90%)
5.8 (2.9)
12 (60%)
2 (20%)
8 (80%)
0 (0%)
8 (80%)
5.5 (4.9)
2 (20%)
7 (70%)
2 (20%)
1 (10%)
10 (100%)
5.8 (2.8)
10 (100%)
Family history 
DLB
PD/PDD
AD/dementia
Combination
3 (15%)
3 (15%)
9 (45%)
5 (25%)
0 (0%)
3 (30%)
2 (20%)
5 (50%)
3 (30%)
0 (0%)
7 (70%)
0 (0%)
Autopsied 11 (55%) 1 (10%) 10 (100%)
Braak α-synuclein stage
5
6
2 (18% b)
9 (82% b)
1 (100% b)
0 (0% b)
1 (10%)
9 (90%)
Braak neurofibrillary tangle stage
1
2
3
4
2 (18% b)
3 (27% b)
5 (45% b)
1 (9% b)
0 (0% b)
0 (0% b)
1 (100% b)
0 (0% b)
2 (20%)
3 (30%)
4 (40%)
1 (10%)
CERAD 
O
A
B
C
2 (18% b)
2 (18% b)
4 (36% b)
3 (27% b)
0 (0% b)
0 (0% b)
1 (100% b)
0 (0% b)
2 (20%)
2 (20%)
3 (30%)
3 (30%)
Thal phase 
0
1
2
3
4
1 (9% b)
1 (9% b)
1 (9% b)
5 (45% b)
3 (27% b)
0 (0% b)
1 (100% b)
0 (0% b)
0 (0% b)
0 (0% b)
1 (10%)
0 (0%)
1 (10%)
5 (50%)
3 (30%)
Data are presented as mean (SD) or n (%). a first symptom until death. b in percentage of patients who were au-
topsied. CERAD: Consortium to Establish a Registry for Alzheimer’s Disease, DLB: dementia with Lewy bodies, 
PD: Parkinson’s disease, PDD: Parkinson’s disease dementia, AD: Alzheimer’s disease.
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APOE ε risk allele analysis
Genotypes for allelic variants rs7412 and rs429358 were determined using Taqman Allelic 
Discrimination (Supplementary Text). Signals were read with the Taqman 7900HT (Applied 
Biosystems Inc.) and analyzed using sequence detection system 2.3 software (Applied 
Biosystems Inc.).
Statistical analysis
Differences in demographic and clinical features between genetic variant carriers and non-
carriers were analysed with the independent Student’s t-test, χ2-test or Fisher’s Exact Test 
where appropriate. Statistical analyses were performed in IBM SPSS Statistics 21.0 for 
Windows (SPSS Inc., IL, USA). P values of <0.05 were considered statistically significant. 
Results
Patient features
Table 1 shows the demographic, clinical and pathological features of the patients. The mean 
age at disease onset of the total group (75% male) was 66.5 ± 8.6 years. The mean disease 
duration was 5.8 ± 2.9 years. Fifteen percent of the patients had relatives with DLB, 15% 
relatives with PD or PD dementia (PDD), 45% relatives with dementia including AD, and 
25% relatives with a combination of the previously mentioned diseases. All patients that 
were autopsied (n=11) had a Braak α-synuclein stage14 of ≥5 and a Braak neurofibrillary 
tangle stage15 of ≤4. CERAD21 was B or C in 64% of the patients and Thal phase21 was ≥3 in 
73% of the patients. 
Genes associated with PD
Seven heterozygous variants in three genes associated with PD (GBA, LRRK2 and PARK2) 
were identified in 45% (9/20) of patients (Table 2; Figure 1). 
Glucocerebrosidase
GBA heterozygous variants were observed in seven of the 20 patients (35%). Two patients 
carried a single rare variant (p.N370S or p.R463C), three patients carried a rare variant 
(p.D140H) in combination with a more common variant (p.E326K), and two patients carried 
a single, more common variant (p.E326K or p.T369M). The observed rare variants cause 
Gaucher disease (in homozygous or compound heterozygous state) and act as confirmed PD 
risk factors (in single heterozygous state). The more common variants do not cause Gaucher 
disease (in homozygous or compound heterozygous state), but still act as a mild risk factors 
for PD (in single heterozygous state)22, 23 (Table 2).
 Co-segregation analysis was possible for three DLB patients from group 1. In family 1, 
the proband (II-1) carried both the p.D140H and p.E326K variant, whereas his half-brother 
with DLB (II-3) carried the p.E326K variant only. In family 2, both the proband (III-2) and 
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her sister with DLB (III-3) carried these two variants, but not the father with DLB (II-3). In 
family 3, the proband (III-1) and his mother with PDD (II-3) carried the p.R463C variant, 
which was absent in his unaffected uncle (II-1) (Figure 1).
Other genes associated with PD
In two patients we detected single rare variants with unknown significance in LRRK2 
(p.R1957L) and in PARK2 (p.A82E).
 The proband of family 4 (II-3) carried the LRRK2 p.R1957L variant, which was absent 
in his brother with PD (II-1) (Figure 1). The MAF of this variant is 0.01% in the GnomAD 
(Genome Aggregation Database (non-Finnish Europeans)), whereas it is absent in GoNL. 
It is predicted to be possibly pathogenic by M-CAP and by four out of nine other in-silico 
programs (Table 2; Supplementary Table 3).
 The proband of family 5 (III-1) carried a heterozygous PARK2 p.A82E variant, which 
was absent in his sister with dementia (III-2) (Figure 1). The MAF of this variant is 0.35% 
in the GnomAD and is predicted to be benign in nearly all in-silico programs (Table 2; 
Supplementary Table 3). 
 No dosage abnormalities in SNCA, PARK2, PARK7 or PINK1 were found by MLPA 
Figure 1: Pedigrees of patients with genetic variants identified.
A circle represents a female patient; a square represents a male patient; a diamond represents a patient 
with unknown sex; black symbols indicate patients affected by DLB; dark grey symbols indicate 
patients with PD or PDD and light grey symbols indicate patients with AD or unspecified dementia. 
V: variant, Ref: reference (wild type genotype), AAO: age at onset, DLB: dementia with Lewy bodies, 
PD: Parkinson’s disease, PDD: Parkinson’s disease dementia, AD: Alzheimer’s disease.
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Table 3: APOE ε allele frequencies.
APOE allele Total
(n=20)
Group 1
 (n=10)
Group 2
 (n=10)
ε2 0 (0%) 0 (0%) 0 (0%)
ε3 25 (63%) 15 (75%) 10 (50%)
ε4 15 (38%) 5 (25%) 10 (50%)
analysis. This analysis was not possible in one patient from the second group, because of low 
DNA quality.
Genes associated with AD
Two heterozygous variants in two genes associated with AD (ABCA7 and SORL1) were 
identified in 10% (2/20) of patients (Table 2; Figure 1). 
 The proband of family 6 (III-4) carried the ABCA7 p.A135T variant, which was absent 
in his unaffected sister (III-2) (Figure 1). This variant is not present in public databases, and 
is predicted to be possibly pathogenic by four out of nine in-silico programs.
 The p.S577P variant in SORL1 is found in one patient from group 2. This variant has a 
MAF of 0.004% in the GnomAD and is predicted to be pathogenic by half of the in-silico 
programs. 
 The allele frequency for APOE ε2, ε3 and ε4 were 0%, 63% and 38%, respectively 
(Table 3). Furthermore, no dosage abnormalities in APP and no pathogenic C9orf72 repeat 
expansions were found. The MLPA analysis was not possible in one patient from the second 
group, because of low DNA quality. Supplementary Table 4 shows an overview of the 
pathological findings in the genetic variant carriers.
Figure 2: Gene structures.
Locations of the variants found in this study are indicated. Genes are displayed with 5’to 3’orientation 
and the number of exons is displayed. Transcript references: NM_001005742 (GBA), NM_198578 
(LRRK2), NM_004562 (PARK2), NM_019112 (ABCA7) and NM_003105 (SORL1).
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Table 4: Demographic and clinical features in GBA variant carriers and non-carriers and APOE ε4 
allele carriers versus non-carriers.
GBA variant 
carriers 
(GBA+)
(n=7)
Non GBA 
variant 
carriers
(GBA-)
 (n=13)
p value APOE 
ε4 allele 
carriers 
(APOE ε4+)
(n=13)
Non APOE 
ε4 allele 
carriers 
(APOE ε4-)
 (n=7)
p value
Sex, male 5 (71%) 10 (77%) 1.0 10 (77%) 5 (71%) 1.0
Age of onset, years 61.4 (9.6) 69.2 (6.9) 0.05* 68.8 (8.1) 62.3 (8.3) 0.11
First symptom 0.77 1.0
Parkinsonism 4 (57%) 5 (38%) 6 (46%) 3 (43%)
Cognition 3 (43%) 7 (54%) 6 (46%) 4 (57%)
Hallucination 0 (0%) 1 (8%) 1 (8%) 0 (0%)
Parkinsonism during disease course 7 (100%) 11 (85%) 0.52 11 (85%) 7 (100%) 0.52
Disease durationa, years (n=4;8|12;2) 8.5 (2.1) 4.4 (2.3) 0.01* 4.9 (2.3) 10.0 (1.4) 0.02*
Family historyb (n=4;8|8;3) 0.15 0.006*
PD/PDD 2 (67%) 1 (13%) 0 (0%) 3 (100%)
AD/dementia 1 (33%) 7 (87%) 8 (100%) 0 (0%)
Data are presented as mean (SD) or n (%). a first symptom until death. b only first-degree relatives, a family history 
of both PD/PDD and AD/dementia were not taken into account.* Statistically different between groups. PD: Parkin-
son’s disease, PDD: Parkinson’s disease dementia, AD: Alzheimer’s disease.
Genotype-phenotype correlations
Demographic and clinical features in GBA variant carriers (GBA+) and non-carriers (GBA-), 
and APOE ε4 allele carriers (APOE ε4+) and non-carriers (APOE ε4-) are displayed in Table 
4. Given the small number of patients, we consider the following results as exploratory. In 
the GBA+ group, age of onset was earlier and disease duration longer than in the GBA- group 
(61.4 ± 9.6 years vs 69.2 ± 6.9 years, p value 0.05; 8.5 ± 2.1 years vs 4.4 ± 2.3 years, p value 
0.01).
 When stratifying on the presence of at least one APOE ε4 allele, disease duration was 
significantly shorter in the APOE ε4+ group than in the APOE ε4- group (4.9 ± 2.3 years 
vs 10.0 ± 1.4 years, p value 0.02). Furthermore, age of onset was significantly earlier in 
the GBA+ group compared to the APOE ε4+ group (58.5 ± 8.2 (n=4) vs 69.8 ± 7.2 (n=10), 
p value 0.03; patients with both a GBA variant and the APOE ε4 allele were excluded). 
 Interestingly, the APOE ε4+ group had significantly more often a family history of AD 
or dementia than with PD or PDD in contrast to the APOE ε4- group (family history AD/
dementia; PD/PDD: 100%; 0% vs 0%; 100%, p value 0.006). When comparing the type of 
family history between the GBA+ group and the APOE ε4+ group, a family history of PD 
or PDD was more often found in GBA+ patients and a family history of AD or dementia in 
APOE ε4+ patients (family history PD/PDD; AD/dementia: 100%; 0% (n=2) vs 0%; 100% 
(n=7), p value 0.03; patients with both a GBA variant and the APOE ε4 allele were excluded). 
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Supplementary Figure 1 gives a graphical overview of the first-degree relatives with DLB 
(in black), PD or PDD (in grey), and AD or dementia (in white) referred among the GBA+ 
(Figure 1a) and APOE ε4+ patients (Figure 1b).
Discussion
Rare and common GBA variants and the APOE ε4 allele were frequently observed in this 
cohort of familial DLB patients. Furthermore, rare variants with unknown significance were 
found in LRRK2, PARK2, ABCA7 and SORL1. This study provides further evidence that 
genes associated with PD and AD are also involved in the etio-pathogenesis of DLB, and 
suggests that genetic risk factors also influence disease course. 
 GBA variants have been associated with PD in several studies10, but they are also 
increasingly recognized as risk factors for DLB7. We found GBA variants in 35% of our 
cohort of familial patients. Twenty-five percent of our patients carried a rare PD-associated 
variant in GBA. GBA variant frequencies in DLB range between studies due to differences in 
population, diagnostic criteria and genetic analysis methods.13 The largest multicenter study 
published so far, reported a rare variant frequency of 7.5% in 721 clinically or pathologically 
diagnosed DLB patients and 0.97% in 1962 controls.7 The higher frequency of these rare 
GBA variants in our study could represent a higher load of genetic factors in our patients who 
were selected on the basis of a positive family history, and the proportion of pathologically 
confirmed patients with a low Braak neurofibrillary tangle stage (<4), which has been 
associated with higher GBA variant frequencies.24 The GBA variants observed in our study 
have all been previously associated with PD and DLB.7,10,22,24-26 PD and DLB-associated 
variants in GBA can be divided into mild and severe27, depending on the severity of the 
phenotype associated in Gaucher disease patients who carry these variants in homozygous 
state. A recent, large study of 1000 Ashkenazi-Jews with PD showed odds ratios for PD as 
different as 2.2 for mild variants (e.g. p.D140H and p.N370S) and 10.3 for severe variants 
(e.g. p.R463C). Furthermore, age of PD onset was significantly earlier in carriers of severe 
variants than those who carried mild variants.27 In our study, we found one severe variant 
(p.R463C) and two mild variants (p.D140H and p.N370S). The combination of the p.D140H 
and E326K variant was found in three of our patients. Interestingly, the p.D140H and E326K 
variant combination has, together with the p.R463C variant, been associated with an increased 
cognitive decline in PD patients.28 Further studies are necessary to determine if these variants 
are more frequently associated with DLB than PD. 
 The APOE ε4 allele is the most frequent, known risk factor for AD11,12, and it has 
repeatedly been associated with DLB4,8,9. In our cohort, the mean APOE ε4 allele frequency 
(38%) is comparable to that previously reported in DLB (approximately 30%).13,29-31
 We found several rare variants of unknown significance in LRRK2, PARK2, ABCA7 and 
SORL1. The LRRK2 p.R1957L variant is of interest, because it is extremely rare in public 
databases (MAF: <0.01%), is predicted to be pathogenic by half of the in-silico programs, 
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and is located in the kinase domain like the G2019S mutation, which is the most common 
genetic cause of PD.32
 Pathogenic repeat expansions in C9orf72 have been found in clinically and pathologically 
diagnosed AD patients33, but not in pathologically confirmed DLB patients34,35. Our results 
are in line with the above-mentioned studies, as no pathogenic C9orf72 repeat expansions 
were identified.
 Given the small number of patients, exploratory analyses were performed concerning 
genotype-phenotype correlations of GBA variants and the APOE ε4 allele. These results must 
be interpreted with caution. Our analysis showed that the age of onset was earlier in the GBA+ 
group versus GBA- group, which has been reported before in previous studies.7,36,37 Disease 
duration was longer in the GBA+ group versus GBA- group. Previous studies reported a 
similar disease duration between these groups.36,37 Likewise, as in previous studies5,8 disease 
duration was shorter in the APOE ε4+ group compared to the APOE ε4- group, which may 
be explained by a higher burden of AD concomitant pathology in APOE ε4+ patients.9,38,39 
Furthermore, we showed that GBA+ patients had more often a family history of PD or PDD 
than AD or dementia, and that APOE ε4+ patients had more often a family history of AD or 
dementia than PD or PDD. Based on these results, we speculate that, when looking at the 
PD-DLB-AD spectrum, DLB GBA+ patients are pathophysiological more related to the PD 
spectrum, and DLB APOE ε4+ patients to AD.
 Our data support a genetic overlap between DLB, PD and AD, and they suggest that these 
diseases share common molecular mechanisms. This study confirms that the same genetic 
variant (e.g. GBA variants or the APOE ε4 allele) can be associated with different phenotypes 
in the DLB-PD or DLB-AD spectrum; this suggests that other genetic or non-genetic factors 
are important for the final resulting clinical and pathological phenotypes. Interestingly, 
studies also suggest4,28,40 that specific variants within the same gene (for example the GBA 
p.D140H and E326K variant combination) may be more often associated with a specific 
phenotype within this spectrum. We also described new variants in DLB patients located 
in genes known to be involved in PD and AD, but whether they play a role in the disease 
development in our patients remains unknown. 
 This study has limitations. The total number of patients is low; clinical data were 
collected retrospectively in half of them; and postmortem examination was not performed 
in all. Particularly, the results of our genotype-phenotype correlations should be interpreted 
with caution, and further studies are necessary to support our findings. 
Conclusion
This study confirms that GBA variants and the APOE ε4 allele play important roles in familial 
DLB. These findings also support the notion that genetic overlaps exist between DLB, PD 
and AD. Future stratification based on GBA and APOE variants may help to predict disease 
course and select patients for clinical trials of disease-modifying drugs.
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Supplementary Information
PCR protocol Sanger sequencing
Our standard PCR mix contained 2 μl PCR buffer, 1.6 μl dNTPs 2.5 mM, 1 μl forward primer 
10 μM, 1 μl reverse primer 10 μM, 0.1 μl Fast-start taq or Platinum taq, 2 μl DNA (12.5 ng/
μl) and 12.3 μl H2O per reaction. An adjusted PCR mix was used to amplify fragment 1 of 
GBA and contained 10 μl TAKARA GCII buffer, 1.6 μl dNTPs 2.5 mM, 1 μl forward primer 
10 μM, 1 μl reverse primer 10 μM, 0.1 μl TAKARA LA taq, 2 μl DNA (12.5 ng/μl) and 4.4 
μl H2O per reaction. PCR cycling consisted of initial denaturation for 5.5 minutes at 96°C, 31 
or 32 cycles with denaturation for 30 seconds at 96°C, annealing for 30 seconds at 60°C and 
extension for 1.5 minutes at 72°C, and a final extension for 5.5 minutes at 72°C. 
PCR protocol APOE ε risk allele analysis
Reactions were performed in a 384-wells format in a total volume of 2 μl containing 2 
ng DNA, 1x genotyping assay (Thermo Fisher Scientific) and 1x genotyping master mix 
(Thermo Fisher Scientific). PCR cycling consisted of initial denaturation for 10 minutes at 
95°C, and 40 cycles with denaturation of 15 seconds at 96°C and annealing and extension 
for 60 seconds at 60°C.
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Supplementary Table 1: Genes with a well-established involvement in Parkinson’s disease or 
Alzheimer’s disease.
Chromosome Start End Mode of inheritance
PD genes
GBA
LRRK2
MAPT
SNCA
VPS35
RAB39B
DJ1
DNAJC6
PARK2
PINK1
1
12
17
4
16
X
1
1
6
1
155204239
40618813
43971702
90645250
46693589
154487526
8021714
65720133
161768590
20959948
155214653
40763087
44105700
90759447
46723144
154493852
8045342
65881552
163148834
20978004
autosomal dominant / risk factor
autosomal dominant
autosomal dominant
autosomal dominant
autosomal dominant
X-linked
autosomal recessive
autosomal recessive
autosomal recessive
autosomal recessive
AD genes
ABCA7
APP
PSEN1
PSEN2
SORL1
APOE
19
21
14
1
11
19
1040102
27252861
73603143
227057885
121322912
45409039
1065571
27543446
73690399
227083804
121504471
45412650
autosomal dominant / risk factor
autosomal dominant
autosomal dominant
autosomal dominant
autosomal dominant / risk factor
risk factor
Coordinates based on human reference genome (hg19; NCBI). PD: Parkinson’s disease, AD: Alzheimer’s disease.
Supplementary Table 2: Primers for Sanger sequencing.
Primer name Sequence Use
GBA_fragment1_Fa
GBA_fragment1_Ra
cctaaagttgtcacccatac
agcagacctaccctacagttt
PCR
PCR + sequencing
GBA_fragment3_Fa
GBA_fragment3_Ra
tgtgtgcaaggtccaggatcag
accacctagaggggaaagtg
PCR + sequencing
PCR
GBA_exon6_F cccaggagcccaagttccc sequencing
GBA_exon9_R ctggacaggaagggcttctg sequencing
GBA_exon10_F
GBA_exon10_R
ctgacctacccacagctgc
tgatgggactgtcgacaaag
sequencing
sequencing
GBA_exon11_F
GBA_exon11_R
gagagccagggcagagcctc
tgagtcacccaaaccattgc
sequencing
sequencing
LRRK2_exon40_F
LRRK2_exon40_R
gaagaaatggaaagtttgctatgatcc
tcagggaaatggtagttttcatcc
PCR + sequencing
PCR + sequencing
PARK2_exon3_F
PARK2_exon3_R
tgtaactgctgtgggcaaagg
caaagtactccacctacagtgatgtctcc
PCR + sequencing
PCR + sequencing
ABCA7_exon5_F
ABCA7_exon5_R
CAACTTCAACGACTCCCTgtgagc
GGAGACTGCTTGGTTGGTTGAGG
PCR + sequencing
PCR + sequencing
SORL1_exon13_F
SORL1_exon13_R
cctttgccttagagactttcactgc
tcaattacctccctatgctttttgc
PCR + sequencing
PCR + sequencing
a As GBA has a pseudogene which is very similar, two different sets of primers were used. Large fragments, specific 
for GBA, were amplified using PCR, after which other primers were used to be able to sequence the smaller regions 
of interest.
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Supplementary Figure 1: Graphical representation of total amount of 1st degree relatives with PD, 
PDD or DLB versus AD or dementia in GBA variant carriers (a) and APOE ε4 allele carriers (b). 
A circle represents a female patient; a square represents a male patient; a diamond represents a patient 
with unknown sex; black indicates patients with DLB, grey indicates patients with PD or PDD; white 
indicates patients with AD or unspecified dementia. DLB: dementia with Lewy bodies, PD: Parkinson’s 
disease, PDD: Parkinson’s disease dementia, AD: Alzheimer’s disease.
GBA variant 
carriers
APOE ε4 allele 
carriers
Relatives Relatives
Supplementary Fig. 1
a b
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Abstract
Introduction
The disease course of dementia with Lewy bodies (DLB) can be rapidly progressive, clinically 
resembling Creutzfeldt-Jakob’s disease (CJD). To better understand factors contributing to 
this rapidly progressive disease course, we describe load and distribution of neuropathology, 
and the presence of possible disease-associated genetic defects in a post-mortem series of 
DLB cases clinically suspected of CJD.
Methods
We included pathologically confirmed DLB cases with a disease duration of 3.5 years or less 
from the Dutch Surveillance Center for Prion Diseases, collected between 1998 and 2014. 
Lewy body disease (LBD) and Alzheimer’s disease (AD)-related pathology were staged and 
semi-quantitatively scored in selected brain regions. Whole exome sequencing analysis of 
known disease-associated genes, copy number analysis, APOE ε genotyping and C9orf72 
repeat expansion analysis were performed to identify defects in genes with a well-established 
involvement in Parkinson’s disease or AD.
Results
Diffuse LBD was present in nine cases, transitional LBD in six cases and brainstem-
predominant LBD in one case. Neocortical alpha-synuclein load was significantly higher 
in cases with intermediate-to-high than in cases with low-to-none AD-related pathology 
(p=0.007). We found two GBA variants (p.D140H and p.E326K) in one patient and two 
heterozygous rare variants of unknown significance in SORL1 in two patients.
Conclusion
A high load of neocortical alpha-synuclein pathology was present in most, but not all DLB 
cases. Additional burden from presence of concomitant pathologies, synergistic effects and 
specific genetic defects in the known disease-associated genes may have contributed to the 
rapid disease progression.
Neuropathological and genetic characteristics of a post-mortem series of cases with dementia 
with Lewy bodies clinically suspected of Creutzfeldt-Jakob’s disease
79
Pa
rt 
3
Introduction
Dementia with Lewy bodies (DLB) is a neurodegenerative dementia characterized by 
parkinsonism, fluctuating cognitive symptoms, visual hallucinations, REM-sleep behavior 
disorders and neuroleptic sensitivity.1 Clinical symptoms of DLB are gradually progressive, 
with a median disease duration of seven to eight years.2 However, DLB may occasionally 
present with a rapid deterioration leading to death within three years from the start of 
the first symptoms.3-9 These rapidly progressive DLB cases frequently show additional 
focal neurological signs such as myoclonus, pyramidal and cerebellar signs, and akinetic 
mutism.3-9 As these neurological signs are core symptoms of Creutzfeldt-Jakob’s disease 
(CJD), a rapidly progressive prion disease10, the clinical differential diagnosis often 
includes CJD. In autopsy-series of clinically possible and probable CJD cases, DLB was 
the neuropathological diagnosis in 2-8% of cases.3-5 To date, it is unknown whether these 
cases should be regarded as a distinct entity within the Lewy body disease (LBD) spectrum. 
Studying the neuropathological and genetic correlates of this clinical phenotype may aid in a 
better understanding of factors contributing to the rapidly progressive disease course in DLB.
 The main neuropathological lesions in DLB are alpha-synuclein immunoreactive 
Lewy bodies (LBs) and Lewy neurites (LNs). In most DLB cases, LB pathology is present 
in brainstem and limbic (transitional LBD), or in brainstem, limbic and neocortical areas 
(diffuse LBD).11 Additionally, Alzheimer’s disease (AD)-related changes including amyloid-β 
plaques, neurofibrillary pathology and neuritic plaques are often present.12 Neuropathological 
correlates of disease progression and survival in DLB have previously been assessed in 
prospectively13 and retrospectively studied DLB14 or combined Parkinson’s disease (PD) 
dementia and DLB15 cohorts. These studies revealed that patients with diffuse LBD had a 
shorter disease duration13-15 and showed a more rapid cognitive decline14 than patients with 
transitional LBD. Both a higher alpha-synuclein load and amyloid-β load, and to a lesser 
extent also neurofibrillary pathology load, were associated with a shorter disease duration.13
 To better understand neuropathological and genetic factors contributing to a rapidly 
progressive disease course in DLB, we describe here the load and distribution of alpha-
synuclein pathology and concomitant pathology, and the presence of possible disease-
associated genetic defects in a post-mortem series of DLB cases suspected of CJD from the 
Dutch Surveillance Centre for Prion Diseases.
Methods
Patient selection
All cases clinically suspected of CJD with LBD at autopsy collected in the period from 
1998 to 2014 by the Dutch Surveillance Center for Prion Diseases at the University Medical 
Center in Utrecht were included. The Dutch Surveillance Center obtained permission for 
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brain autopsy and written informed consent for use of clinical, pathological and genetic data 
for research purposes from the patients during life or from their next of kin after death. The 
medical ethics committee (MEC) of the University Medical Center Utrecht approved all 
procedures of autopsy. We retrieved information from medical records on symptoms and 
signs of DLB and sporadic CJD as described by the McKeith criteria and the criteria from 
the World Health Organization (WHO).10,11 Symptoms were only regarded as present or not 
present when explicitly stated in the clinical information. An experienced neurologist (AL) 
classified all patients to the clinical criteria for DLB11 and WHO criteria for CJD10.
 Inclusion criteria for this study were: 1) presence of LBD at autopsy, 2) negative screen 
for prion protein at autopsy, 3) disease duration of 3.5 years or less from the start of first 
symptoms, 4) no other major neurological or systemic diseases that provided sufficient 
explanation for a rapid deterioration, and 5) presence of sufficient clinical data. 
Neuropathological assessment
Post-mortem examination was performed within 4 to 8 hours post-mortem. A total of 25 
tissue blocks were taken from the following regions: frontal, parietal, temporal and occipital 
cortices, hippocampus, striatum, thalamus, mesencephalon, pons, medulla oblongata and 
cerebellum.
 After decontamination using 98% formic acid for five minutes, brain tissue blocks 
were formalin-fixed, paraffin-embedded and cut into sections of 10 μm thickness. Routine 
histological stainings were performed with haematoxylin-eosin, Gallyas silver staining and 
combined Luxol fast blue-periodic acid-Schiff. All regions were examined for the presence 
of prion protein with the use of monoclonal antibody 3F4 (1:400, Signet labs, United States). 
Immunohistochemistry was performed using primary antibodies against alpha-synuclein 
(clone KM51; 1:500; Monosan, the Netherlands), hyperphosphorylated tau (clone AT8; 
1:1000; Innogenetics, Belgium), and amyloid-β (clone 6f/3d; 1:100; Dako, United States). For 
staging and semi-quantitative scores of alpha-synuclein pathology, Brain Net Europe (BNE) 
consensus guidelines16 and modified McKeith criteria17 were used. LBs and LNs were scored 
in brainstem regions, LNs in the CA2 regions and LBs in other limbic and neocortical regions. 
For pathological staging of neurofibrillary tangles, amyloid-β plaques and neuritic plaques, 
National Institute on Aging - Alzheimer Association (NIA-AA) criteria were used.17 Mean 
cerebral load of alpha-synuclein, neurofibrillary and amyloid-β pathology was calculated 
based on semi-quantitative load of pathology in selected regions used for pathological staging 
(Supplementary Methods). Presence of age-related astrogliopathy (ARTAG)18, argyrophilic 
grain disease19, atherosclerosis, ischemic or hemorrhagic lesions and small vessel disease17 
was reported, and cerebral amyloid angiopathy (CAA)20 was classified. Spongiform changes 
were assessed based on presence of vacuoles in the entorhinal and temporo-occipital cortex. 
Neuropathological assessment was performed by an experienced neuropathologist (AR), and 
semi-quantitative load of pathology was scored according to consensus criteria16,17,21 by the 
same assessor (HG) in all cases.
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Genetic analysis
Fresh-frozen temporal cortex was available for eleven cases (Table 2). Genomic DNA was 
isolated from this tissue with the AllPrep DNA/RNA/miRNA Universal Kit of Qiagen. The 
Nimblegen SeqCap EZ Exome v.2.0 44Mb kit (Roche Nimblegen, Inc., Madison, WI) was 
used on a HiSeq2000 sequencer (paired-end 2x100) for the whole exome sequencing (WES). 
We selected non-synonymous, stop-gain or stop-loss variants in exons and variants near 
splice sites with a mean allele frequency of <1% in the ExAC-NFE (Exome Aggregation 
Consortium-Non Finnish Europeans) database and the GoNL (Genome of the Netherlands) 
database in genes with a well-established involvement in Parkinson’s disease (PD) (SNCA, 
Parkin, PINK1, DJ1, LRRK2, GBA, VPS35, DNAJC6, RAB39B), AD (APP, PSEN1, PSEN2, 
SORL1, TREM2, APOE, ABCA7) and frontotemporal dementia (MAPT, GRN). All variants 
in GBA were selected regardless the mean allele frequency reported in public databases. 
Subsequently, Sanger sequencing was performed to validate selected variants and to exclude 
false-negative results in exons and intron-exon boundaries with low coverage (<10 reads).
 Furthermore, copy dosage analysis of SNCA, Parkin, PARK7, PINK1 and APP was done 
using Multiplex Ligation-dependent Probe Amplification (MLPA, MRC Holland), APOE ε 
genotyping using Taqman Allelic Discrimination and C9orf72 repeat expansions analysis 
using a repeat-primed PCR assay. Further details on genetic analyses techniques are provided 
in the Supplementary Methods.
Statistical analyses
Mean and standard deviation were calculated for normally distributed continuous data (age 
at onset, age at death), median and interquartile range was used for not normally distributed 
data (disease duration) and ordinal data (load of different types of pathology). Correlation 
between cerebral alpha-synuclein, neurofibrillary and amyloid-β load was assessed with 
Spearman’s rank correlations, and the cerebral alpha-synuclein load in a group of cases with 
low-to-none versus a moderate-to-high level of AD-related pathology was compared using 
the Mann-Whitney U test. Data were considered significant if p<0.05. All statistical analyses 
were done using IBM SPSS version 22.
Results
Neuropathological diagnoses in all cases suspected of CJD
Of 512 consecutive autopsy cases between 1998 and 2014, autopsy revealed a prion disease 
in 296 cases (58%), including 259 cases with sporadic CJD. Neurodegenerative diseases 
were the most frequent alternative diagnoses (48%), followed by immune diseases (17%), 
malignant diseases (10%), toxic metabolic disorders (10%), vascular diseases (9%) and other 
causes (6%) (Supplementary Table 1). LBD was found in 26 cases (12%), of whom sixteen 
cases fulfilled inclusion criteria (Supplementary Methods).
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Clinical diagnosis and demographics
All sixteen cases were diagnosed during life with rapidly progressive dementia. CJD was 
considered the most likely clinical diagnosis or was included in the differential diagnosis 
in all cases by the treating neurologists, and DLB was explicitly listed in the differential 
diagnosis in eight cases. In retrospect, thirteen cases fulfilled clinical criteria for probable 
DLB and three cases for possible DLB.11 Clinical criteria categorized one case as probable 
CJD, eight cases as possible CJD, and seven cases as no CJD.10 Median disease duration was 
12 months (interquartile range 6.5 to 24 months), with a mean age at onset of 77 years and 
a mean age at death of 78 years (SD 7.3; range 62 to 87 years). Basic demographic features, 
clinical symptoms, ancillary investigations and clinical diagnoses of CJD and DLB are listed 
in Table 1.
Distribution and load of alpha-synuclein pathology 
Mild to moderate atrophy was present in 50% of cases (Table 2). Moderate to severe neuronal 
loss in the substantia nigra was present in all cases.  Brainstem-type LBD was present in 
one case (Figure 1, 5a-c), transitional LBD in six cases and diffuse LBD in nine cases. 
Eleven cases showed Braak alpha-synuclein stage 6 (Table 2). A large proportion of the cases 
showed a moderate to severe load of alpha-synuclein pathology in the substantia nigra (81%), 
temporo-occipital cortex (75%), temporal cortex (56%), and frontal cortex (38%, Figure 2). 
Presence of concomitant AD-related pathology, vascular pathology and spongiform 
changes
All cases showed neurofibrillary pathology, with nine cases reaching Braak neurofibrillary 
stage 3 or higher. One case (case 8) showed ARTAG, none of the cases showed argyrophilic 
grain disease. Diffuse and/or classical amyloid-β positive plaques were present in thirteen 
cases and neuritic plaques were present in the neocortex of nine cases (Table 2). The level of 
AD-related pathology was none in two cases, low in six cases, intermediate in six cases and 
high in two cases (case 1 and 11; Figure 1, 2d-e, Table 2). 
 Case 16 showed severe capillary CAA, Thal stage 3 (Figure 1, 3e). Additionally, CAA 
type 2 was present in six cases. Signs of small vessel disease were present in three cases, 
and severe atherosclerosis of large vessels combined with multiple cortical and subcortical 
infarctions were present in two cases (case 13 and 15). Mild to severe spongiform cortical 
changes were present in twelve cases (75%) (Table 2). 
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Table 1: Basic demographic features, clinical symptoms, ancillary investigations and diagnoses of 
dementia with Lewy bodies and Creutzfeldt-Jakob’s disease in sixteen cases with dementia with Lewy 
bodies clinically suspected of Creutzfeldt-Jakob’s disease.
Sex 9 M / 7 F
Disease duration, months 12 (4–42)
Age at onset, years 77 (7.3)
Age at death, years 78 (7.3)
Presence of clinical symptoms (yes / no / NA)
- Dementia
- Parkinsonism
- Fluctuating cognition
- Visual hallucinations
- Delusions
- Neuroleptic sensitivity
- History of depression
- Autonomic dysfunction
- Myoclonus
- Pyramidal symptoms
- Cerebellar symptoms
- Akinetic mutism
16 (100%)/ 0 / 0 
14 (88%)/ 2 / 0 
11 (69%)/ 1 / 4
12 (75%)/ 0 / 4
9 (56%)/ 0 / 7
9 (56%)/ 1 / 6
5 (31%)/ 0 / 11
3 (19%)/ 0 / 13
10 (63%)/ 1 / 5
6 (38%)/ 5 / 5
4 (25%) / 8 / 4
3 (19%)/ 4 / 9
Ancillary investigations
- PSWCs on EEG
- Hyperintensities on MR-DWI
- 14-3-3 protein in CSF
Present in 0 of 11 cases with a reported EEG (non-periodic bi- or triphasic 
complexes in 3 cases)
Present in 0 of 7 cases with a reported MRI 
2 negative; 1 inconclusive; 2 positive of 5 cases with a reported 14-3-3 CSF 
test
Clinical diagnosis of DLB11 0 no; 3 possible; 13 probable
Clinical diagnosis of CJD10 7 no; 8 possible; 1 probable
Data are presented as mean (SD), median (range) or n (%). PSWCs: periodic sharp wave complexes, EEG: electro-
encephalogram, MR-DWI: magnetic resonance diffusion weighted imaging, CSF: cerebrospinal fluid, NA: not 
available.
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Figure 1: Representative overview of the neuropathological features visualized with immunohisto-
chemistry in sixteen cases with dementia with Lewy bodies clinically suspected of Creutzfeldt-Jakob’s 
disease. 
Load of alpha-synuclein pathology was high in limbic and neocortical regions in most cases (1b-4b, 
1c-4c), but a few cases only showed brainstem-predominant (5a-c) or transitional Lewy body disease 
(LBD). Neurofibrillary and amyloid-β pathology were absent or low in some (1d-e, 4d-e, 5d-e), but 
severe in other cases (2d-e). One case showed severe capillary cerebral amyloid angiopathy (3e). 
A case with  two GBA variants (p.D140H and p.E326K)  showed diffuse LBD (4a-c) and low levels of 
Alzheimer’s disease (AD)-related pathology (4d-e). One case showed nigral degeneration and brain-
stem-predominant LBD (5a-c) without signs of AD-related pathology (5d-e). 
Representative microscopy images from case 4 (1a-e), 11 (2a-e), 16 (3a-e), 7 (4a-e) and 10 (5a-e). 
Immunohistochemistry against alpha-synuclein (clone KM51) was performed on a: substantia nigra, 
b: trans-entorhinal cortex and c: temporal cortex. d: Immunohistochemistry against hyperphosphorylated 
tau (clone AT8) on temporal cortex. e: Immunohistochemistry against amyloid-β (clone 6f/3d) on 
temporal (1e, 2e, 4e and 5e) and frontal (3e) cortex. The scale bar in 5a represents 50 μm and applies to 
1a-5a, 1b-5b and 1c-5c. The scale bar in 5d represents 50 μm and applies to 1d-5d. The scale bar in 5e 
represents 100 μm and applies to 1e-5e.
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Correlations between cerebral load of alpha-synuclein, neurofibrillary and amyloid-β 
pathology 
Cases with an intermediate-to-high load of AD-related pathology (n=8) had a significantly 
higher cerebral load of alpha-synuclein pathology compared to cases with no-to-low level 
of AD-related pathology (n=8, p=0.007). The load of alpha-synuclein pathology was 
significantly correlated to both the load of neurofibrillary (Spearman’s rho 0.757; p=0.001) 
and amyloid-β pathology (Spearman’s rho 0.707; p=0.002). 
Presence of genetic defects and their neuropathological correlates
In three of the eleven cases (45%) analyzed, possible disease-associated variants were 
detected in genes with a well-established involvement in PD or AD (Supplementary Table 2). 
 In case 7, a rare variant and a common variant were detected in GBA (p.D140H and 
p.E326K) and confirmed by Sanger sequencing. E326K and E326K+D140H variants have 
been associated with a more rapid cognitive decline in PD.22,23 At autopsy, case 7 showed a 
high load of neocortical alpha-synuclein and a low level of AD-related pathology (Figure 1, 
4a-e). 
 Additionally, the p.R1799Q and p.D140N variants in SORL1 were found in case 2 and 13 
respectively, and confirmed by Sanger sequencing. These variants have an allele frequency 
Figure 2: Semi-quantitative load of alpha-synuclein pathology in brainstem, limbic and neocortical 
brain regions in sixteen cases with dementia with Lewy bodies clinically suspected of Creutzfeldt-Ja-
kob’s disease. 
Lewy bodies (LBs) and Lewy neurites (LNs) were scored in brainstem regions, LNs in the CA2 regi-
on and LBs in other limbic and neocortical regions. Bars represent mean values, error bars represent 
standard deviations. LC: locus coeruleus, SN: substantia nigra, CA2: cornu ammonis region 2, temp-
occ: temporo-occipital cortex, cingulate: posterior cingulate gyrus, temporal: medial temporal gyrus, 
frontal: frontal gyrus (Brodmann area 10), parietal: inferior parietal lobe.
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of 0.005% and 0.03% in the GnomAD (Genome Aggregation Database) respectively. The 
p.D140N variant is predicted to be pathogenic by half of the in-silico programs, whilst the 
p.R1799Q variant is predicted to be likely benign by the majority of programs. The case with 
the p.D140N variant showed an intermediate level of AD-related pathology, whereas the case 
with the likely benign p.R1799Q variant showed only a low level of AD-type pathology. 
 No SNCA, Parkin, PARK7, PINK1 or APP dosage abnormalities and no pathogenic 
C9orf72 repeat expansions were found. Three cases carried an APOE ε4 allele, of which one 
had no AD-related pathology and two had an intermediate level of AD-related pathology 
(Table 2).
Discussion
Until now, few studies have reported the neuropathological characteristics of DLB cases 
suspected of CJD. Here, we describe neuropathological and genetic features in sixteen of 
these cases collected by the Dutch Surveillance Center for Prion Diseases. A high load of 
neocortical alpha-synuclein pathology was present in most, but not all DLB cases, and cases 
showed a variable load of AD-related pathology. We found two GBA variants in one patient 
and two heterozygous rare variants of unknown significance in SORL1 in two patients.
 In the current study, ten cases retrospectively fulfilled clinical criteria for possible or 
probable CJD, and all cases retrospectively fulfilled clinical criteria for possible or probable 
DLB, with a median disease duration of 12 months. The overlap of clinical symptoms in 
cases with rapidly progressive dementias is well-known, and it has been proven difficult to 
discriminate rapidly progressive DLB and CJD based on clinical symptoms and signs.3-5,7
 The neuropathological correlates of rapidly progressive DLB have only been studied in 
few case-studies and very small case-series. Transitional LBD was present in four cases, and 
diffuse LBD in 16 out of 20 cases described.4,7,8,24 The level of AD-related pathology according 
to the NIA-AA17 ranged from none to severe.7-9 Additionally, concomitant pathology included 
argyrophilic grain disease7, TDP-43 positive inclusions8, atherosclerosis8, infarctions8, small 
vessel disease7-9, CAA7, and a subarachnoidal hemorrhage8. In conclusion, the neuropathology 
described in these cases was variable, but studies were small with heterogeneous inclusion 
criteria.
 In 56% of DLB cases suspected of CJD in the current study, the neuropathology was 
characterized by diffuse LBD, with an intermediate to high load of alpha-synuclein pathology 
in neocortical regions. In comparison, a previous large post-mortem series of 807 DLB 
cases (mean disease duration 8.8 ± 4.0 years) revealed diffuse LBD in 57% of the cases.14 
However, due to differences in case selection, a direct comparison of different cohorts should 
be interpreted with caution.25 Although diffuse LBD has been related to a more rapidly 
progressive disease course in DLB13,14 and LBD15, our results show that the pathological 
correlate of rapidly progressive DLB can be transitional LBD or even brainstem-predominant 
LBD. 
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 The load of AD-related pathology varied from none to severe in this study. A negative 
correlation between load of AD-related pathology and survival in DLB has been shown by 
neuropathological studies13,15 and a recent cerebrospinal fluid biomarker study26. However, 
the current study shows that DLB symptoms can also progress rapidly in cases with little 
concomitant pathology. Also, concomitant vascular pathology was present in several cases, 
which may have added to disease progression. 
 Spongiform changes were found in 75% of cases in the current study, which is in line with 
a previous post-mortem study of 40 DLB cases, where 82% showed spongiform changes.27 
In this study, there was no correlation between spongiform changes and disease duration27, 
which is corroborated by the low frequency of severe spongiform changes in the current 
series. The heterogeneous neuropathology in our cases is in line with previous reports on 
the presence of neuropathological hallmarks in DLB cases suspected of CJD7-9, and with the 
neuropathology of DLB cases in general13,14.
 In this study, a higher alpha-synuclein load was associated with a higher load of AD-
related pathology. This is in line with results from previous autopsy studies, that revealed 
a correlation between alpha-synuclein pathology and AD-related pathology in LBD15, and 
DLB13 cases. Together with evidence from in vitro and animal cross-seeding experiments, 
this suggests synergistic interactions between hyperphosphorylated tau, amyloid-β and 
alpha-synuclein aggregates.28
 The relation between genetic defects and a rapidly progressive phenotype in DLB has 
been understudied. In a few rapidly progressive DLB cases, a genetic screening has been 
performed, without finding evidence for presence of genetic defects.8,24 
 Interestingly, in one diffuse LBD case with a low level of AD-related pathology, 
a combination of two genetic variants was found in GBA (p.D140H and p.E326K). This 
combination of variants has been described before in Gaucher disease23 and PD22. PD carriers 
of the p.E326K variant and the D140H+E326K complex allele were shown to have a faster 
cognitive decline than non-GBA associated PD cases.22 As GBA variants have been shown 
to be associated with more severe motor and cognitive dysfunction in DLB29, these variants 
may have contributed to the rapid cognitive decline. 
 Furthermore, two other heterozygous variants in the SORL1 gene (p.D140N and 
p.R1799Q) were observed in two different cases. According to recent criteria for SORL1 
variants in AD, both variants are categorized as ‘likely benign’.30 However, as these criteria 
have been adopted for AD, the role of these variants in DLB disease progression is still 
uncertain. 
 Limitations of the current study are the small sample size, limited availability of tissue 
for genetic analysis, inclusion of cases based on clinical referrals, and the retrospective 
nature of the clinical data. Additionally, rapid clinical deterioration in DLB can be induced 
by a hypersensitive reaction to neuroleptic treatment, which may be misinterpreted as signs 
of CJD.6 This iatrogenic cause of disease progression may play a role in some cases in this 
study. Studies in larger, prospectively followed cohorts of patients are needed to draw more 
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generalizable conclusions on the neuropathological or genetic substrates of rapid disease 
progression in DLB, especially regarding the clinical and pathological heterogeneity in this 
group of patients. However, this may be difficult to realize in clinical practice, as DLB cases 
clinically suspected of CJD are very rare.
 In short, a high load and neocortical distribution of alpha-synuclein pathology is present 
in some, but not all DLB cases in this post-mortem series. This suggests that a different set 
of factors contribute to the rapidly progressive disease course in cases with no or a low load 
of neocortical alpha-synuclein pathology. Additional burden from presence of concomitant 
pathologies, synergistic effects and specific genetic defects may have contributed to the 
disease progression in some cases. Understanding which factors contribute to a rapid 
disease progression in DLB could aid in the search for biomarkers that enable clinicians and 
researchers to select patients for therapeutic strategies.
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Supplementary Information
Case selection
Of 26 cases with LBD without presence of prion protein, collected from 1998 to 2014, 16 
were included in the study whereas the remaining 10 cases did not meet the inclusion criteria. 
A disease duration of four years or longer was present in five cases, other neurological 
diseases were apparent in three cases (one case with an intracerebral B-cel lymphoma, one 
case with a large recent infarction, and one case with microcephaly), and sepsis with multiple 
organ failure or bronchopneumonia coincided with the neurological decline in two cases. 
Thus, sixteen cases were included in the current study.
Calculation of mean load of neurofibrillary, amyloid-β and alpha-synuclein pathology
Alpha-synuclein pathology was calculated as the mean of temporo-occipital, cingulate, 
temporal, frontal and parietal scores. Neocortical load of neurofibrillary pathology was 
calculated as the mean of the entorhinal, temporo-occipital, temporal, occipital-peristriatal 
and occipital-striatal scores, and neocortical amyloid-β load was calculated as the mean of 
entorhinal, temporo-occipital, cingulate, temporal, frontal, parietal and occipital scores.
DNA quality assessement
All samples were snap frozen in liquid nitrogen at autopsy and stored at -80°C until use. 
Degradation of DNA was assessed using DNA electrophoresis on agarose gels, which did not 
reveal DNA degradation in any of the samples. Quantification of DNA purity by Nanodrop® 
showed 260/280 ratios above 1.8 for all samples.
Whole exome sequencing
The Burrows-Wheeler alignment tool was used to align reads to the human reference genome 
(hg19). Picard (http://broadinstitute.github.io/picard) and the Genome Analysis Toolkit 
(GATK) were used to process aligned reads following standard procedures.1 We determined 
single nucleotide variations using GATKs HaplotypeCaller, and used ANNOVAR for 
functional annotation.2
Sanger sequencing
Direct sequencing of both strands was done using the Big Dye Terminator chemistry version 
3.1 (Applied Biosystems), and fragments were run on an ABI3130 or ABI3730 sequencer. 
SeqScape (version 2.6) was used for analysis.
Neuropathological and genetic characteristics of a post-mortem series of cases with dementia 
with Lewy bodies clinically suspected of Creutzfeldt-Jakob’s disease
93
Pa
rt 
3
Multiplex Ligation-dependent Probe Amplification 
The P051-D1 Parkinson and P170-C2 APP MLPA kits (MRC Holland) were used according to 
the manufacturer’s protocol. An ABI3130 or ABI3730 genetic analyzer (Applied Biosystems, 
Foster City, CA, USA) and GeneMarker Ver.2.4.0 (SoftGenetics, State College, PA, USA) 
were used for further analysis.
APOE ε genotyping
APOE ε genotyping (rs7412 and rs429358) was done using Taqman Allelic Discrimination. 
Signals were read with the Taqman 7900HT (Applied Biosystems Inc.) and analyzed using 
sequence detection system 2.3 software (Applied Biosystems Inc.).
C9orf72 repeat expansions analysis
To detect pathogenic C9orf72 repeat expansions, a previously described repeat-primed PCR 
assay3 was used. An ABI3130 or ABI3730 genetic analyzer (Applied Biosystems, Foster 
City, CA, USA) and GeneMarker Ver.2.4.0 (SoftGenetics, State College, PA, USA) were 
used for further analysis. A pathogenic C9orf72 expansion was defined as more than 30 
repeats.3
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Supplementary Table 1: Neuropathological diagnosis in 512 consecutive autopsy cases in period 
1998-2014 at the Dutch Surveillance Center for Prion Diseases.
Prion disease 296
Sporadic CJD
Sporadic CJD
Sporadic CJD + AD
259
252
7
Other prion diseases 37
Non-prion disease 216
Neurodegenerative diseases
AD
LBD
Mixed AD + vascular pathology
PSP
FTD-tau or FTD-TDP
ALS
Multiple sclerosis
104
46
26
14
4
8
2
4
Immune diseases
Limbic encephalitis
Viral infections
Neurocoeliac disease 
HIV encephalopathy
37
27
4
4
2
Malignant diseases
Myeloproliferative disease
Metastases
Intravascular lymphoma
Astrocytoma or glioblastoma
22
11
5
3
3
Toxic metabolic disorders 21
Vascular diseases
Thrombotic or vascular lesions
Non-CAA angiopathy
20
18
2
Other 12
Total 512
CJD: Creutzfeldt-Jakob's disease, AD: Alzheimer's disease, LBD: Lewy body disease, PSP: progressive supranuclear 
palsy, FTD: frontotemporal dementia, ALS: amyotrophic lateral sclerosis, HIV: human immunodeficiency virus, 
CAA: cerebral amyloid angiopathy.
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Abstract
Objective
To analyse LRP10 variants, recently associated with the development of Parkinson’s disease 
(PD), Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB), in a series 
of patients and controls from the South-West of the Netherlands (Walcheren).
Methods
A series of 130 patients with PD, PDD or DLB were clinically examined, and a structured 
questionnaire used to collect information about family history of PD and dementia. The 
entire LRP10 coding region was sequenced by Sanger methods in all patients, and haplotype 
analysis was performed for one recurrent LRP10 variant. The fragments containing possibly 
pathogenic LRP10 variants were sequenced in 62 unaffected control subjects from the same 
region. Other known PD-associated genes were analyzed by exome sequencing and gene 
dosage in the carriers of LRP10 variants.
Results
Four patients were carriers of a rare heterozygous, possibly pathogenic LRP10 variant: 
p.Arg151Cys, p.Arg263His, and p.Tyr307Asn. None of these variants was detected among 
the controls, nor were additional mutations identified in known PD-associated genes in the 
four LRP10 variant carriers. The previously reported p.Tyr307Asn variant was identified in 
two patients (with PD and PDD), who are connected genealogically within six generations, 
and in one of their relatives with cognitive decline. Haplotype analysis suggests a common 
founder for the p.Tyr307Asn variant carriers analyzed.
Discussion
We report three possibly pathogenic LRP10 variants in patients with PD and PDD from a 
local Dutch population. The identification of additional patients carrying the p.Tyr307Asn 
variant provides some further evidence that this variant is pathogenic for PD and PDD.
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Introduction
Parkinson’s disease (PD), Parkinson’s disease dementia (PDD) and dementia with Lewy 
bodies (DLB) are common neurodegenerative diseases, which share clinical, pathological 
and genetic features.1,2 These disorders occur in approximately 1-2% of the population above 
60 years old3,4, and their common hallmark is Lewy pathology, observed primarily in the 
brainstem in PD, and more diffusely throughout the brain in PDD and DLB2,5.
 Although PD, PDD and DLB manifest mostly as sporadic diseases, during the last 
decades mounting evidence showed that genetic factors play an important role in the disease 
etiopathogenesis.6-8 Recently, genetic defects in the low-density lipoprotein receptor related 
protein 10 gene (LRP10) have been reported in familial PD, PDD and DLB.9
 The aim of this study was to screen LRP10 in a series of patients and unaffected subjects 
from an isolated region in the South-West of the Netherlands. 
Methods
Participants 
Between 2007 and 2010 we ascertained a series of 130 patients with PD (n=71), PDD (n=55), 
or DLB (n=4), as well as 62 unrelated and unaffected subjects originating from a region in 
the South-West of the Netherlands (Walcheren). This area had maintained the features of an 
island until 1870, and for centuries its population remained geographically isolated from 
the surrounding areas. All patients were neurologically examined by a neurologist (AR). 
Structured questionnaires were used to collect information about family history of PD and 
dementia and The Mini Mental State Examination (MMSE) was administered as screening 
tool for the cognitive status. Clinical follow-up was available until July 2018. The diagnosis 
of PD required the exclusion of secondary causes of parkinsonism, and the presence of at 
least two of the following signs: bradykinesia, rigidity, or rest tremor; or, presence of one of 
these signs together with improvement with dopaminergic medications. Diagnosis of DLB or 
PDD was made according to the criteria described by McKeith and co-workers10 and by Emre 
and co-workers11, respectively. Unaffected spouses of patients or of relatives were recruited 
as controls. Blood samples were collected from patients, available relatives and controls for 
DNA isolation. The study protocol was approved by the Medical Ethics Committee of the 
Erasmus Medical Center Rotterdam, the Netherlands (MEC-2005-206) and written informed 
consent was obtained by all participating subjects.
Genetic Studies
The entire open reading frame and the intron-exon boundaries of LRP10 were sequenced 
in all patients using a reported Sanger protocol9 with minor modifications (Supplementary 
Information). Variants were considered as possibly pathogenic if they were: (1) present in 
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heterozygous state (as expected for variants acting in a dominant fashion); (2) rare, defined 
as with a minor allele frequency (MAF) <0.001 by the Genome Aggregation Database 
(GnomAD v2.1.1; https://gnomad.broadinstitute.org/); (3) exonic and non-synonymous, 
or predicted to affect splicing; and (4) predicted as pathogenic by at least five of 11 in-
silico programs (Supplementary Information). The LRP10 fragments containing possibly 
pathogenic variants identified in the patients were sequenced in the controls.
 Whole exome sequencing (WES) and multiple ligation probe amplification (MLPA, 
P051-Parkinson mix 1, MRC Holland) were also performed in the patients who carried 
possibly pathogenic LRP10 variants to rule out mutations in other known genes associated 
with PD or parkinsonism (Supplementary Table 1).
 Haplotype analysis of a 6-Mb genomic region flanking LRP10 was performed in the 
carriers of one recurrent LRP10 variant (c.919T>A, p.Tyr307Asn), by typing short tandem 
repeat (STR) markers. DNA of the Italian PDD patient previously reported by us with the 
same variant9, was also included in this analysis (Supplementary Figure 1). 
 LRP10 protein conservation analysis was performed using the T-Coffee multiple 
sequence alignment program (https://www.ebi.ac.uk/Tools/msa/tcoffee/) (Supplementary 
Figure 2). Details on the methodologies are reported in the Supplementary Information. 
Results
The demographic and clinical characteristics of the 130 index patients are reported in 
Supplementary Table 2. The index patients had a mean age at disease onset of 62.4 ± 9.6 
years and the 62 unrelated and unaffected participants had a mean age of 63.5 ± 12.3 years 
at recruitment. 
 Four index patients carried LRP10 variants that fulfill our criteria for being considered as 
possibly pathogenic: c.451C>T/p.Arg151Cys (GnomAD MAF 0.000056, 16 alleles) in one 
patient; c.788G>A/p.Arg263His (GnomAD MAF 0.000007, 2 alleles) in another patient; and 
c.919T>A/p.Tyr307Asn (GnomAD MAF 0.000059, 15 alleles) in two other patients (Table 
1). None of these variants were detected among the 62 unaffected subjects. Additional variants 
detected in patients but not fulfilling our criteria to be considered as possibly pathogenic 
are reported in Supplementary Table 3. Our WES and MLPA analyses in the four patients 
carrying LRP10 possibly pathogenic variants detected no pathogenic variants in any of the 
other known genes associated with PD or parkinsonism (WES reached an average depth 
>190x, with 99.1% of the target region covered >20x). 
 Two patients, whose genealogy can be traced back to a common ancestor within six 
generations, carry the LRP10 p.Tyr307Asn heterozygous variant. The diagnosis of PD in 
the first patient (Family 1, II-2) was established based on rigidity, bradykinesia, reduced 
arm swing and reduced facial expression, after he presented with rest tremor of the left hand 
at 63 years of age. The patient had multiple depressive episodes. He did not report PD or 
dementia among his first-degree relatives (Figure 1). DNA was available from two of his 
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offspring, asymptomatic at the age of 33 and 47 years, respectively; both also carried the 
LRP10 p.Tyr307Asn variant in heterozygous state (Figure 1 and Supplementary Figure 1). 
The second patient carrying the LRP10 p.Tyr307Asn variant (Family 2, II-2) developed 
motor difficulties in the right leg at the age of 69. PD was diagnosed one year later based 
on bradykinesia, reduced facial expression, hypersalivation and orthostasis, in absence of 
rest tremor. He developed a paresis of the left arm after a small intracerebral hemorrhage in 
the right basal ganglia at the age of 75, followed by cognitive deterioration and periods of 
confusion. A dementia was diagnosed one year later and he died at 79 years old. He did not 
report PD among his first-degree relatives. However, his brother was recently diagnosed with 
a progressive cognitive decline of neurodegenerative nature, and DNA testing revealed that 
he also carries the LRP10 p.Tyr307Asn variant (Figure 1 and Supplementary Figure 1).
 A third patient (Family 3, III-1), carrying a LRP10 p.Arg263His variant, developed a rest 
tremor of both hands and bradykinesia at 68 years of age. The PD diagnosis was established 
two years later, when rigidity and reduced facial expression were also present. He has mild 
memory impairments, concentration and orientation problems at the current age of 78. One 
of his cousins was also diagnosed with PD (paternal side), the patient’s father had memory 
complaints and his three sisters were affected by dementia (Figure 1). Unfortunately, co-
segregation studies could not be performed in the affected relatives due to unavailability of 
DNA. 
 A fourth patient (Family 4, II-2), carrying a LRP10 p.Arg151Cys variant, was diagnosed 
with PD based on hypokinesia and rest tremor of the left hand at 66 years of age. He developed 
rigidity, hallucinations and depression several years later, and memory complaints at the age 
of 70. A diagnosis of dementia was established at 73 years of age, one year before he died. 
His father suffered from Alzheimer’s disease, walking problems and frequent falls which 
started at the end of his seventies.
 As expected from the genealogical links, our haplotype studies showed that the patients 
in the two Dutch families with the LRP10 p.Tyr307Asn variant share an extended haplotype 
of several megabases flanking the LRP10 gene. The Italian PDD patient previously reported 
by us with the same variant 9 shares a smaller haplotype of ~1Mb, therefore compatible with 
a common but more distant ancestor. 
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Figure 1: Pedigrees of patients carrying LRP10 variants.
Circles indicate females, squares indicate males, diamonds indicate sex-disguised individuals; black 
symbols indicate patients affected by Parkinson’s disease or Parkinson’s disease dementia; grey sym-
bols indicate patients with Alzheimer’s disease, cognitive decline or unspecified type of dementia; 
diagonal lines indicate deceased individuals; arrows indicate index patients; numbers within a circle, 
square or diamond indicate the number of individuals; question marks indicate that there is no infor-
mation about individuals’ disease status. AAD: age at death, AAO: age at onset, AAS: age at sampling, 
wt: wild-type, var: variant.
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Discussion
Here, we report three rare, possibly pathogenic LRP10 variants in a relatively small series of 
130 patients from the South-West of the Netherlands. The identified variants were absent in 
62 unaffected subjects from the same region, and extremely rare in public databases (Table 1). 
Moreover, WES and MLPA performed in our four index patients with LRP10 variants 
detected no pathogenic variants in any of the other genes previously associated with PD or 
parkinsonism. 
 Of interest, the p.Tyr307Asn variant identified here in two Dutch patients with PD and 
PDD and in one relative with cognitive decline, was initially observed by us in one patient 
with PDD from Italy 9. The same variant was subsequently reported in a parent-offspring pair 
with PD, in a screening of 25 PD/DLB French families12; another two relatives affected by 
PD in that family did not share the p.Tyr307Asn variant, and might represent phenocopies. 
 Thus, the LRP10 p.Tyr307Asn variant has been identified at least three times so far, 
in independent studies targeting patients of European ancestry with familial forms of PD, 
PDD or DLB, and including a total of 701 unrelated probands: 608 patients of European 
ancestry in our initial study9; 25 French patients studied by Tesson and colleagues12; and 68 
Dutch patients in the current study (here we consider Family 1 an 2 as part of one extended 
kindred). The frequency of this variant among patients with familial forms of PD, PDD or 
DLB (3/701) is significantly higher compared to that present in GnomAD v2.1.1 (13/74109, 
only considering non-Finnish Europeans and Latino individuals, two-sided Fisher’s Exact 
test, p=0.0048). Furthermore, functional studies showed that this variant leads to decreased 
stability of the LRP10 protein compared to the wild-type9. Taken together, these genetic 
and functional data support the contention that this variant plays a role in the development 
of PD and PDD. The penetrance of the p.Tyr307Asn variant as well as of the p.Arg151Cys 
and p.Arg263His variants might be incomplete. However, an accurate estimation is currently 
impossible because, although PD occurred sporadically in some carriers, in many of them the 
parents had died before the age at disease development observed in their offspring, and the 
patients’ offspring are still younger than that age. 
 Considering together all patients with p.Tyr307Asn reported so far (n=6), the initial 
diagnosis was PD in five patients and progressive cognitive decline of neurodegenerative 
nature in one, rest tremor was the presenting sign in four out of the five patients diagnosed 
with PD, and mean age at onset was 66.5 years (SD:11.6; range:45-78; Table 1). During the 
course of PD, two patients developed dementia (one Italian patient and the Dutch patient 
II-2 - Family 2), two had no cognitive impairments (French patients), and one had multiple 
depressive periods (Dutch patient II-2 - Family 1). 
 Limited data are available for the p.Arg263His and p.Arg151Cys variants reported here 
in two patients with PD and PDD, respectively. Besides being very rare, predicted to be 
pathogenic by the majority of in-silico programs used here, and to replace highly conserved 
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amino acids located within conserved protein stretches (Supplementary Figure 2), no 
additional affected carriers have been reported so far, and functional data are not available. 
Therefore pathogenicity cannot be confidently established. Of note, the p.Arg151Cys 
substitution was previously found by us9 in one of 645 Dutch patients with abdominal aortic 
aneurysms. However, the neurological status of this subject is unknown. 
 In conclusion, we report LRP10 possibly pathogenic variants in patients with PD, 
PDD and dementia from a local Dutch population. Although our data cannot conclusively 
prove pathogenicity, the identification of additional patients with PD, PDD and dementia 
carrying the LRP10 p.Tyr307Asn variant provides further evidence that this variant might be 
pathogenic.
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Supplementary Information
Sanger sequencing of LRP10
Amplification of DNA fragments was performed in a total volume of 20 μl, containing 
2.0 μl of 10X FastStart Taq DNA Polymerase buffer, 1.6 μl of 2.5 mM dNTPs, 1.0 μl of 
10 μM forward primer, 1.0 μl of 10 μM reverse primer, 0.10 or 0.15 μl of FastStart Taq. 
DNA Polymerase (Roche, Basel, Switzerland), and 25 ng of genomic DNA. In addition, 
4 μl of 1X GC-RICH solution (Roche) was used for exon 1, 5 and 7. We used the same 
primers that have been previously reported by us.1 Initial denaturation was performed for 
5 minutes at 94˚C, followed by 30 cycles of 30 seconds at 94˚C, 30 seconds at 60˚C, and 
90 seconds at 72˚C. The final extension step was done for 5 minutes at 72˚C. Removal of 
unconsumed dNTPs and primers was performed with 3μl of PCR product, using 5 units of 
ExoI and 0·5 unit of Fast AP (Thermo Fisher Scientific, Waltham, MA, USA) for 45 minutes 
at 37˚C and 15 minutes at 80˚C. DNA strands were sequenced directly using the Big Dye 
Terminator (version 3·1; Thermo Fisher Scientific) according to the manufacturer’s protocol. 
SephadexG50 (GE Healthcare, Little Chalfont, UK) was used to remove dye terminators. 
Fragments were loaded on an ABI 3730XL Genetic Analyzer (Thermo Fisher Scientific). 
Sequences were analyzed using the software packages Seqscape v3·0 (Thermo Fisher 
Scientific) and Sequencing Analysis v6·0 (Thermo Fisher Scientific). For annotating LRP10 
sequence variants transcript NM_0140445.4 was adopted and the Human Genome Variation 
Society (HGVS) nomenclature was applied to describe the sequence variants.2
Whole exome sequencing and copy number analysis of LRP10 variant carriers
Whole exome sequencing (WES) was performed in the possibly pathogenic LRP10 variant 
carriers by Nimblegen SeqCap EZ MedExome 47 Mb in combination with Illumina Paired-
End Library Preperation and 2x 150 bp Sequencing on an Illumina HiSeq2000 sequencer. 
Using standard procedures3, reads were aligned to the human reference genome (hg19) using 
the Burrows-Wheeler alignment4 tool and processed using Picard (http://broadinstitute.
github.io/picard) and the Genome Analysis Toolkit (GATK)5. GATKs Haplotype Caller was 
used for variant calling and ANNOVAR for the annotation (version 2018Apr16)6.
 To screen for copy number variants of SNCA, PARK7, PINK1, and PARK2, Multiplex 
Ligation-dependent Probe Amplification (MLPA) was performed. The P051-D1 Parkinson 
kit (MRC Holland) was used according to the manufacturer’s protocol. Analysis was done 
using an ABI 3730XL Genetic Analyzer (Thermo Fisher Scientific) and Seqscape v3·0 
(Thermo Fisher Scientific).
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Haplotype analysis
Nine short tandem repeat (STR) markers located within a ~6 Mb genomic region containing 
the LRP10 locus were genotyped. PCR reactions were performed in a total volume of 20 μl, 
containing 30 ng of genomic DNA, 1x PCR buffer (FastStart, Roche), 200 µM dNTPs, 0.5 
µM fluorescent forward primer, 0.5 µM reverse primer, and 0.5 unit FastStart Taq Polymerase 
(Roche). Primers for the amplification of markers D14S261, D14S283 and D14S275 were 
taken from the available ABI Prism Linkage Mapping Set Version 2.5. Details of the other 
primers used for STR markers genotyping are available in Supplementary Table 5. PCR was 
carried out following an initial denaturation at 94˚C for 4 minutes, followed by 30 cycles of 
30 seconds at 94˚C, 30 seconds at 60˚C, and 90 seconds at 72˚C. The final extension step 
was done for 7 minutes at 72˚C. Fluorescent PCR products were mixed with GeneScan 500-
LIZ Size Standard (Applied Biosystems), loaded on an ABI 3730XL automated sequencer 
(Thermo Fisher Scientific), and analyzed using GeneMarker v.2.4.0 software package 
(SoftGenetics, State College, PA, USA).
Supplementary Table 1: Genes with established or proposed association with PD or parkinsonism.
Chr Start End Gene Mode of inheritance
1
1
1
1
2
6
15
21
22
22
8021714
17312453
20959948
65720133
25013136
161768590
62144588
33997269
32870707
38507502
8045342
17338467
20978004
65881552
25016251
163148834
62352664
34100351
32894818
38577857
PARK7
ATP13A2
PINK1
DNAJC6
PTRHD1
PARK2
VPS13C
SYNJ1
FBXO7
PLA2G6
AR
AR
AR
AR
AR
AR
AR
AR
AR
AR
1
1
3
4
7
12
14
16
17
17
20
11072462
155204239
132136361
90645250
56169266
40618813
23340822
46693589
42422491
43971702
5049129
11085549
155214653
132257876
90759447
56174187
40763087
23350789
46723144
42430474
44105700
5093736
TARDBP
GBA*
DNAJC13
SNCA
CHCHD2
LRRK2
LRP10
VPS35
GRN
MAPT
TMEM230
AD
AD
AD
AD
AD
AD
AD
AD
AD
AD
AD
X 154487526 154493852 RAB39B X-linked R
* Heterozygous variants in GBA are known risk factors for PD. GRCh37: genome reference consortium human 37. 
AR: autosomal recessive, AD: autosomal dominant, PD: Parkinson's disease.
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Supplementary Table 2: Demographic and clinical characteristics of the patients included in the study.
Sex, male 81 (62%)
Diagnosis at baseline PD 130 (100%)
Age at baseline, years 69.9 (8.4)
Age at onset, years 62.4 (9.6)
MMSE at baseline* 26.8 (3.8)
Family history of PD only 1st-degree 21 (16%)
only 2nd-degree 13 (10%)
1st- and 2nd-degree 3 (2%)
absent 93 (72%)
Family history of dementia only 1st-degree 31 (23%)
only 2nd-degree 8 (6%)
1st and 2nd-degree 4 (3%)
absent 87 (68%)
Family history of PD and/or dementia 1st- and/or 2nd-degree 68 (52%)
Diagnosis at follow up PD 71 (55%)
PDD 55 (42%)
DLB 4 (3%)
Follow up, years 7.0 (3.2)
N. of deceased patients 70 (54%)
Disease duration**, years  14.0 (8.3)
Data are presented as mean (SD) or n (%).*MMSE data was available in 128 patients; ** Data on disease duration 
was available in 70 patients. MMSE: Mini Mental State Examination, PD: Parkinson’s disease, PDD: Parkinson’s 
disease dementia, DLB: dementia with Lewy bodies.
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Supplementary Table 5: PCR Primers for markers genotyping.
Marker Oligo Name Oligo Sequence
CGR6800
CGR6800-FAM-FWD 5’-TGCCTGGCAAAACACACACAC-3’
CGR6800-REV 5’-GGCTGAGGCAGGACAATCAC-3’
CGR4118
CGR4118-FAM-FWD 5’-ATTTCCAGCCTCCCTCTAGCC-3’
CGR4118-REV 5’-GCCCAGTGTCTGGGGAGTAGG-3’
CGR7011
CGR7011-FAM-FWD 5’-GGCCACATTCGACTGTCATAGC-3’
CGR7011-REV 5’-CTTCCAAGCCGACAGGATGG-3’
D14S1023
D14S1023-FAM-FWD 5’-AAAGGACCTCACAAATTCCTTCTAGC-3’
D14S1023-REV 5’-TCTTGATAGTCTTAAGGTAGCAACAACAGC-3’
D14S990
D14S990-FAM-FWD 5’-ATATTGGGGGTGGGCTGTGG-3’
D14S990-REV 5’-GCTGAATAAAGTTGCACTGTGACTGG-3’
D14S972
D14S972-FAM-FWD 5’-GAGGTACAAGAAACTTAGAGAACCTCAAGC-3’
D14S972-REV 5’-TGTCTACAGATTCAATGCAATACTAACAGG-3’
Primers for the amplification of markers D14S261, D14S283 and D14S275 were according to the ABI Prism 
Linkage Mapping Set Version 2.5.
Chapter 4.1
116
Supplementary Figure 2: LRP10 protein structure and variants conservation analysis.
Representation of LRP10 protein structure and conservation analysis between LRP10 orthologs of 
p.Arg151, p.Arg263 and p.Tyr307 amino acids. CUB: compement C1R/C1S, urchin EGF, BMP1, 
LDLA: low-density lipoprotein receptor class A, TM: transmembrane domain, R-rich: Arginine-rich 
domain, YXXφ: a motife of Tyrosine plus two other amino acids, then an amino acid with a large bulky 
hydrophobic side chain, P-rich: Roline-rich domain, DXXLL: a motif of an aspartic acid, two other 
amino acids, then two leucines. We used the following National Centre for Biotechnology Information 
(NCBI) LRP10 Reference Sequence: Human, Homo Sapiens NP_054764.2; Chimpanzee, Pan troglo-
dytes XP_509843; Rhesus monkey, Macaca mulatta NP_001244860.1; Pongo, Sumatran orangutan 
NP_001125058; Dog, Canis lupus familiaris XP_537364; Mouse, Mus musculus NP_075369; Rattus 
norvegicus NP_001032866.
CUBSignal peptide
LDLA TM
YXXφ motif R-rich
P-rich DXXLL motif
Y307N
1 713
Extracellular Cytoplasmic
R151C R263H
Human           LQEEFQCLNHRCVSAVQRCDG 
Chimpanzee      LQEEFQCLNHRCVSAVQRCDG 
Rhesus Monkey          LQEEFQCLNHRCVSAVQRCDG 
Pongo            LQEEFQCLNHRCVSAVQRCDG 
Dog             LPEEFQCLNHRCVPLAQRCDN 
Mouse           LQEEFQCLNHRCIPAAQRCDG 
Rat          LQEEFQCLNHRCIPAAQRCDG 
                * **********:.  ****:. 
PGPPESSRLLRSLTHFSNGKA 
PGPPESSRLLRSLTHFSNGKA 
PGPPESSRLLRSLTHFSNGKA 
PGPPESSRLLRSLTHFSNGKA 
PGPPKTPRLLRSLTHFSNGKA 
GPPETPRLLRSLTHFSNGKA 
GPPETPRLLRSLTHFSNGKA  
.** :: :******:****** 
GFNATYHVRGYCLPWDRPCGL 
GFNATYHVRGYCLPWDRPCGL 
GFNATYHVRGYCLPWDRPCGL 
GFNATYHVRGYCLPWDRPCGL 
GFNATYHVRGYCLPWDRPCGL 
GFNATYHVRGYCLPWDRPCGL 
GFNATYHVRGYCLPWDRPCGL 
********************* 
Legend
A
A
* * *
Supplementary Figure 1: Haplotype analysis.
Haplotype analysis of the LRP10 region in two Dutch families (genealogically related within six ge-
nerations) and one Italian patient reported previously with the same LRP10 c.919T>A, p.Tyr307Asn 
variant (* Patient II-1, in Quadri et al., 2018); for pedigree position refer to Figure 1 in the manuscript. 
All LRP10 p.Tyr307Asn variant carriers share three markers flanking the variant, displayed in red. The 
individuals from the two Dutch families share a longer haplotype (displayed in orange), in keeping 
with a more recent common founder. Other markers specific to each family are reported in blue and 
green. Genomic positions are according to the Genome Reference Consortium human genome build 
38 (GRCh38).
D14S261 299 297 297 297297 297 301 297 301 297 297 297 295 303 20,472,545
D14S1023 296 294 296 294296 294 292 294 292 294 294 294 296 294 21,074,061
D14S283 135 129 129 129129 129 149 129 149 129 149 141 149 149 22,319,885
CGR6800 294 294 298 294294 294 294 294 294 294 294 292 294 294 22,826,800
LRP10 p.Tyr307Asn T A T AT A T A T A T T T A 22,881,580
CGR4118 390 390 390 390390 390 390 390 390 390 390 390 392 390 22,884,118
CGR7011 270 270 290 270270 270 290 270 290 270 290 270 290 270 22,997,011
D14S990 201 207 195 207201 207 191 207 191 207 191 199 193 199 23,217,423
D14S972 257 255 253 255253 255 253 251 253 251 253 253 251 253 23,978,736
D14S275 153 149 153 149155 149 155 151 155 151 155 153 149 155 26,327,814
II-2 III-2III-1 II-2 II-3 III-2
Italian
Patient*
Genomic
Position (bp)
Family 1 Family 2
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Abstract
The aim of this study was to explore whether variants in LRP10, recently associated with 
Parkinson’s disease and dementia with Lewy bodies, are observed in two large cohorts 
(discovery and validation cohort) of patients with progressive supranuclear palsy (PSP). 
A total of 950 PSP patients were enrolled: 246 PSP patients (n=85 possible (35%), n=128 
probable (52%), n=33 definite (13%)) in the discovery cohort, and 704 patients with 
definite PSP in the validation cohort. Sanger sequencing of all LRP10 exons and exon-
intron boundaries was performed in the discovery cohort, and whole exome sequencing was 
performed in the validation cohort. Two patients from the discovery cohort and eight patients 
from the validation cohort carried a rare, heterozygous, possibly pathogenic LRP10 variant 
(p.Gly326Asp, p.Asp389Asn, and p.Arg158His, p.Cys220Tyr, p.Thr278Ala, p.Gly306Asp, 
p.Glu486Asp, p.Arg554*, p.Arg661Cys). In conclusion, possibly pathogenic LRP10 variants 
occur in a small fraction of PSP patients and may be overrepresented in these patients 
compared to controls. This suggests that possibly pathogenic LRP10 variants may play a role 
in the development of PSP.
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Introduction
Progressive supranuclear palsy (PSP) is an adult-onset, progressive neurodegenerative 
disorder clinically characterized by parkinsonism, vertical supranuclear gaze palsy, and 
postural instability with falls. Other PSP features include frontal lobe and bulbar dysfunction, 
and cognitive decline.1,2 The clinical presentation of PSP is heterogeneous, and ten different 
clinical phenotypes have been described in patients with PSP neuropathology.3 PSP brain 
pathology includes neurofibrillary tangles, neutrophil threads, tufted astrocytes, neuronal 
loss and gliosis in multiple subcortical areas and other regions.4
 PSP is usually considered a sporadic tauopathy of unknown etiology.5 However, rare 
familial forms have been reported.6,7 Mutations in the microtubule-associated protein tau 
(MAPT) gene have been reported as the likely disease cause in a few pathologically confirmed 
PSP patients.8,9 Furthermore, genome-wide association studies have shown associations 
between PSP and the MAPT, syntaxin-6 (STX6), myelin-associated oligodendrocyte basic 
protein (MOBP), and eukaryotic translation initiation factor 2-alpha kinase (EIF2AK) 
genes, modulating the risk of developing PSP.10,11 Mutations in the leucine-rich repeat 
kinase 2 (LRRK2) gene have also been implicated in a small number of PSP cases12,13 and 
are the most common genetic cause of Parkinson’s disease (PD)14. Interestingly, pleomorphic 
neuropathology has been observed in PD patients with LRRK2 mutations, ranging from 
typical alpha-synuclein-positive pathology (seen in most cases), to PSP-like pathology.15 
Indeed in the original Japanese family, which nominated the linkage region for LRRK2, the 
affected members presented with tauopathy.16 Because of these genetic and pathological 
overlaps between PD and PSP, we hypothesized that variants in the low-density lipoprotein 
receptor related protein 10 (LRP10) gene, recently associated with PD and dementia with 
Lewy bodies (DLB)17,18, might also be implicated in PSP. LRP10 is a surface protein, which 
function is largely elusive. However, some studies have suggested a role of LRP10 in 
ligand trafficking between the trans-Golgi network, endosomes, and the plasma membrane. 
Furthermore, LRP10 has been linked to the metabolism of amyloid-β and α-synuclein.19,20,21 
 The aim of this study is to explore whether possibly pathogenic variants in LRP10 are 
observed in a large Dutch cohort of PSP patients (discovery cohort) using Sanger sequencing. 
Additionally, we try to validate our findings in a large cohort of PSP patients (validation 
cohort) from the USA and Europe using whole exome sequencing (WES).
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Methods
Subjects
PSP patients from two large cohorts were enrolled in this study. PSP was diagnosed according 
to the criteria of the National Institute for Neurological Disorders and Stroke / Society for 
PSP (NINDS-SPSP)1. The discovery cohort consisted of 246 PSP patients enrolled from a 
large Dutch cohort22, consecutively collected between 2003 and 2012 (Table 1). Patients 
were ascertained at the outpatient clinic of the Erasmus Medical Center Rotterdam, at 
home or at nursing homes. At inclusion, information about patient’s medical and family 
history and current medical status was collected. Furthermore, neurological examination 
was performed and a blood sample was collected. The validation cohort consisted of 704 
neuropathologically confirmed PSP patients enrolled form a large cohort of patients from 
the USA and Europe23 (Table 1). These patients were identified from brain banks, research 
hospitals and neuropathologists. The study was approved by the relevant Institutional Ethical 
Authorities and all participants or legal representatives signed informed consent.
Table 1: Demographic and clinical characteristics.
  n=246 n=704
Sex, male  127 (52%) 377 (54%)
Diagnosis (NINDS-SPSP) possible PSP 
probable PSP 
definite PSP
85 (35%) 
128 (52%) 
33 (13%)
0 (0%) 
0 (0%) 
704 (100%)
Age at onset, years (n=246;476)  65.8 (7.5) 68.1 (8.4)
Family history of neurodegenerative diseases (n=244;0) 1st-degree 
2nd-degree 
no
71 (29%) 
21 (9%) 
152 (62%)
NA 
NA 
NA
Deceased (n=244;704) 242 (98%) 704 (100%)
Age at death, years (n=241;698) 73.7 (7.3) 75.3 (8.2)
Data are presented as n (%) or mean (SD). NINDS-SPSP: National Institute for Neurological Disorders and Stroke 
/ Society for PSP, PSP: progressive supranuclear palsy, NA: not available.
Genetic analyses
Genetic analyses in the two cohorts
Genomic DNA was isolated from blood in the discovery cohort and from brain tissue in 
the validation cohort using standard methods. Sanger sequencing was performed for the 
entire open reading frame and exon-intron boundaries of LRP10 in the discovery cohort 
(protocol reported by Vergouw et al., 201918). WES was performed in the validation cohort 
(Supplementary Information). Possibly pathogenic LRP10 variants identified by WES in 
the validation cohort were validated by Sanger sequencing (Supplementary Information). 
LRP10 variants in progressive supranuclear palsy
145
Pa
rt 
4
We considered variants as possibly pathogenic according to the following criteria: (1) 
heterozygous state; (2) rarity, defined as a frequency <0.1% in the Genome Aggregation 
Database (GnomAD v2.1); (3) exonic location and non-synonymous, or predicted to 
affect splicing; and (4) predicted as pathogenic by at least five of 11 in-silico programs 
(Supplementary Information).
Additional genetic analyses in possibly pathogenic LRP10 variant carriers in the discovery 
cohort
WES, multiple ligation-dependent probe amplification (MLPA, P051-Parkinson mix 1), 
and C9orf72 repeat expansion analysis were performed in patients who carried possibly 
pathogenic LRP10 variants to exclude possibly pathogenic variants in other known genes 
causing parkinsonism or dementia (Supplementary Table 1). The presence of possibly 
pathogenic variants in known genes causing parkinsonism or dementia in possibly pathogenic 
LRP10 variant carriers decreases the chance of the LRP10 variant to be truly pathogenic. 
WES and MLPA were performed as reported previously by Vergouw et al., 201918. Details 
of the methods of the C9orf72 repeat expansion analysis can be found in the Supplementary 
Information.
Results
Demographic and clinical characteristics of the two cohorts
The discovery cohort consisted of 85 (35%) patients with possible PSP, 128 (52%) with 
probable PSP (52%), and 33 (13%) with definite PSP. The mean disease onset age in this 
cohort was 65.8 ± 7.5 years and 52% of patients were male; 29% of patients had at least one 
first-degree relative and 9% had at least one second-degree relative with a neurodegenerative 
disease. The validation cohort consisted of 704 definite PSP patients. The mean disease onset 
age in this cohort was 68.1 ± 8.4 years (data only available in n=476) and 54% of patients 
were male (Table 1).
Genetic findings
Two possibly pathogenic LRP10 variants were detected in the discovery cohort, each in 
single patients (p.Gly326Asp and p.Asp389Asn). In the validation cohort, seven possibly 
pathogenic LRP10 variants were detected in eight patients (p.Arg158His, p.Cys220Tyr, 
p.Thr278Ala, p.Gly306Asp, p.Glu486Asp, p.Arg554*, and p.Arg661Cys; see Table 2 and 
Supplementary Table 2 for specifications). Supplementary Figure 1a shows the LRP10 gene 
structure with the location of the identified variants and Supplementary Figure 1b shows the 
LRP10 protein structure with the location of the amino acid changes. Other variants in LRP10 
which did not fulfill the criteria for possible pathogenicity, as described in section 2.2.1., are 
depicted in Supplementary Table 3. Additional WES analysis (average depth of  >170x with 
99% of the target region covered >20x) in the possibly pathogenic LRP10 variant carriers 
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from the discovery cohort revealed a heterozygous VPS13C variant (p.Gln2546*, absent in 
GnomAD v2.1) in one patient (Supplementary Table 4). No other mutations in genes causing 
parkinsonism or dementia were found.
Clinical information of possibly pathogenic LRP10 variant carriers
An overview of the clinical information of the possibly pathogenic LRP10 variant carriers 
is shown in Table 2. Patient 1 from the discovery cohort (LRP10 p.Asp389Asn variant) 
experienced falls from the age of 61, followed by swallowing problems. At the age of 63, 
a mild downward vertical supranuclear gaze palsy, dysarthric speech, reduced arm swing, 
palatal tremor and impaired balance, but no clear ataxia were observed. He had a favorable 
response to levodopa. At neuropsychological examination deficits were observed in attention, 
concentration and executive functioning. Furthermore, mild memory and naming problems 
were seen. Brain MRI showed mild parieto-occipital and cerebellar atrophy and hypertrophy 
of the olivary nuclei. The patient died at the age of 66. Family history was negative for 
parkinsonism, dementia or motor neuron disease. Brain autopsy was not performed. This 
patient was diagnosed with probable PSP during life according to the NINDS-SPSP criteria1 
and can retrospectively be classified as probable PSP with Richardson’s syndrome (PSP-RS) 
according to the MDS criteria23. Patient 2 from the discovery cohort (LRP10 p.Gly326Asp 
variant) experienced tremor of the right leg from the age of 55, followed by falls, rigidity, 
swallowing, speech and memory problems from the age of 60. At the age of 64, vertical 
supranuclear gaze palsy, bradykinesia, intermittent rest tremor of arms and legs and balance 
problems were observed. She had a favorable response to levodopa. Neuropsychological 
examination showed severe deficits, especially with frontal subcortical and language 
problems. Brain MRI was unremarkable. The patient died at the age of 65. Family history 
was negative for parkinsonism, dementia or motor neuron disease. Brain autopsy was not 
performed. This patients was diagnosed with possible PSP during life according to the 
NINDS-SPSP criteria1 and can retrospectively be classified as probable PSP with predominant 
parkinsonism (PSP-P) according to the MDS criteria23.
Discussion
In this study we explored the presence of LRP10 variants in two cohorts with a total of 950 
PSP patients (discovery cohort n=246, validation cohort n=704). The PSP diagnosis was 
pathologically confirmed in 78% of these patients. Two possibly pathogenic LRP10 variants 
(p.Gly326Asp and p.Asp389Asn) were identified in two patients from the discovery cohort 
and seven possibly pathogenic LRP10 variants (p.Arg158His, p.Cys220Tyr, p.Thr278Ala, 
p.Gly306Asp, p.Glu486Asp, p.Arg554*, and p.Arg661Cys) were identified in eight patients 
from the validation cohort. These variants are very rare, are predicted to be pathogenic by ≥5 
in-silico programs and are mostly located in LRP10 exon 5, where other probably pathogenic 
variants were previously found17. Interestingly, the frequency of possibly pathogenic LRP10 
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variants is significantly higher in the validation cohort (8/1408 alleles=0.6%) compared 
to a previous published control cohort of patients with abdominal aneurysms17 (1/1248 
alleles=0.08%; Fishers’s Exact test p value 0.04). In addition, the p.Gly306Asp variant has 
been identified previously in two out of 2835 PD patients and one out of 5343 controls24, 
the p.Gly326Asp variant in one out of 264  patients with multiple system atrophy and in no 
controls25, and the p.Glu486Asp variant in three out of 2835 PD patients and one out of 111 
DLB patients compared to none in 5343 and 233 controls, respectively24. The p.Arg158His, 
p.Arg554* and p.Arg661Cys variants have previously been identified in single controls24-26 
(Supplementary Table 5).
 Both patients from the discovery cohort displayed uncommon PSP clinical features. 
Patient 1 had a palatal tremor, inferior olivary hypertrophy and cerebellar atrophy. Inferior 
olivary hypertrophy is observed in 1.5% of pathologically confirmed PSP patients27, 
but associated palatal tremor is very rare in PSP27,28. The syndrome of progressive ataxia 
and palatal tremor29 may retrospectively also be considered in patient 1, yet the clinical 
phenotype is most consistent with PSP. An uncommon feature in patient 2 was the presence 
of an isolated tremor of the right leg in the first 5 years of the disease. Unfortunately, autopsy 
studies were not performed in these patients, and therefore the diagnosis could not be verified 
at pathological level. The absence of a family history of PSP or other neurodegenerative 
disorders in these two patients would be compatible with an incomplete penetrance or a de 
novo occurrence of the LRP10 variants.
 Of note, a VPS13C variant (p.Gln2546*) was observed in one LRP10 variant carrier. 
Mutations in VPS13C are associated with autosomal recessive forms of early-onset 
parkinsonism.30 In our patient the variant was found in heterozygous state and is therefore 
most likely an incidental finding.
 Strengths of this study are the large sample size of the two PSP cohorts, the validation 
of our findings in an independent cohort, and the high percentage of neuropathologically 
confirmed PSP patients. Limitations are the lack of screening for LRP10 genomic deletions 
of multiplications (not detectable by Sanger methods).
 In conclusion, this is the first study of LRP10 in two large PSP cohorts. We showed that 
rare, possibly pathogenic LRP10 variants occur in a small, but substantial fraction of PSP 
patients. Furthermore, possibly pathogenic LRP10 variants may be overrepresented in PSP 
patients compared to controls and may therefore play a role in disease pathogenesis. Further 
studies are warranted to replicate our findings and to study which molecular mechanisms 
underlie the possible association between LRP10 and PSP.
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Supplementary Information
Whole exome sequencing in validation cohort
Whole exome sequencing (WES) was performed using the Nimblegen's VCRome v2.1 
(36Mb) capture kit on an Illumina HiSeq sequencer. Sequencing data were analyzed using 
the in-house DNA Resequencing analysis workflow (DRAW)1. Reads were aligned to the 
human reference genome (hg19) using the Burrows-Wheeler alignment tool (0.7.5)2 and 
processed using Picard (http://picard.sourceforge.net/) and the Genome Analysis Toolkit 
(GATK)3. Additional sequencing was done for samples where coverage did not reach 20x 
for more than 80% of the targeted region and 10x for more than 90% of the targeted regions. 
Data from multiple sequencing experiments from the same individual were merged using 
SAMtools4. Variant calling was performed by GATKs Haplotype Caller and annotated using 
SNPEff5. An average depth of  33x was reached.
Sanger sequencing in validation cohort
Genomic DNA (~50ng) was amplified using a SimpliAmp Thermal Cycler (Applied 
Biosystems) in a 20 µl reaction volume with HotStarTaq Master Mix (Qiagen) in the 
presence of 2 µM primers (IDT). The PCR conditions used were: 95°C 15min followed by 
30 cycles of 95°C 20sec, 55°C 30sec, 72°C 2min with a final extension of 72°C 7min. The 
amplified PCR products were prepared for Sanger sequencing by adding ExoSAP-IT (USB) 
and incubating at 37°C for 45min followed by 80°C for 15min. The PCR products were 
then Sanger sequenced using the BigDye® Terminator v3.1 Cycle Sequencing kit (Part No. 
4336917 Applied Biosystems). The sequencing reaction contained BigDye® Terminator v3.1 
Ready Reaction Mix, 5X Sequencing Buffer, 5M Betaine solution (Part No. B0300 Sigma) 
and 0.64uM sequencing primer (IDT) in a total volume of 5ul. The sequencing reaction 
was performed in a SimpliAmp Thermal Cycler (Applied Biosystems) using the following 
program: 96°C 1min followed by 25 cycles of 96°C 10sec, 50°C 5sec, 60°C 1min15sec. 
The products were cleaned using XTerminator and SAM Solution (Applied Biosystems) 
with 30 min of shaking at 1800 rpm followed by centrifugation at 1000 rpm for 2min.  The 
sequencing products were analyzed on a 3130XL Genetic Analyzer (Applied Biosystems) 
and the sequencing traces were analyzed using Sequencer 5.4 (Gene Code). Information on 
primers can be given by the Authors on request.
C9orf72 repeat expansion analysis 
C9orf72 repeat expansion analysis was performed to screen for the presence of a pathogenic 
chromosome 9p21 GGGGCC hexanucleotide repeat expansion. A previously described 
repeat-primed PCR assay6 was used. An ABI3730XL Genetic Analyzer (Thermo Fisher 
Scientific) and GeneMarker Ver.2.4.0 (SoftGenetics, State College, PA, USA) were used for 
analysis. A pathogenic C9orf72 expansion was defined as more than 30 repeats.6
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Supplementary Table 1: Known genes causing parkinsonism or dementia.
Chr Start End Gene Mode of inheritance
1
1
1
1
2
6
15
21
22
22
8021714
17312453
20959948
65720133
25013136
161768590
62144588
33997269
32870707
38507502
8045342
17338467
20978004
65881552
25016251
163148834
62352664
34100351
32894818
38577857
PD genes
PARK7
ATP13A2
PINK1
DNAJC6
PTRHD1
PARK2
VPS13C
SYNJ1
FBXO7
PLA2G6
AR
AR
AR
AR
AR
AR
AR
AR
AR
AR
1
1
3
4
7
12
14
16
17
17
20
11072462
155204239
132136361
90645250
56169266
40618813
23340822
46693589
42422491
43971702
5049129
11085549
155214653
132257876
90759447
56174187
40763087
23350789
46723144
42430474
44105700
5093736
TARDBP
GBA*
DNAJC13
SNCA
CHCHD2
LRRK2
LRP10
VPS35
GRN
MAPT
TMEM230
AD
AD
AD
AD
AD
AD
AD
AD
AD
AD
AD
X 154487526 154493852 RAB39B X-linked R
1
3
7
9
16
17
17
11072462
87276413
144149034
35056065
31191431
43971702
42422491
11085549
87304698
144533488
35072739
31206192
44105700
42430474
FTD genes
TARDBP
CHMP2B
TBK1
VCP
FUS
MAPT
GRN
AD
AD
AD
AD
AD
AD
AD
X 56590025 56593443 UBQLN2 X-linked D
1
11
14
19
21
227057885
121322912
73603143
1040102
27252861
227083804
121504471
73690399
1065571
27543446
AD genes
PSEN2
SORL1
PSEN1
ABCA7*
APP
AD
AD
AD
AD
AD
2 74588281 74619214
Perry syndrome gene 
DCTN1 AD
14
18
74942900
21086148
74960084
21166581
Niemann-Pick C genes
NPC2
NPC1
AR
AR
* also risk gene. The Genome Reference Consortium Human Build 37 (hg19) was used. AR: autosomal recessive, 
AD: autosomal dominant or Alzheimer’s disease, PD: Parkinson’s disease, FTD: frontotemporal dementia.
LRP10 variants in progressive supranuclear palsy
153
Pa
rt 
4
Su
pp
le
m
en
ta
ry
 T
ab
le
 2
: I
n-
si
li
co
 p
at
ho
ge
ni
ci
ty
 p
re
di
ct
io
ns
.
Va
ri
an
t-e
ffe
ct
 p
re
di
ct
io
ns
 so
ftw
ar
e 
(s
co
re
s)
G
en
om
ic
 
po
si
tio
n
N
uc
le
ot
id
e 
ch
an
ge
A
m
in
o 
ac
id
 
ch
an
ge
G
E
R
P
SI
FT
Po
ly
ph
en
2 
H
D
IV
Po
ly
ph
en
2 
H
VA
R
L
R
T
M
ut
at
io
n 
Ta
st
er
M
ut
at
io
n 
A
ss
es
so
r
FA
T
H
M
M
M
et
aS
V
M
M
et
aL
R
C
A
D
D
 
ph
re
d
M
-C
A
P
D
isc
ov
er
y 
co
ho
rt
14
:2
33
45
13
4
c.
97
7G
>A
p.
G
ly
32
6A
sp
4.
14
T 
(0
.3
68
)
B 
(0
.2
97
)
B 
(0
.1
72
)
N
 (0
.0
09
)
D
 (0
.8
87
)
L 
(1
.2
45
)
D
 (-
3.
23
)
D
 (0
.0
67
)
D
 (0
.6
44
)
15
.5
9
D
 (0
.0
34
)
14
:2
33
45
32
2
c.
11
65
G
>A
p.
A
sp
38
9A
sn
4.
9
T 
(0
.5
84
)
B 
(0
.0
22
)
B 
(0
.0
07
)
D
 (0
.0
00
)
D
 (1
.0
00
)
L 
(1
.1
65
)
D
 (-
2.
67
)
T 
(-0
.2
26
)
D
 (0
.5
35
)
17
.5
7
D
 (0
.0
30
)
14
: 2
33
41
95
1
c.
39
C>
T
p.
G
ly
13
=
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
14
:2
33
45
19
5
c.
10
38
 C
>T
p.
A
sp
34
6=
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
14
:2
33
46
27
9
c.
16
85
G
>A
p.
A
rg
56
2H
is
5.
23
T 
(0
.6
8)
D
 (0
.9
99
)
D
 (0
.9
72
)
D
 (0
.0
00
)
D
 (1
.0
00
)
M
 (2
.2
)
D
 (-
3.
37
)
D
 (0
.4
51
)
D
 (0
.7
72
)
26
.6
N
A
14
:2
33
46
63
0
c.
20
36
A
>C
p.
H
is6
79
Pr
o
3.
84
T 
(0
.1
43
)
B 
(0
.0
72
)
B 
(0
.0
37
)
N
 (0
.2
26
)
D
 (1
.0
00
)
L 
(0
.9
75
)
D
 (-
3.
05
)
T 
(-0
.2
02
)
D
 (0
.5
61
)
9.
05
4
D
 (0
.0
93
)
Va
lid
at
io
n 
co
ho
rt
14
:2
33
44
63
0
c.
47
3G
>A
p.
A
rg
15
8H
is
5.
03
T 
(0
.0
64
)
(0
.0
21
)
B 
(0
.0
07
)
N
 (0
.0
00
)
D
 (1
.0
00
)
L 
(1
.4
)
D
 (-
3.
85
)
D
 (0
.3
59
)
D
 (0
.7
68
)
22
.3
D
 (0
.0
58
)
14
:2
33
44
81
6
c.
65
9G
>A
p.
Cy
s2
20
Ty
r
5.
73
D
 (0
.0
)
D
 (1
.0
)
D
 (0
.9
99
)
D
 (0
.0
00
)
D
 (1
)
M
 (2
.6
35
)
T 
(-0
.2
)
D
 (0
.1
27
)
D
 (0
.5
20
)
25
.6
D
 (0
.0
93
)
14
:2
33
44
98
9
c.
83
2A
>G
p.
Th
r2
78
A
la
5.
97
T 
(0
.2
92
)
P 
(0
.9
11
)
P 
(0
.6
21
)
D
 (0
.0
00
)
D
 (0
.9
95
)
L 
(0
.9
75
)
T 
(1
.6
)
T 
(-1
.0
87
)
T 
(0
.0
67
)
22
.7
T 
(0
.0
06
)
14
:2
33
45
07
4
c.
91
7G
>A
p.
G
ly
30
6A
sp
5.
97
T 
(0
.0
55
)
D
 (0
.9
59
)
P 
(0
.6
)
D
 (0
.0
00
)
D
 (0
.9
97
)
L 
(1
.2
05
)
D
 (-
3.
35
)
D
 (0
.6
01
)
D
 (0
.7
52
)
23
.5
D
 (0
.0
48
)
14
:2
33
45
93
1
c.
14
58
G
>C
p.
G
lu
48
6A
sp
5.
91
D
 (0
.0
36
)
D
 (0
.9
99
)
D
 (0
.9
63
)
D
 (0
.0
00
)
D
 (1
.0
00
)
M
 (1
.9
5)
D
 (-
3.
44
)
D
 (0
.8
41
)
D
 (0
.8
61
)
28
.1
D
 (0
.0
39
)
14
:2
33
46
25
4
c.
16
60
C>
T
p.
A
rg
55
4*
5.
23
N
A
N
A
N
A
D
 (0
.0
00
)
D
 (1
)
N
A
N
A
N
A
N
A
42
N
A
14
:2
33
46
57
5
c.
19
81
C>
T
p.
A
rg
66
1C
ys
4.
97
T 
(0
.0
81
)
D
 (0
.9
99
)
P 
(0
.7
61
)
D
 (0
.0
00
)
D
 (1
.0
00
)
L 
(1
.1
)
D
 (-
3.
18
)
D
 (0
.7
30
)
D
 (0
.8
05
)
33
D
 (0
.2
67
)
14
:2
33
41
95
1
c.
39
C>
T
p.
G
ly
13
=
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
14
:2
33
44
57
2
c.
41
5A
>G
p.
M
et
13
9V
al
2.
05
T 
(0
.3
02
)
B 
(0
.0
02
)
B 
(0
.0
03
)
N
 (0
.6
65
)
N
 (1
.0
00
)
N
 (-
0.
62
5)
D
 (-
2.
19
)
T 
(-1
.0
10
)
T 
(0
.0
26
)
3.
32
1
N
A
14
:2
33
44
84
8
c.
69
1C
>T
p.
A
rg
23
1T
rp
3.
79
D
 (0
.0
05
)
D
 (1
.0
)
D
 (0
.9
81
)
D
 (0
.0
00
)
D
 (0
.9
36
)
M
 (2
.0
85
)
T 
(2
.1
4)
T 
(-1
.0
68
)
T 
(0
.0
32
)
33
N
A
14
:2
33
45
04
8
c.
89
1C
>T
p.
G
ly
29
7=
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
14
:2
33
45
12
9
c.
97
2C
>T
p.
G
ly
32
4=
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
14
:2
33
45
13
3
c.
97
6G
>A
p.
G
ly
32
6S
er
4.
07
T 
(0
.5
84
)
B 
(0
.0
06
)
B 
(0
.0
19
)
N
 (0
.0
09
)
D
 (0
.8
61
)
N
 (0
.2
05
)
D
 (-
3.
16
)
T 
(-0
.9
50
)
T 
(0
.1
15
)
16
.8
5
T 
(0
.0
07
)
14
:2
33
46
02
5
c.
15
52
G
>A
p.
A
sp
51
8A
sn
5.
24
D
 (0
.0
11
)
D
 (0
.9
93
)
P 
(0
.7
02
)
D
 (0
.0
00
)
D
 (0
.9
87
)
L 
(1
.3
9)
D
 (-
3.
11
)
D
 (0
.4
28
)
D
 (0
.6
45
)
25
.2
N
A
14
:2
33
46
27
9
c.
16
85
G
>A
p.
A
rg
56
2H
is
5.
23
T 
(0
.6
8)
D
 (0
.9
99
)
D
(0
.9
72
)
D
 (0
.0
00
)
D
 (1
.0
00
)
M
 (2
.2
)
D
 (-
3.
37
)
D
 (0
.4
51
)
D
 (0
.7
72
)
26
.6
N
A
14
:2
33
46
51
7
c.
19
23
G
>A
p.
Le
u6
41
=
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
14
:2
33
46
68
2
c.
20
88
G
>C
p.
Le
u6
96
=
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
G
E
R
P
: 
G
en
om
ic
 E
vo
lu
ti
on
ar
y 
R
at
e 
P
ro
fi
li
ng
, 
S
IF
T
: 
S
or
ti
ng
 I
nt
ol
er
an
t 
F
ro
m
 T
ol
er
an
t, 
P
ol
yP
he
n2
 H
D
IV
: 
P
ol
ym
or
ph
is
m
 P
he
no
ty
pi
ng
 v
er
si
on
 2
 h
um
an
 d
iv
er
si
ty
, 
P
ol
yP
he
n2
 
H
VA
R:
 P
ol
ym
or
ph
ism
 P
he
no
ty
pi
ng
 v
er
sio
n 
2 
hu
m
an
 v
ar
ia
tio
n,
 L
RT
: L
ik
el
ih
oo
d 
Ra
tio
 T
es
t, 
FA
TH
M
M
: F
un
ct
io
na
l A
na
ly
sis
 T
hr
ou
gh
 H
id
de
n 
M
ar
ko
v 
M
od
el
s, 
SV
M
: S
up
po
rt 
Ve
ct
or
 M
ac
hi
ne
, L
R:
 L
og
ist
ic
 R
eg
re
ss
io
n,
 C
A
D
D
: C
om
bi
ne
d 
A
nn
ot
at
io
n 
D
ep
en
de
nt
 D
ep
le
tio
n,
 M
-C
A
P:
 M
en
de
lia
n 
Cl
in
ic
al
ly
 A
pp
lic
ab
le
 P
at
ho
ge
ni
ci
ty
, T
: t
ol
er
at
ed
, D
: d
am
ag
-
in
g/
di
se
as
e 
ca
us
in
g,
 B
: b
en
ig
n,
 N
: p
ol
ym
or
ph
ism
/n
eu
tra
l, 
P:
 p
ol
ym
or
ph
ism
 a
ut
om
at
ic
, L
: l
ow
, M
: m
ed
iu
m
, N
A
: n
ot
 a
va
ila
bl
e.
 T
ra
ns
cr
ip
t r
ef
er
en
ce
s: 
N
M
_0
14
04
5-
4.
 A
N
N
O
VA
R 
(v
er
sio
n 
20
18
A
pr
16
).
Chapter 4.3
154
Su
pp
le
m
en
ta
ry
 T
ab
le
 3
: O
th
er
 L
RP
10
 v
ar
ia
nt
s 
w
hi
ch
 d
id
 n
ot
 f
ul
fi
ll
 o
ur
 c
ri
te
ri
a 
fo
r 
po
ss
ib
le
 p
at
ho
ge
ni
ci
ty
.
Pa
tie
nt
(s
)
G
en
om
ic
 
po
si
tio
n
N
uc
le
ot
id
e 
ch
an
ge
A
m
in
o 
ac
id
 
ch
an
ge
E
xo
n 
C
od
in
g 
ef
fe
ct
db
SN
P 
14
2 
ac
ce
ss
io
n 
nu
m
be
r
A
lle
le
 fr
eq
ue
nc
y 
G
no
m
A
D
 (a
lle
le
s)
Fu
nc
tio
na
l p
re
di
ct
io
ns
: 
pa
th
og
en
ic
 (t
ot
al
)
Sp
lic
in
g 
pr
ed
ic
tio
ns
: 
de
le
te
ri
ou
s (
to
ta
l)
D
isc
ov
er
y 
co
ho
rt
3-
7
14
:2
33
41
95
1
c.
39
C>
T
p.
G
ly
13
=
2
sy
no
ny
m
ou
s
rs
34
29
44
71
2.
7%
 (7
72
5)
N
A
n.
a.
8
14
:2
33
45
19
5
c.
10
38
 C
>T
p.
A
sp
34
6=
5
sy
no
ny
m
ou
s
rs
20
16
57
63
1
0.
00
7%
 (2
0)
N
A
n.
a.
9,
10
14
:2
33
46
27
9
c.
16
85
G
>A
p.
A
rg
56
2H
is
7
m
iss
en
se
rs
14
21
53
00
1
0.
7%
 (1
97
4)
9/
10
n.
a.
 
11
14
:2
33
46
63
0
c.
20
36
A
>C
p.
H
is6
79
Pr
o
7
m
iss
en
se
rs
14
96
85
15
4
0.
02
%
 (5
2)
4/
10
n.
a.
Va
lid
at
io
n 
co
ho
rt
9-
18
14
:2
33
41
95
1
c.
39
C>
T
p.
G
ly
13
=
2
sy
no
ny
m
ou
s
rs
34
29
44
71
2.
7%
 (7
72
5)
N
A
n.
a.
19
, 2
0
14
:2
33
44
57
2
c.
41
5A
>G
p.
M
et
13
9V
al
5
m
iss
en
se
rs
28
53
49
29
0.
7%
 (1
97
4)
1/
11
0/
4
21
14
:2
33
44
84
8
c.
69
1C
>T
p.
A
rg
23
1T
rp
5
m
iss
en
se
rs
35
04
32
11
0.
2%
 (6
63
)
7/
11
n.
a.
22
, 2
3
14
:2
33
45
04
8
c.
89
1C
>T
p.
G
ly
29
7=
5
sy
no
ny
m
ou
s
rs
76
88
01
09
6
0.
03
%
 (9
4)
N
A
n.
a.
24
, 2
5
14
:2
33
45
12
9
c.
97
2C
>T
p.
G
ly
32
4=
5
sy
no
ny
m
ou
s
rs
75
08
33
99
5
0.
00
2%
 (5
)
N
A
n.
a.
26
, 2
7
14
:2
33
45
13
3
c.
97
6G
>A
p.
G
ly
32
6S
er
5
m
iss
en
se
rs
13
81
70
86
5
0.
2%
 (4
50
)
3/
11
n.
a.
28
14
:2
33
46
02
5
c.
15
52
G
>A
p.
A
sp
51
8A
sn
6
m
iss
en
se
rs
74
35
71
67
0.
4%
 (1
05
3)
9/
10
0/
4
29
-4
0
14
:2
33
46
27
9
c.
16
85
G
>A
p.
A
rg
56
2H
is
7
m
iss
en
se
rs
14
21
53
00
1
0.
7%
 (1
97
4)
9/
10
n.
a.
41
14
:2
33
46
51
7
c.
19
23
G
>A
p.
Le
u6
41
=
7
sy
no
ny
m
ou
s
rs
37
14
30
50
8
0.
02
%
 (6
0)
N
A
n.
a.
42
14
:2
33
46
68
2
c.
20
88
G
>C
p.
Le
u6
96
=
7
sy
no
ny
m
ou
s
rs
14
83
91
88
4
0.
00
2%
 (6
)
N
A
1/
4
O
nl
y 
va
ria
nt
s i
n 
ex
on
s o
r a
t t
he
 e
xo
n-
in
tro
n 
bo
un
da
ry
 (-
10
/+
10
) a
re
 d
isp
la
ye
d.
 T
he
 G
en
om
e 
Re
fe
re
nc
e 
Co
ns
or
tiu
m
 H
um
an
 B
ui
ld
 3
7 
(h
g1
9)
 a
nd
 N
M
_0
14
04
5-
4 
LR
P1
0 
tra
ns
cr
ip
t 
w
er
e 
us
ed
. G
no
m
A
D
: G
en
om
e A
gg
re
ga
tio
n 
D
at
ab
as
e,
 N
A
.: 
no
t a
va
ila
bl
e,
 n
.a
.: 
no
t a
pp
lic
ab
le
. S
pl
ic
in
g 
pr
ed
ic
tio
n 
pr
og
ra
m
s: 
SS
F,
 M
ax
En
t, 
N
N
SP
LI
CE
, G
en
e 
Sp
lic
er
.
Su
pp
le
m
en
ta
ry
 T
ab
le
 S
4:
 P
os
sib
ly
 p
at
ho
ge
ni
c 
va
ria
nt
s i
n 
kn
ow
n 
ge
ne
s c
au
sin
g 
pa
rk
in
so
ni
sm
 o
r d
em
en
tia
.
Pa
tie
nt
G
en
e
G
en
om
ic
 
po
si
tio
n
N
uc
le
ot
id
e 
ch
an
ge
A
m
in
o 
ac
id
 
ch
an
ge
E
xo
n 
C
od
in
g 
ef
fe
ct
db
SN
P 
14
2 
ac
ce
ss
io
n 
nu
m
be
r
A
lle
le
 fr
eq
ue
nc
y 
G
no
m
A
D
 (a
lle
le
s)
Fu
nc
tio
na
l p
re
di
ct
io
ns
: 
pa
th
og
en
ic
 (t
ot
al
)
1
VP
S1
3C
15
:6
22
11
49
0
c.
76
36
C>
T
p.
G
ln
25
46
*
58
sto
pg
ai
n
.
.
n.
a.
O
nl
y 
va
ria
nt
s i
n 
ex
on
s o
r a
t t
he
 e
xo
n-
in
tro
n 
bo
un
da
ry
 (-
10
/+
10
) a
re
 d
isp
la
ye
d.
 T
he
 G
en
om
e 
Re
fe
re
nc
e 
Co
ns
or
tiu
m
 H
um
an
 B
ui
ld
 3
7 
(h
g1
9)
 a
nd
 N
M
_0
20
82
1 
V
PS
13
C 
tra
ns
cr
ip
t 
w
er
e 
us
ed
; G
no
m
A
D
: G
en
om
e A
gg
re
ga
tio
n 
D
at
ab
as
e,
 n
.a
..:
 n
ot
 a
pp
lic
ab
le
.
LRP10 variants in progressive supranuclear palsy
155
Pa
rt 
4
Supplementary Table 5: Overview of identified variants in current and previous studies.
Genomic 
position
Nucleotide  
change
Amino acid 
change
Study Present in 
number of
patients 
(diagnosis)
Present in
number of 
controls
Discovery 
cohort
14:23345322 c.1165G>A p.Asp389Asn Current 1/950 (PSP) 0/645
14:23345134 c.977G>A p.Gly326Asp Current 1/950 (PSP) 0/645
Pihlström et al., 20187 1/264 (MSA) 0/462
Validation 
cohort
14:23344630 c.473G>A p.Arg158His Current 1/950 (PSP) 0/645
Kia et al., 20188 0/2835 (PD) 1/5343
14:23344816 c.659G>A p.Cys220Tyr Current 1/950 (PSP) 0/645
14:23344989 c.832A>G p.Thr278Ala Current 1/950 (PSP) 0/645
14:23345074 c.917G>A p.Gly306Asp Current 2/950 (PSP) 0/645
Kia et al., 20188 2/2835 (PD) 1/5343
14:23345931 c.1458G>C p.Glu486Asp Current 1/950 (PSP) 0/645
Kia et al., 20188 3/2835 (PD) and 
1/111 (DLB)
0/5343 and 
0/233
14:23346254 c.1660C>T p.Arg554* Current 1/950 (PSP) 0/645
Guerreiro et al., 20189 0/1040 (DLB) 1/1422
14:23346575 c.1981C>T p.Arg661Cys Current 1/950 (PSP) 0/645
Pihlström et al., 20187 0/264 (MSA) 1/462
Kia et al., 20188 0/2835 (PD) 1/5343
PSP: progressive supranuclear palsy, MSA: multiple system atrophy, PD: Parkinson’s disease, DLB: dementia with 
Lewy bodies.
Supplementary Figure 1: 
(a) LRP10 gene structure with the location of found variants. (b) LRP10 protein structure with the 
location of amino acid changes.
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Dementia with Lewy bodies (DLB) is a common neurodegenerative disease of the elderly1 
and is characterized by progressive cognitive decline, parkinsonism, visual hallucinations, 
fluctuating cognition, and REM-sleep behavior disorders.2 Clinical features, pathological 
hallmarks and genetic factors of DLB overlap with those of Alzheimer’s disease (AD) and 
Parkinson’s disease (PD).1 Genetic factors seem to play a considerable role in DLB, as the 
heritable component of DLB has been estimated to be approximately 60%.3,4 However, few 
genetic studies, often with small sample sizes and candidate gene-based (biased) approaches, 
have been undertaken in DLB (as described in our review in Chapter 1.2).5 The first genome 
wide association (GWA) studies of DLB have only been performed recently, and whole 
exome sequencing (WES) studies have not been published yet. The paucity of genetic studies 
in DLB could be due to several reasons. Firstly, DLB has only been recognized as a separate 
disease since 1984. Up until that time, DLB was referred to as the Lewy body variant of AD 
or grouped under the umbrella term Lewy body diseases, which is comprised of PD, PD 
dementia (PDD) and DLB. Secondly, the accuracy of the clinical criteria for DLB is relatively 
low and many DLB patients are misdiagnosed or overlooked.6 This could have led to small 
and heterogeneous study groups. Thirdly, DLB patients with multiple relatives suffering from 
DLB, AD, or PD have only rarely been recognized, which hampers the identification of 
rare, highly-penetrant genetic variants in this disease. As a consequence, only several genetic 
factors (the APOE ɛ4 allele, specific disease-associated variants in GBA and SNCA) have 
been associated with DLB up until now. These genetic factors seem to explain only a small 
percentage of the total heritability4, which suggests that many genetic factors still remain to 
be discovered.
 This thesis describes our findings on the familial aggregation in DLB, the role for 
variants in known AD and PD genes in DLB, and the search for novel genes associated 
with DLB. This Part begins with a discussion of these findings in light of current literature. 
Subsequently, an overview is provided on how the identified genes may play a role in the 
molecular mechanisms leading to DLB, and on how these genes may aid in developing 
biomarkers and disease-modifying treatment options in the future. Hereafter, the strengths 
and limitations of the studies contained in this thesis are discussed. Finally, suggestions for 
future study directions are provided. 
Familial aggregation
The precise frequencies of DLB patients with relatives with DLB, AD, or PD are currently 
unknown. Nonetheless, it has been noted that AD and PD occur more frequently in relatives 
of DLB patients than in relatives of controls7,8, and that DLB has a higher prevalence in 
relatives of DLB patients than in relatives of AD patients.9 Families with multiple members 
with DLB, compatible with an autosomal dominant pattern of inheritance, have rarely been 
described. Mutations in SNCA, LRRK2, PSEN1, PSEN2, and APP have been identified in 
a handful of DLB patients with relatives with DLB, PD, or dementia.5 These genes have 
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previously been associated with PD (SNCA, LRRK2) or AD (PSEN1, PSEN2, APP). Genetic 
factors associated with DLB, PD, and AD seem, therefore, to overlap, but little is known 
about the magnitude of this overlap and its effect on different phenotypes. 
 In this thesis, we studied possible differences in phenotype between DLB patients with 
relatives with dementia or PD (familial patients) and DLB patients without relatives with 
these diseases (sporadic patients) (Chapter 2.1) and between DLB patients with and without 
known, well-established genetic risk factors (Chapter 3.1). In Chapter 2.1 we showed 
that familial DLB patients have a shorter survival than sporadic DLB patients. We also 
found a higher percentage of familial DLB patients with elevated AD biomarkers in their 
cerebrospinal fluid (CSF) compared to sporadic DLB patients. This suggests that genetic 
factors influence the course of the disease, possibly by affecting the amount of concomitant 
AD pathology. The exploratory study elaborated in Chapter 3.1 suggested that DLB patients 
with the APOE ε4 allele more often have a positive family history of AD or dementia than 
non-carriers. Furthermore, a family history of PD or PDD was present at a greater frequency 
in DLB patients with disease-associated GBA variants than in DLB patients with the APOE 
ε4 allele. Interestingly, we also found that DLB patients with relatives with PD more often 
show parkinsonism as first symptom than DLB patients with a family history of dementia 
(Chapter 2.1). 
 These findings suggest that different subgroups may be identified within the DLB 
population: patients with a phenotype which more closely resembles PD, with possibly 
underlying PD-associated genetic factors, and patients with a phenotype which more 
closely resembles AD, with possibly underlying AD-associated genetic factors and mixed 
neuropathology. 
 In the next paragraph, I will discuss which well-established genes are associated with 
DLB and how they overlap with genes associated with AD and PD.
Well-established genes associated with DLB
There are three well-established genes associated with DLB: APOE, GBA and SNCA. 
Variants in these genes have been associated with DLB in multiple different candidate 
gene studies (Chapter 3.1 and Chapter 3.2)10,11 and in two recent GWA studies.12,13 The 
APOE ε4 allele is the most common risk factor for DLB.10,12-14 An odds ratio of 2.9 has been 
reported for carriers of one APOE ε4 allele and of 5.9 for carriers of two APOE ε4 alleles for 
developing DLB.15 DLB patients with an APOE ε4 allele have a shorter survival than DLB 
patients without this allele.16-18 Conversely, APOE ε2 allele carriers have a reduced risk of 
developing DLB compared to controls.15 For GBA, the risk of developing DLB is dependent 
on the specific disease-associated variant.19,20 An odds ratio of 8 for developing DLB has 
been reported for carriers of disease-associated GBA variants in one study.11 DLB patients 
with disease-associated GBA variants display an earlier age of onset and earlier age of death 
than patients without these variants.11,14,21,22 Disease-associated variants in SNCA can modify 
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the risk of developing DLB, and can be, very rarely, the cause of DLB. Families with SNCA 
mutations show a large heterogeneity in diagnosis (DLB, PDD, PD), age of onset and disease 
progression.23-26 The SNCA locus has been found and replicated in a GWA study of DLB, 
including 1743 cases and 4454 controls.12 However, the exact SNCA variants which increase 
the risk of developing DLB remain controversial. Furthermore, the magnitude of this risk and 
the effect of these genetic variants on phenotype remain unexplored. 
 The three well-established genes which are associated with DLB (APOE, GBA and 
SNCA), also play a role in the development of AD or PD. The APOE ε4 allele is the most 
important genetic risk factor for AD, and disease-associated GBA variants increase the 
risk of developing PD and cognitive decline in PD.27,28 Rare causal variants and common 
disease-associated variants in SNCA have repeatedly been identified in PD patients.29-31 
Intriguingly, different association profiles in SNCA have been found for PD and DLB.12 
The single nucleotide polymorphism (SNP) showing the highest association with DLB for 
the SNCA locus (rs7681440) was not significantly associated with PD. Equally, the SNP 
showing the highest association with PD for the SNCA locus (rs356182) was not significantly 
associated with DLB. Thus, it may be hypothesized that these differences lead to different 
gene expression profiles and different molecular mechanisms between DLB and PD.
 Besides APOE, GBA and SNCA, other genetic loci associated with AD or PD, have not 
been identified by GWA studies in DLB.12,13 Furthermore, a recent study has shown that 
known AD and PD genetic risk loci only explain a very small percentage (̴ 1.3% and  ̴ 0.4%, 
respectively) of the phenotypic variance in DLB4. 
 To summarize, some genetic factors are shared between DLB and AD or PD, which may 
lead to similar molecular mechanisms and possible clinical features; however, the majority of 
genetic factors associated with DLB might be independent of those associated with AD and 
PD and still have to be discovered. 
Novel genes associated with DLB 
LRP10
Rare variants in the low-density lipoprotein receptor related protein 10 gene (LRP10) were 
reported for the first time in familial forms of PD, PDD, and DLB by Quadri et al., in 2018.32 
In this study, genome-wide linkage analysis in a family with dominantly inherited PD (10 
affected members) was performed to map the disease locus to a region in chromosome 
14. Subsequently, WES identified a single nucleotide substitution in LRP10, leading to a 
missense change (Gly603Arg) as the most likely disease-causing variant. This was followed 
by the sequencing of the whole LRP10 coding region in 660 unrelated PD, PDD, and DLB 
patients and 645 controls, and by the sequencing of specific possibly pathogenic LRP10 
variants in additional series of 1448 PD patients and 811 controls. Eight patients and one 
control from the first series and three patients and no controls from the second series were 
identified with a possibly pathogenic LRP10 variant. Furthermore, the variant present in the 
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index cases was also present in 9 out of 10 additional affected relatives with DNA available 
for testing. Three patients carrying one of the possibly pathogenic LRP10 variants could be 
studied post-mortem and they all had a severe burden of Lewy pathology. Functional studies 
in cell cultures showed that the LRP10 variants affected mRNA stability, protein stability or 
protein localization.
 Several studies have tried to replicate these initial findings. Five studies failed to find 
evidence for an association between LRP10 variants and PD, PDD, DLB, progressive 
supranuclear palsy (PSP), multiple system atrophy (MSA), or frontotemporal dementia 
(FTD).33-37 However, the absence of evidence in these studies does not allow to conclude 
for the absence of association. There are several reasons why these replication studies might 
have failed to detect a role of LRP10 in these diseases. 
 First, and most importantly, case-control association studies are not a powerful strategy 
to detect or replicate the role of rare, highly-penetrant variants in the disease etiology, unless 
only large series of patients with familial forms of the disease are considered. In some of the 
above-mentioned studies, the power to detect rare variants was not optimal because of limited 
sample sizes. In the original paper, the research sample was comprised of predominantly 
familial patients with late-onset disease. Three of the replication studies included sporadic 
patients33-35, and one analyzed patients with young-onset disease.33 Second, possibly 
pathogenic LRP10 variants may be population specific. The ethnicity of the patients in two 
of the replication studies were substantially different than the original study.33,37 Third, the 
control groups may have introduced bias, as they also included relatively young, unaffected 
participants who could still develop a late-onset neurodegenerative disease like PD or 
DLB.33,34 Furthermore, some control groups also contained participants who had not been 
clinically examined.34 Fourth, almost all replication studies adopted more relaxed filtering 
criteria for possibly pathogenic variants than those used in the original paper. This may have 
biased the results, as truly pathogenic and benign variants might have been grouped together. 
It is also possible that only some, specific variants are truly pathogenic and that these variants 
are more frequently found in patients than in controls. These variants will not be recognized 
as such with the used analysis methods.
 We (Chapter 4.1, Chapter 4.2 and Chapter 4.3) and three other research groups36,38,39 
found further evidence for an involvement of LRP10 in PD, dementia with parkinsonism 
without Lewy pathology, dementia with Lewy pathology, and PSP. Of particular interest 
is one of the variants, p.Tyr307Asn, as this variant was identified in the original study in a 
familial PDD patient from Italy, and subsequently in a mother and daughter with PD from 
France, and then in a PD and PDD patient with a shared ancestor from the Netherlands 
(Chapter 4.1).36,40,41 Considering all these studies together, the frequency of this specific 
variant seems significantly higher in familial PD and PDD patients in comparison to large 
control groups such as the Genome Aggregation Database (total 15 alleles in 251,270).41 The 
p.Tyr307Asn variant has also been shown in functional studies to decrease LRP10 protein 
stability.40 However, it should be noted that the p.Tyr307Asn variant was not found in another 
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two relatives affected with PD in the same French family mentioned earlier, and they may 
represent phenocopies. In our study of patients with dementia and parkinsonism without 
Lewy pathology, and patients with dementia and Lewy pathology, we identified three rare 
and possibly pathogenic LRP10 variants (Chapter 4.2). Interestingly, in previous studies, 
all these three variants were identified in additional unrelated patients with PDD, PD, MSA 
and in a single unaffected person (not neurologically examined)33,35,40,41. Interestingly, no 
Lewy pathology was observed in one of our patients with AD and parkinsonism carrying a 
possibly pathogenic LRP10 variant. Our PSP study (Chapter 4.3) showed that an increased 
fraction of these patients carries a possibly pathogenic LRP10 variant compared to controls. 
These results suggest that LRP10 variants may be associated with several neurodegenerative 
diseases with different underlying neuropathologies. 
  In conclusion,  our studies provide additional evidence for a role of LRP10 in PD, DLB, 
PSP and possibly AD. Nonetheless, there is still no firm consensus about the role of LRP10 
in these neurodegenerative diseases, and additional robust and independent replication is 
warranted, preferably from studies in large families with co-segregation of the variant in 
multiple affected members. 
A multimodal approach to find novel genes
In a parallel effort, we tried to find novel genes for DLB by combining WES data and CSF 
proteomics data. We described the results of the CSF proteomics analysis in Chapter 5.1, 
and the combination of the WES data and CSF proteomics data in the Appendix to Chapter 
5.1. Besides the use of CSF proteomics to find novel genes for DLB, this analysis is also 
very interesting to find novel fluid biomarkers for the disease. In Chapter 5.1 we identified 
and validated six novel candidate CSF biomarkers (VGF, SCG2, NPTX2, PDYN and 
PCSK1N) for DLB. These proteins are, amongst others, involved in neurotransmitter release, 
the packaging of neuropeptides in secretory vesicles and the formation of new excitatory 
synapses42-44, and may be markers of synaptic dysfunction. Synaptic dysfunction is observed 
in many neurodegenerative diseases, which led to the question of whether the identified 
biomarkers are specific for DLB. We analyzed these markers, therefore, in cohorts of AD, 
PD and FTD patients, which showed that the CSF levels of PDYN, SCG2 and VGF are 
significantly lower in DLB than in the other groups. To improve the discrimination of DLB 
and the other neurodegenerative diseases, machine learning was used to identify the most 
optimal biomarker panel. This resulted in a panel of PDYN, SCG2 and VGF with an accuracy 
of 0.82, specificity of 0.83 and sensitivity of 0.69. Further studies in larger and independent 
cohorts are needed to investigate the possible clinical usefulness of these markers. 
 In the pilot study described in the Appendix to Chapter 5.1 we combined these CSF 
proteomics data and WES data to identify novel candidate genes associated with DLB. The 
hypothesis behind this approach is that a pathogenic genetic variant will lead to a differential 
expression of the corresponding protein in the CSF. Our pilot study focused on DLB patients 
with relatives with dementia or PD to increase the likelihood of detecting disease-associated 
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findings. Although we identified an overlap between eight genes and proteins, the evidence of 
an association with DLB is limited. We discuss the limitations of this study and suggestions 
for improving such study designs in the future in the ‘Strenghts and limitations’ and ‘Future 
study directions’ sections. 
Molecular mechanisms underlying DLB
The identification of genes associated with DLB might contribute to a better understanding 
of the underlying molecular disease mechanisms. Multiple molecular pathways are likely 
implicated in the development of neurodegeneration due to primary defects in APOE, GBA, 
SNCA, and LRP10, but many of these molecular mechanisms are not fully elucidated. Here, 
I describe the key molecular mechanisms in which these genes have been implicated up until 
now. 
 APOE encodes the protein Apolipoprotein E, which plays a role in lipid transport, synaptic 
integrity, neuroplasticity, neuroinflammation, tau phosphorylation, glucose metabolism, 
and cerebrovascular function.45 APOE has been shown to affect amyloid-β clearance and 
aggregation leading to AD pathology. Several studies have indicated an APOE isoform-
dependent effect, in which the APOE ε4 isoform is less efficient in amyloid-β trafficking and 
degradation than the APOE ε3 isoform.46,47 It has also been demonstrated that the APOE ε4 
isoform promotes the formation of amyloid-β fibrils and amyloid-β production.45 At autopsy, 
the majority of patients with DLB have both Lewy as well as AD pathology.48,49 Interestingly, 
one study has indicated that the APOE ε4 allele is not only associated with DLB with AD 
pathology, but also with DLB without AD pathology.10 This suggests that the APOE ε4 allele 
also plays a role in amyloid-β independent mechanisms leading to DLB. 
 GBA encodes the protein Glucocerebrosidase (GCase), a lysosomal enzyme. GCase 
dysfunction has been shown to be related to an impaired autophagy-lysosomal system, 
increased endoplasmic stress, mitochondrial dysfunction and α-synuclein aggregation.50-52 
GCase hydrolyses glucosylceramide (GlcCer) and glucosylsphingosine (GLSph). Mutations 
in GBA result in a reduction of the enzymatic function of GCase, which leads to the 
accumulation of GlcCer and GLSph in lysosomes. This could lead to autophagy-lysosomal 
and mitochondrial dysfunction, and the accumulation of α-synuclein. Conversely, α-synuclein 
accumulation may result in the retention of GCase in the endoplasmic reticulum, leading 
to impaired GCase trafficking to the lysosome and to endoplasmic reticulum stress.53 This 
indicates that GCase and α-synuclein might be part of a bidirectional pathogenic loop.54 
 SNCA encodes the protein α-synuclein, one of the major constituents of Lewy bodies and 
neurites.55 α-Synuclein has been implicated in synaptic plasticity, neurotransmitter release, 
and synaptic vesicle pool maintenance.56-58 Disease-causing mutations in SNCA seem to 
increase the susceptibility of the protein to aggregate.59 
 LRP10 encodes a plasma membrane receptor (LRP10) whose function remains 
largely elusive. It has been suggested that LRP10 plays a role in the metabolism of 
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APOE lipoproteins60 and APP trafficking and processing, which may influence amyloid-β 
homeostasis.61 Interestingly, a decreased expression of LRP10 in the brains of AD patients 
compared to controls has been reported, even if caution is warranted here, as the specificity of 
the antibody used to detect the LRP10 protein in the human brain tissue was not adequately 
demonstrated.61 LRP10 may also interact with VPS35, a component of the retromer complex 
and the product of another PD-causing gene, and with GGA proteins, which have been 
shown to promote α-synuclein aggregation.62-64 Further research is warranted to study if 
LRP10 expression is also modified in the brains of PD or DLB patients, and to elucidate the 
interactions between LRP10, APOE, APP, and α-synuclein aggregation.
 In conclusion, the current evidence suggest that APOE, GBA, SNCA and LRP10 may 
be involved in similar or interacting neurobiological pathways driving Lewy and AD 
pathology. Further studies are needed to gain more information about the different molecular 
mechanisms leading to DLB. This is important for future development of biomarkers and 
disease-modifying treatments.
Future applications
Biomarkers
The identification of genes associated with DLB could lead to the implementation of these 
genes or their derivatives (e.g. encoded or interacting proteins in CSF or blood) as biomarkers 
in clinical practice. Biomarkers can be useful in 1) the diagnostic process, 2) the prognostic 
process, 3) the identification of at-risk persons, and 4) personalized medicine.
  Diagnostic biomarkers which improve the accuracy of the DLB diagnosis are highly 
needed, as the accuracy of current clinical criteria for DLB is still relatively low.6 GCase and 
α-synuclein in blood or CSF are interesting candidate biomarkers, which could possibly be 
used for this purpose in the future. Several studies have indicated that CSF levels of GCase 
are not only decreased in PD patients with disease-associated GBA variants, but also in PD 
patients without these genetic variants.65,66 GCase has also been found at decreased levels in 
the blood of sporadic PD patients as compared to controls. Furthermore, GCase correlated 
with α-synuclein levels in the brain of PD patients, possibly due to the effects of α-synuclein 
on GCase.54 GCase CSF levels are also decreased in DLB patients with disease-associated 
GBA variants compared to controls.67 However, it is currently unknown whether GCase CSF 
levels are also downregulated in DLB patients without disease-associated genetic variants, 
and in the blood of DLB patients. In addition, CSF levels of total α-synuclein have been found 
to be decreased in DLB patients compared to AD patients and controls, but not in comparison 
to PD patients.68,69 Conversely, CSF levels of oligomeric α-synuclein are increased in DLB 
patients compared to AD patients and controls, but not compared to PD patients.13 These 
findings suggest that levels of GCase, total α-synuclein, and oligomeric α-synuclein may be 
useful in differentiating DLB patients from AD patients and controls. 
 Prognostic biomarkers based on genetic factors are not yet used in clinical practice. The 
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main reason for this is that the disease course of carriers of a specific genetic variant is 
very variable. Indeed, even in families with SNCA mutations the disease course is largely 
unpredictable.23,26 However, several differences between genetic variant carriers and non-
carriers have been found at group level: DLB patients carrying the APOE ε4 allele have a 
shorter survival than non-carriers16-18, and DLB patients carrying disease-associated GBA 
variants have an earlier onset and an earlier death than non-carriers.11,14,21,22 Our study described 
in Chapter 2.1 also showed a different disease course between familial and sporadic DLB 
patients. This provides further evidence that genetic factors can be useful to estimate the 
prognosis in different patient groups. Further studies are needed to clarify whether genetic 
factors can also be used to generate individual predictions of disease course. 
 In DLB, the prediction of disease development and the selection of at-risk persons 
for medical trials by using biomarkers, is not yet a reality. One exception to this is in the 
testing of causal mutations in SNCA in families with multiple patients with DLB, PDD, and 
PD. The results of this test could identify individuals who have a high risk of developing 
DLB, PDD or PD. LRP10 genetic testing in clinical practice awaits conclusive replication 
of the role of variants in this gene in independent studies. Furthermore, current evidence 
points to a reduced penetrance for at least some LRP10 variants, which limits the predictive 
value for an individual person. Genetic testing for risk factors of DLB, such as the APOE ε4 
allele and disease-associated GBA variants, is also not currently recommended for clinical 
purposes. Results of such testing explain only a very small fraction of the total prediction, 
which is not informative by itself. However, polygenic risk scores, in which the combined 
risk of multiple genetic factors is considered, may ultimately be useful to predict the risk 
of disease development. The general belief is that the pathological process that leads to 
neurodegenerative diseases can only be reversed or prevented when medication is taken 
in the early pre-symptomatic phase of the disease. The identification of at-risk persons is, 
therefore, of utmost importance to detect alterations in molecular mechanisms and apply 
novel treatment options, before the onset of clinical symptoms. Furthermore, genetic status 
may be crucially important if treatment options are only found to be effective in the carriers 
of specific genetic variants.
Treatment 
The ultimate goal of studying genes associated with DLB is to increase our understanding 
of the disease pathogenesis, which could eventually aid in the development of disease-
modifying treatments. Treatment options targeting genes or related molecular mechanisms 
associated with DLB may not only be beneficial to patients with disease-associated genetic 
variants, but to all DLB patients. Unfortunately, no clinical trials have yet been performed or 
are currently underway in DLB specifically, targeting well-established genes associated with 
DLB or related molecular mechanisms. However, related clinical trials are presently being 
performed on patients with AD, patients with mild cognitive impairment (MCI), PD and 
PDD concerning APOE, GBA, and SNCA.
General discussion 
217
Pa
rt 
6
 Recently, two phase 1 clinical trials have commenced targeting the APOE gene in patients 
with AD and MCI due to AD pathology. The target of one of these trials is to assess the safety 
and toxicity of the intracisternal administration of adeno-associated viral vectors (AAVs) 
expressing the cDNA coding APOE ɛ2 in patients with two APOE ɛ4 alleles (ClinicalTrials.
gov identifier NCT03634007). In the other trial, the safety of plasma infusion from young 
adults with two APOE ɛ3 alleles to MCI patients with two APOE ɛ4 alleles will be determined 
(ClinicalTrials.gov identifier NCT03887741). The rationale behind these studies is that the 
detrimental effects of  carrying two APOE ɛ4 alleles will be diminished.70 
 At present, several clinical trials are being performed in PD and PDD, which target GBA 
and associated molecular mechanisms. One such phase 2 trial in PD patients with disease-
associated GBA variants assesses the drug dynamics, efficacy, and safety of Venglustat, a 
GlcCer synthase inhibitor (ClinicalTrials.gov identifier NCT02906020).71 Two other phase 2 
clinical trials, one in PD and one in PDD patients with disease-associated GBA variants, test 
the safety, tolerability, pharmacodynamics, and clinical effects of Ambroxol (ClinicalTrials.
gov identifier NCT02941822 and NCT02914366). Ambroxol is a small molecular chaperone, 
which aids physiological posttranslational folding of mutant GCase, resulting in the 
upregulation of GCase trafficking to the lysosome.72 Another potential disease-modifying 
treatment option for disease-associated GBA carriers is gene therapy, in which AAVs coding 
for GBA increases GCase activity. A phase 1/2a trial has recently begun to evaluate the 
safety of intracisternal administration of AAVs in PD patients with at least one GBA disease-
associated variant (ClinicalTrials.gov identifier NCT04127578). The results of these trials 
are still pending.
 For SNCA, different compounds have been examined with the aim to decrease α-synuclein 
aggregation, increase α-synuclein degradation, or decrease extracellular α-synuclein. For 
instance, one phase 2 trial concerned the small molecule, Nilotinib, an inhibitor of c-Abl 
tyrosine kinase, which is involved in many essential cellular processes, such as cell growth, 
neurogenesis and neurite extension.73 The non-blinded, non-placebo-controlled safety trial 
with the aforementioned drug showed some improvement in motor function of DLB patients 
and PDD patients.74 Different trials utilizing both passive and active immunotherapies to 
reduce extracellular α-synuclein are currently ongoing. Other promising therapies involving 
SNCA involve the reduction of the production of α-synuclein by gene silencing mechanisms 
using antisense oligonucleotide therapy and altering histone acetylation of the promotor and 
enhancer regions of SNCA.71
 Positive results originating from these trials will stimulate the development and testing 
of treatment options in DLB. Personalized medicine, in which a combination of different 
drugs targets different genes and molecular mechanisms based on the genetic profile of the 
patient, is a very promising approach in the future. 
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Strengths and limitations of the studies described in this thesis
The first strength of the described studies is the relatively large sample size of the studies 
in Part 2 and Part 4. We collaborated with several research groups to obtain such a large 
quantity of patients. It should be noted, nonetheless, that the sample sizes of the patient groups 
in Part 3 and Part 5 were relatively small. However, these study groups were carefully 
selected subgroups of patients, which had never been studied in such a comprehensive or 
novel manner before. As the accuracy of the clinical diagnosis of DLB remains suboptimal6, 
we did not only study clinical diagnosed DLB patients, but also pathologically confirmed 
DLB patients. We have found similar results in clinical as well as in pathologically confirmed 
patients (Part 3), which underpins the reliability of our findings. Other strengths include the 
use of Sanger sequencing for the initial analyses or validation of genetic variants in Part 3 
and Part 4, and the replication of our findings in independent cohorts in Chapter 4.3 and 
Chapter 5.1.
 The marked limitation of the described studies is that bias may have been introduced by 
relying on retrospective clinical data. Only a portion of the data on family history was obtained 
by means of a structured patient/caregiver interview, and patient/caregivers were often not 
able to provide accurate information on which diagnoses were made in their relatives. A bias 
in family history may also be introduced by relatives who died before symptom onset, and 
by asymptomatic relatives at time of inclusion who developed the disease later in life (Part 
2 and Part 3). Another limitation is that co-segregation studies could only be performed 
in a small percentage of patients with relatives with neurodegenerative diseases (Part 3, 
Part 4, and Appendix to Chapter 5.1). The main reason  for this is that often no DNA 
was available from deceased relatives and that younger relatives were not (yet) affected 
by disease. Limitations of the CSF proteomics study (Part 5) are, amongst others, that 
proteins could have been missed due to a bias towards the identification of peptides with 
higher concentrations in mass spectrometry studies, and that the control group consisted 
of individuals with subjective cognitive complaints. Furthermore, a bias could have been 
introduced by comparing the levels of the candidate biomarkers between DLB patients 
and the patients with other neurodegenerative diseases for which different control groups 
and techniques were used. The limitations of the pilot study (Appendix to Chapter 5.1) 
are, amongst others, that it is possible that CSF protein levels may not be altered at all by 
pathogenic genetic defects, and that we did not use an adjusted reference protein database, 
which may have led to the missing of altered peptides.
Future study directions
Although this thesis has contributed to the knowledge of the genetics of DLB, many genetic 
factors associated with the disease remain unknown. In general, future genetic studies will 
benefit from a more accurate clinical diagnosis, a better documentation of family history, 
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larger samples sizes and the use of novel research strategies and techniques.
 In clinical practice, DLB remains markedly under-recognized. This could be due to 
unacquaintance of family doctors and specialists with the concept and the clinical criteria 
of DLB, resulting in a failure to ask and examine the patients for all the possible symptoms 
and signs of DLB.1,75 Additionally, the accuracy of clinical diagnostic criteria for DLB is 
still relatively low and DLB is often misdiagnosed as AD.6,76 Especially the sensitivity of 
the clinical criteria of DLB should increase to improve an early diagnosis. Enhancing these 
aspects of disease identification will ultimately lead to larger and more homogeneous study 
groups. Furthermore, it is important to estimate how often DLB patients have relatives with 
DLB or related disorders. This has yet to be understood and could alter our perception of the 
genetics of DLB, leading to more refined and powered genetic research into rare variants 
associated with DLB. Therefore, taking a careful and structured family history in DLB is 
essential and should be promoted among health care providers.
 To find novel, common variants associated with DLB, samples sizes of GWA studies 
have to increase drastically. To date, the largest GWA study performed in DLB included 
1743 patients and 4454 controls12, which are relatively small numbers for a GWA study. The 
statistical power to find novel risk factors with low effect sizes is limited with these relatively 
low sample sizes. Larger GWA studies are necessary to find new genetic factors with a small 
to moderate effect size. In AD and PD, GWA studies reach sample sizes of around 15.000 
patients and >40.000 controls. Such large cohorts are necessary to identify risk factors with 
effect sizes as low as 1.1 - 1.4.30,77 GWA studies with more patients are, therefore, essential to 
find more risk factors with small effect sizes associated with DLB. National and international 
collaborations are essential in these efforts. 
 To find novel, rare variants associated with DLB different study approaches can be 
pursued. For instance, WES or whole genome sequencing (WGS) could be performed in 
large cohorts or in subgroups of patients in which the chances of finding rare variants is higher 
than in the total DLB population, such as families with multiple patients with DLB, PD(D), 
or dementia. Another possibility is to use a multimodal approach, such as the combination 
of genetics and proteomics, as shown in our pilot study (Appendix to Chapter 5.1). Future 
research combining genetics and proteomics with the aim to identify new genes associated 
with disease are promising if: 1) a strong family history is present, 2) DNA of multiple 
relatives is available, 3) a small set of possibly pathogenic genetic variants is obtained after 
genetic analysis, 4) tissue of interest is available in preferably >1 relative, and 5) the protein 
reference database is adjusted to recognize mutated peptides. The preferable tissue of interest 
when combining genetic and proteomic data in DLB might be neurons or brain inclusions. 
However, it should be considered that these data represent proteomic changes in late stage 
disease, which may not reflect protein differences due to a primary genetic defect. Other 
omics data, such as epigenomic, transcriptomics and metabolomic data, could also be used in 
multimodal approaches.
 Novel common and rare variants identified by future GWA, WES and WGS studies will 
contribute to a higher percentage of explained heritability for DLB. Furthermore, a part of the 
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heritability will probably be explained by copy number variation (CNV) and epigenetics, such 
as enhancers and other regulatory elements, gene-gene interactions and gene-environment 
interactions. Unbiased studies into these domains are still in its infancy concerning DLB.
Conclusion
Despite the appreciation that DLB has a substantial heritable component, only few genetic 
studies have been performed. This thesis adds to the understanding of the genetics of DLB. 
First, it showed that DLB patients with relatives with dementia or PD have a different 
phenotype than DLB patients without a positive family history. Second, we confirmed that 
the APOE ɛ4 allele and disease-associated variants in GBA are important genetic factors 
associated with familial DLB and DLB with a rapidly progressive disease course. Third, we 
found more evidence that the recently identified LRP10 gene is associated with PD, DLB, 
PSP and possibly AD. Fourth, we found several new candidate CSF biomarkers associated 
with DLB, which could potentially increase the accuracy of the DLB diagnosis.
 Nonetheless, known genetic factors associated with DLB still explain only a small 
part of the total heritability of DLB. The majority of genetic factors associated with DLB 
still remain to be discovered.  Large, homogeneous cohorts of DLB patients and very well-
defined families with DLB and related disorders are needed to find new genetic variants 
associated with DLB. These genetic factors, in combination with environmental, epigenetic, 
and stochastic factors, will likely all play important roles to determine the resulting individual 
risk of developing DLB.78
 The coming years promise to be exciting as many new genetic factors are likely to 
be discovered. These findings may lead to more accurate diagnosis, a better prediction of 
prognosis, and, ultimately the development of disease-modifying treatments.
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Summary
Dementia with Lewy bodies (DLB) is a common neurodegenerative disease in the elderly. 
The disease is characterized by progressive cognitive decline accompanied by parkinsonism, 
hallucinations, fluctuating cognition, and REM-sleep behavior disorders. To date, no 
disease-modifying treatment options are available and the median survival of patients with 
DLB is approximately four years from diagnosis. The pathological hallmarks of DLB are 
cortical Lewy bodies and Lewy neurites. However, Alzheimer's disease (AD) pathology is 
also observed in the majority of patients. In addition to these pathological features, clinical 
symptoms and genetic factors also overlap with those of AD and Parkinson’s disease (PD).
 It is likely that genetic factors play a considerable role in DLB. Recently, the heritable 
component has been estimated to be approximately 60%. However, to date, only few genetic 
studies have been performed in DLB. The aim of this thesis was to shed more light on the 
genetics of DLB by studying 1) familial aggregation in DLB, 2) known AD and PD genes 
associated with DLB, and 3) novel genes associated with DLB.
 Part 1 provides a general introduction to the thesis and summarizes the genetic research 
on DLB up until the beginning of this work in 2016. Up until that time, genetic studies 
were only performed in small study groups with candidate gene-based (biased) approaches. 
Unbiased genome wide association studies and whole exome sequencing (WES) studies had 
not yet been performed by then. The candidate gene studies showed that the APOE ɛ4 allele 
and specific variants in GBA and SNCA are associated with DLB. These genetic factors had 
previously been shown to play a role in AD (APOE ɛ4 allele) and PD (GBA and SNCA). 
Besides the fact that little was known about which genetic factors play a role in DLB, it 
was also largely unknown what effect these genetic factors have on the phenotype of DLB 
patients.
 In Part 2 we, therefore, examined the differences in phenotype between DLB patients 
with relatives with dementia or PD (familial patients) and DLB patients without relatives 
with these diseases (sporadic patients). We showed that familial DLB patients have a shorter 
survival than sporadic DLB patients. Furthermore, we demonstrated that a higher percentage 
of familial DLB patients have elevated AD biomarkers in their cerebrospinal fluid (CSF) 
compared to sporadic DLB patients. These findings suggest that genetic factors contribute to 
disease course, possibly by influencing the amount of concomitant AD pathology.
 Owing to the genetic overlap between DLB, PD and AD, we investigated more profoundly 
if known genes associated with PD and AD also play a role in DLB. Part 3 describes these 
genetic analyses in carefully selected study groups, namely familial DLB patients (Chapter 
3.1) and pathologically confirmed DLB patients with a rapidly progressive disease course 
(Chapter 3.2). We showed that the APOE ɛ4 allele and specific variants in GBA are also 
important genetic risk factors in these patient groups.
 The search for novel genes associated with DLB is described in Part 4 and Part 5. 
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In Part 4 we studied the association between the LRP10 gene and DLB, and other related 
disorders. The LRP10 gene was recently nominated as a novel gene associated with PD, PD 
dementia, and DLB. The function of LRP10 is largely elusive. However, the protein has 
been suggested to play a role in the aggregation of amyloid-β and α-synuclein. Chapter 4.1 
illustrates that rare, possibly pathogenic variants in LRP10 are detected in clinically diagnosed 
PD and PD dementia patients from the South West of the Netherlands. In Chapter 4.2 and 
Chapter 4.3  we described that rare, possibly pathogenic LRP10 variants may also play a 
role in patients with dementia and Lewy pathology, dementia patients with parkinsonism 
without Lewy pathology, and patients with progressive supranuclear palsy. In Part 5, we 
searched for novel genes by combining WES and CSF proteomics. Chapter 5.1 outlines 
the identification of six novel CSF candidate biomarkers for DLB: VGF, SCG2, NPTX2, 
NPTXR, PDYN, and PCSK1N. These proteins play a role in, amongst others, synaptic 
dysfunction, and show promise to improve the diagnostic accuracy of DLB. The data from 
Chapter 5.1 and the WES data were combined in the pilot study described in the Appendix 
to Chapter 5.1. The hypothesis behind this approach was that a pathogenic genetic variant 
will lead to a differential expression of the corresponding protein in the CSF. Although we 
identified overlap between eight genes and proteins, the evidence that these genes or proteins 
are associated with DLB remains very limited at this stage.
 Part 6 provides a general discussion of the findings of this thesis in the context of the 
current literature and provides suggestions for future study directions.
Summary and samenvatting
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Samenvatting 
Dementie met Lewy bodies (DLB) is een vaak voorkomende neurodegeneratieve ziekte bij 
ouderen. De ziekte wordt gekenmerkt door progressieve cognitieve achteruitgang met hierbij 
parkinsonisme, een fluctuerend bewustzijn en REM-slaap gedragstoornissen. Er is geen 
medicatie die aangrijpt op het ziekteproces en de mediane overleving van patiënten met DLB 
is ongeveer 4 jaar vanaf de diagnose. De pathologische kenmerken van DLB zijn corticale 
Lewy bodies en Lewy neurieten. De meeste patiënten hebben daarnaast ook Alzheimer 
pathologie. Niet alleen pathologische kenmerken, maar ook klinische en genetische 
kenmerken overlappen met kenmerken die voorkomen bij de ziekte van Alzheimer (ZvA) en 
de ziekte van Parkinson (ZvP).
 Genetische factoren lijken een belangrijke rol bij DLB te spelen. Recent is de erfelijke 
component zelfs geschat op ongeveer 60%.  Er is echter nog maar weinig genetisch onderzoek 
bij DLB verricht. Het doel van dit proefschrift was om meer inzicht te krijgen in de genetica 
van DLB door het bestuderen van 1) het familiair voorkomen van DLB, 2) bekende ZvA en 
ZvP genen die geassocieerd zijn met DLB, en 3) nieuwe genen die geassocieerd zijn met 
DLB.
 Deel 1 bevat een algemene introductie van het proefschrift en vat het genetisch 
onderzoek bij DLB samen tot de start van dit promotieonderzoek in 2016. Tot die tijd 
waren er alleen onderzoeken uitgevoerd in kleine studiegroepen waarbij gezocht werd naar 
varianten in kandidaatgenen. Genome wide association studies en whole exome sequencing 
(WES) studies waren tot dan toe nog niet uitgevoerd. De onderzoeken naar varianten in 
kandidaatgenen hebben aangetoond dat het APOE ε4 allel en specifieke varianten in GBA 
en SNCA geassocieerd zijn met DLB. Deze variaties zijn tevens genetische risicofactoren 
voor de ZvA (APOE ε4 allel) en de ZvP (GBA en SNCA). Naast dat er nog maar weinig 
bekend was over welke genetische factoren een rol spelen bij DLB, was het ook grotendeels 
onbekend welk effect deze genetische factoren hebben op de klinische kenmerken (fenotype) 
van patiënten met DLB.
 In Deel 2 hebben wij daarom de verschillen in fenotype tussen DLB patiënten met 
familieleden met dementie of de ZvP (familiaire patiënten) en DLB patiënten zonder 
familieleden met deze ziektes (sporadische patiënten) onderzocht. We hebben laten zien 
dat familiaire patiënten een kortere overleving hebben dan sporadische patiënten. Hiernaast 
hebben we laten zien dat relatief meer familiaire patiënten dan sporadische patiënten 
Alzheimer eiwitten in het hersenvocht hebben. Deze resultaten suggereren dat genetische 
factoren invloed hebben op het ziektebeloop, mogelijk door het beïnvloeden van Alzheimer 
pathologie.
 Aangezien er een genetische overlap is tussen DLB, de ZvA en de ZvP, hebben wij 
verder onderzocht welke bekende genen die geassocieerd zijn met de ZvA en de ZvP ook een 
rol spelen bij DLB. Deel 3 beschrijft deze genetische analyses bij zorgvuldig geselecteerde 
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AAD age at death
AAO age at onset
AAS age at sampling
AAV adeno-associated viral vector
ABCA7 ATP binding cassette subfamily A member 7 gene
AD Alzheimer’s disease / autosomal dominant
AHNAK AHNAK nucleoprotein gene
ALS amyotrophic lateral sclerosis
APOE apolipoprotein E gene
APP amyloid precursor protein gene
AR autosomal reccessive
ARTAG age-related astrogliopathy
Aβ1-42 amyloid-β1-42
B benign
BNE Brain Net Europe
BuChE butyrylcholinesterase gene
C9orf72 chromosome 9 open reading frame 72 gene
CA2 cornu ammonis region 2
CAA cerebral amyloid angiopathy
CADD Combined Annotation Dependent Depletion
CERAD Consortium to Establish a Registry for Alzheimer’s disease 
CHCHD2 coiled-coil-helix-coiled-coil-helix domain containing 2 gene
CHMP2B charged multivesicular body protein 2B gene
CI confidence interval
cingulate posterior cingulate gyrus
CJD Creutzfeldt-Jakob’s disease
CLTC clathrin heavy chain gene
CNV copy number variation
CSF cerebrospinal fluid
CV coefficient of variation
D damaging / disease causing
DaT-SPECT 123I[FP-CIT] single photon emission computed tomography 
DLB dementia with Lewy bodies
e.g. exempli gratia (for example)
EEG electro-encephalogram
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EIF4G1 eukaryotic translation initiation factor 4 gamma 1 gene
ELISA enzyme-linked immunosorbent assay
ExAC-NFE Exome Aggregation Consortium - Non Finnish Europeans
EXT2 exostosin glycosyltransferase 2 gene
FATHMM Functional Analysis Through Hidden Markov Models
FCGBP Fc fragment of IgG binding protein gene
FDR false discovery rate
FREM2 FRAS1 related extracellular matrix protein 2 gene
frontal frontal gyrus (Brodmann area 10)
FTD frontotemporal dementia
GATK Genome Analysis Toolkit
GBA glucocerebrosidase gene
Gcase glucocerebrosidase
GERP Genomic Evolutionary Rate Profiling
GGA golgi associated, gamma adaptin ear containing, ARF binding protein
GIGYF2 GRB10 interacting GYF protein 2 gene
GlcCer glucosylceramide
GLSph glucosylsphingosine
GnomAD Genome Aggregation Database
GoNL Genome of the Netherlands
GRCh37 genome reference consortium human 37
GRN granulin gene
GWA genome wide association
HEG1 heart development protein with EGF like domains 1 gene
HEX Healthy Exomes
i.e. id est (in other words)
IQR interquartile range
KRT73 keratin 73 gene
L low
LB Lewy body / likely benign
LBD Lewy body disease
LC locus coeruleus / liquid chromatography
LFQ label-free quantification
LN Lewy neurite
LR logistic regression
LRP10 low-density lipoprotein receptor related protein 10 gene 
LRRK2 leucine-rich repeat kinase 2 gene
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LRT Likelihood Ratio Test
M medium
MAF minor allele frequency
MAPT microtubule-associated protein tau gene
M-CAP Mendelian Clinically Applicable Pathogenicity
MCI mild cognitive impairment
MEC medical ethics committtee
MLPA Multiplex Ligation dependent Probe Amplification
MMSE Mini-Mental State Examination
MR-DWI magnetic resonance diffusion weighted imaging
MRI magnetic resonance imaging
MS multiple sclerosis
MSA multiple system atrophy
MS/MS tandem mass spectrometry
MTA medial temporal lobe atrophy
N polymorphism / neutral
n.a. not applicable
NA not available
ND not done
NIA-AA National Instittue on Aging - Alzheimer Association
NPTX2 neuronal pentraxin 2
NPTXR neuronal pentraxin receptor
P polymorphism automatic
parietal inferior parietal lobe
PARK2 parkin gene
PCSK1N ProSAAS
PC prohormone convertase
PD Parkinson’s disease
PDD Parkinson’s disease dementia
PDYN proenkephalin-B
PINK1 PTEN induced putative kinase 1 gene
PolyPhen2 HDIV Polymorphism Phenotyping version 2 human diversity
PolyPhen2 HVA Polymorphism Phenotyping version 2 human variation
PP probably pathogenic
PRKAR1B protein kinase cAMP-dependent type I regulatory subunit beta gene
PRNP prion protein gene
PSEN1 presenilin 1 gene
PSEN2 presenilin 2 gene
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PSP progressive supranuclear palsy
PSWC periodic sharp wave complex
p-tau tau phosphorylated at threonine 181
RBD rapid eye movement-sleep behaviour disorder
Ref reference
REM rapid eye movement
SCARB2 scavenger receptor class B member 2 gene
SCG2 secretogranin-2
SD standard deviation
SE standard error
SIFT Sorting Intolerant From Tolerant
SN substantia nigra
SNCA α-synuclein gene
SNCB β-synuclein gene
SNP single nucleotide polymorphism
SORL1 sortilin related receptor 1 gene
SQSTM1 sequestosome gene
SRM selected reaction monitoring
STR short tandem repeat
SVM Support Vector Machine
SYNE1 spectrin repeat containing nuclear envelope protein 1 gene
T tolerated
temp-occ temporo-occipital cortex
temporal medial temporal gyrus
TREM2 triggering receptor expressed on myeloid cells 2 gene
t-tau total tau
UN unknown
var / V variant
VGF neurosecretory protein VGF
VPS13C vacuolar protein sorting 13 homolog C gene
VPS35 vacuolar protein sorting-associated protein 35 gene
WES whole exome sequencing
WGS whole genome sequencing
WHO World Health Organization
wt wild-type
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